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ABSTRACT

The epigenetic “reader” modules bromodomains (BRDs) exert their diverse cellular
functions through the recognition of acetylated lysines on histones and other proteins. Small
molecule inhibitors of bromodomains have emerged as a promising therapeutic strategy to treat
atherosclerotic cardiovascular diseases and cancers. Therefore, a large number of small molecule
bromodomain inhibitors have been developed in the last decade, some of which are currently being
assessed in the clinic. However, the success of bromodomain inhibitors is currently limited to the
bromodomain and extra-terminal domain (BET) subfamily.
To address these, bromodomains outside the BET subfamily (non-BETs) such as TAF1,
BRD7/9, TRIM28, and BRD8 were studied in detail. The first dual non-BET BRD-kinase
inhibitors were discovered for TAF1 (chapter 2) and BRD7/9 (chapter 3), which includes the dual
TAF1-ATR inhibitor AZD6738, and dual BRD7/9-kinase inhibitors TG003, sunitinib, and
PF477736. Structural and biochemical studies with TAF1 showed that inhibitor binding to the
tandem bromodomain of TAF1 induces large conformational changes, and bromodomain
inhibition of TAF1 invokes p53-mediated DNA damage response. Moreover, a comprehensive
characterization of diverse BRD7/9 inhibitors, along with the newly discovered dual BRD7/9kinase inhibitors, provides a new structural framework for the development of BRD7/9 inhibitors
with improved selectivity or additional polypharmacologic properties.

xvii

To develop a selective and effective BET bromodomain inhibitor, structure-activity
relationship studies, and biophysical characterization of various dual BET-kinase inhibitors and
bivalent inhibitors were conducted. The dual BET-JAK2 inhibitor lead compounds developed
from the studies (chapter 4 part I) will serve as potential drug candidates for testing in preclinical
disease models. Moreover, studies with a set of PLK1/ERK5/LRRK2 inhibitors against the BET
BRDs (chapter 4 part II) provide a structural basis for developing a dual BET-PLK1/ERK5
inhibitor for synergistic pharmacological benefits. Finally, studies with the bivalent inhibitors
(chapter 5) showed that homomeric bivalent inhibitors of BRD4 and BRDT induce the
dimerization of BRDs, and the potent bivalent inhibitor NC-III-49-1 engages the tandem BRD of
BRDT in an intramolecular fashion. Combined, these studies provide valuable chemical tools that
can be utilized to progress towards the development of selective and effective BET bromodomain
inhibitors as potential therapeutic candidates.
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CHAPTER 1: INTRODUCTION TO THE BROMODOMAINS

EPIGENETICS AND ITS ROLE IN GENE REGULATION

Epigenetics, a term originated from epigenesis, was first coined by embryologist Conrad
Waddington in 1942.1 The meaning of epigenetics has evolved from Waddington’s developmental
processes of the organism to Riggs and Holliday’s “mitotically or meiotically heritable changes in
gene function that cannot be explained by changes in the DNA sequence”,2, 3 and later from
transient gene regulation mechanism4-6 to heritable phenotypes from chromosomal changes.7 In
simplified terms, epigenetics is the study of macromolecules and related transient or heritable gene
regulatory mechanisms without altering the DNA sequence.5,
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Recent advancements in

epigenetics show that functions of specific genes and certain cell phenotypes can be altered through
epigenetic mechanisms. Therefore, the idea of altering the functions of a gene without changing
its DNA sequence makes the epigenetics an interesting topic to pursue. In the epigenetic process,
a set of enzymes called epigenetic “writers” change the chemical groups on DNA or histone tails.
These chemical groups are usually very small such as methyl (-CH3), acetyl (-CO- CH3), and
hydroxyl (-OH). The second set of proteins called epigenetic “readers” can recognize these
chemical groups and subsequently recruit other proteins to form large multi-subunit containing
cellular machinery to control chromatin remodeling, gene splicing, and gene expression.
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Epigenetic processes in eukaryotes are essentially linked to the chromatin structure, and
accessibility as well as processability of genomic DNA.8 Packaging of genomic DNA wrapping
around the octameric histones H2A, H2B, H3 and H4 in coordination with non-histone proteins
(e.g., heterochromatin protein 1, Polycomb) forms the chromatin.9 Nucleosome is the structural
and functional unit of chromatin, which consists of 147 bp of DNA wrapping around a dimeric
complex of histone H2A, H2B, H3 and H4 forming the “nucleosome core particle” (Fig. 1.1),
linker DNA and a linker histone H1.10 Nucleosomes act as a barrier for DNA transcription through
a physical obstruction or DNA coiling. Post-translational modifications (PTMs) of histones play a
vital role to surpass the nucleosome barrier by regulating the DNA accessibility through the
formation of euchromatin or heterochromatin, induction of chromatin remodeling, and providing
an epigenetic “bookmark” recognition mechanism (Fig. 1.2).11 Among the various histone PTMs
(i.e.,

acetylation,

methylation,

phosphorylation,

ubiquitinylation,

sumoylation,

ADP

ribosylation,11 and recently reported crotonylation, propionylation, and butyrylation12) acetylation
and methylation on the N-terminal tails of histones are well-characterized.8, 13, 14 These epigenetic
“bookmarks” are deposited by the epigenetic “writers” (e.g., histone acetyltransferases (HATs),
and histone methyltransferases (HMTs)), recognized by the epigenetic “readers” (e.g.,
bromodomains (BRDs), and chromodomains (Chromo)), and removed by the epigenetic “erasers”
(e.g., histone deacetylases (HDACs), and lysine demethylases (KDMs)).15

EPIGENETIC “READER” MODULE – BROMODOMAIN (BRD)

Bromodomains (BRD) are ~110 amino acid consisting evolutionarily conserved protein
fold that acts as epigenetic “reader” module to specifically recognize the N-acetylated lysine (KAc)
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residues on histones tails,16-18 such as bromodomain of BRD4 recognizes the acetylated lysine of
H4 histone peptide (Fig. 1.3).19 BRD fold consists of a bundle of four left-handed alpha helices,
named ⍺Z, ⍺A, ⍺B and ⍺C, and two connecting loops, named ZA and BC loops, which combinedly
form a deep hydrophobic KAc binding pocket with a characteristic open channel on one side,
named ZA channel (Fig. 1.3b). In some instances, N-term or C-term of a non-canonical BRD
contains an additional helix, such as the second BRD of TAF1 or TAF1L has a kinked extended
alpha helix at its C-term. The KAc binding pocket of BRD is surrounded by hydrophobic residues
forming flanks on the two sides while the polar groups of the KAc site surrounding residues reside
at the base (Fig. 1.3c). In BRDs, a conserved asparagine, critical for KAc binding, is positioned at
the base of the pocket in between the two hydrophobic flanks while the opposite side, the ZA
channel, remains solvent accessible. In an unperturbed state, five to six highly coordinated
bridging water molecules spanning from deep inside the pocket to the ZA channel connect the
conserved asparagine (N140BRD4) and tyrosine (Y97BRD4) to WPF shelf residues to maintain a
structurally conserved water network, and stabilizes the BRD (Fig. 1.3c).20 Specific acetylated
lysine on a histone tail enters into the pocket and binds to the BRD. Carbonyl oxygen of the acetyl
group of acetylated lysine on histone tail interacts with the side chain of conserved asparagine
(N140BRD4) and tyrosine (Y97BRD4) through a direct hydrogen bonding and a water-mediated
hydrogen bonding. This hydrogen bonding network in association with hydrophobic interactions
stabilizes the acetylated histone binding to the KAc pocket of BRD4 bromodomain and other
BRDs.
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BRD FAMILY

In the phylogenetic tree of the BRD protein family, 61 individual bromodomains from 46
different proteins are grouped in eight classes (I to VIII) (Fig. 1.4). BRDs do not exert any
enzymatic activity and mostly function as scaffolding proteins to initiate and support the formation
of large multi-subunit containing cellular machinery e.g., BRD4 in transcription pause release
complex, TAF1 in pre-initiation complex and BRD7/9 in BAF complex. Through the recognition
of acetylated lysine motif and formation of complex cellular machinery, BRD-containing proteins
play regulatory roles in a wide range of cellular events such as post-translational modification of
histones, chromatin remodeling, cell identity, DNA damage response, transcription factor
recruitment, gene expression, and transcription.21, 22
Some of the BRD-containing proteins comprise more than one BRD such as BET
(bromodomain and extra terminal domain) proteins or TAF1 (TBP associated factor 1) contains a
tandem BRD, and PB1 contains six BRDs in tandem (Fig. 1.5). In some instances, BRD acts as a
functional domain in association with a second or third domain at the proximal N-term or C-term,
for example, PHD-BRD is the functional module in TRIM28 and PHD-BRD-PWWP is the
functional module in PRKCBP1 (ZMYND8). Notably, other domains in the BRD-containing
proteins can alter the protein-protein interaction functions of BRD.
The phylogenetic classification of the BRD family is complicated by diverse sequence
features within the BRD fold especially variable loop lengths connecting the alpha helices and low
sequence homology within a class. Therefore, the phylogenetic classification was done based on
the three-dimensional structural features and conserved sequence motif alignment (Fig. 1.6).19
However, functional diversity or similarity of two BRD-containing proteins even within a class is
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notable, which is most probably dictated by the overall function of the protein rather than the
bromodomains. As an example, BRD7 and BRD9 are close homologs with high sequence
homology (identity 66.3% and similarity 82.7%) and structural similarity, yet they mediate
different biological functions through the formation two sub-types of BAF (BRG associated factor)
complex (SWI/SNF chromatin remodeling complex) – presumably due to overall low sequence
homology of the entire protein (identity 23.6% and similarity 39.9%).
Some of the BRD family members, especially outside the BETs (non-BETs), contain
atypical bromodomain fold where the conserved asparagine in the KAc pocket is not in place (e.g.,
BRD8-2 in silico model) or is replaced with tyrosine (e.g., ASH1L, PB1(1), SP110A/C, SP100,
SP140, SP140/LOC93349, and ZMYND11) or threonine (e.g., WDR9(2), PHIP(2), BRWD3(2)
and TRIM28) or aspartic acid (e.g., MLL) (Fig. 1.6). However, it is not clear if these atypical
BRDs recognize acetyl-lysine on histone tails or other proteins.

DRUG DISCOVERY TARGETING THE BRDS

BRDs were initially identified in transcription activator and transcriptional adaptor
proteins,23, 24 some of which were later characterized as multi-domain containing proteins with
histone acetyltransferase, ATPase dependent chromatin remodeler or helicase activity.25 After the
discovery and establishment of bromodomain as a distinct domain in the early 1990s,26, 27 research
in the next decades unambiguously revealed that BRDs play their cellular functions through
protein-protein interactions mechanism,19, 28-30 and the early reported enzymatic activity of the
BRD-containing proteins were contributed by the non-BRD domains. Due to the significant
cellular effects of the non-BRD domains, elucidation of biological functions of the bromodomains
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using genetic manipulation methods such as gene knockout or knockdown and ectopic expression
were unsuccessful. The landmark discovery of JQ1, the first potent small molecule inhibitor of
BET bromodomains,30 provided an excellent chemical tool to explore the function of BET proteins
in disease states for the first time (Fig. 1.7). JQ1 binds to the KAc site of BET BRDs and inhibit
BRD mediated functions. The architecture of the KAc site renders BRD a viable target for small
molecule inhibitor discovery and development.31, 32 Since then a large number of small molecule
inhibitors of BRD4 have been developed, and some of them has entered in clinical trials for
oncology and cardiovascular indications (Table 1.1).33-35 More recently, inhibitors targeting the
non-BET bromodomains (e.g., BRD7/9 and TAF1), for which the physiological functions are not
yet well understood, have been the subject of intense efforts in academia and pharmaceutical
industry alike.34, 36 Such inhibitors are valuable probes to unravel the function of bromodomains
outside the BET family, their relevance in cancer, and their potential as drug targets.37

DEVELOPMENT OF BRD INHIBITORS

After the first report of JQ1, several small molecule inhibitors of BRDs have been reported
covering nearly all classes of the BRD family (Fig. 1.8). Initially, BRD inhibitor (BRDi) discovery
was based on phenotypic screening.22 However, extensive utilization of the biophysical
characterization and excellent tractability of the BRDs by small molecules propelled the targeted
drug discovery approaches. As a result, numerous BETis have been reported using fragment-based
drug discovery, virtual screening, and structure-based drug discovery approaches – some of which
have reached the clinic. Moreover, highly collaborative research and availability of the early BETis
as a chemical probe provided by the Bradner group at Harvard University, and by the Structural
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Genomics Consortium (SGC, UK) catalyzed the rapid progress in the much-needed understanding
of the cellular functions of BETs. Although BETis served as excellent chemical tools to unravel
the biological functions of BRD, particularly BRD4, and reached the clinic for trials in humans,
drug development targeting other bromodomains (non-BETs) is still in the early stage. A clinical
trial with CBP/EP300 BRD inhibitor CCS1477, the first non-BETi in the clinic, has just been
initiated.38
In the last decade, BRD targeted drug development has seen some of the groundbreaking
creative approaches. The applied approaches in BRD drug development can be considered (Fig.
1.9) in four conceptual phases – first-generation potent BRDis were developed for potent
inhibition,21 second-generation dual BRD-kinase inhibitors were developed for specific disease
indication,39 third-generation homomeric bivalent inhibitors were developed for improved
selectivity and potency,40 and the fourth-generation heterobifunctional inhibitors, the PROTACs
(proteolysis targeting chimeras),41 were developed for target BRD-containing protein degradation.
Among the four generations of BRDis, only first-generation inhibitors are being extensively
assessed in clinical trial phase I-III, and a second-generation dual BET-PI3K kinase inhibitor has
entered in the first clinical trial phase I/II (Table 1.1).42, 43 None of the third or fourth generation
BRDis have reached the clinic yet. However, the selectivity of the BRDis within the BRD family,
and among the homologous family members remained a considerable challenge in BRD inhibitor
development.
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DISCOVERY OF DUAL BROMODOMAIN-KINASE INHIBITORS

Although bromodomains (BRDs) are epigenetic reader modules that recognize acetylated
lysine (KAc) on histone tails and devoid of enzymatic activity, intriguingly, BRD containing
protein BRD4 was reported as an atypical kinase.44 This unusual discovery warranted a rational
approach to testing the hypothesis that currently available ATP site-directed kinase inhibitors can
bind to the KAc recognition site of BRD. In the process of detailed investigation to test this
hypothesis, our lab discovered that CDK2 kinase inhibitor dinaciclib binds to the KAc site of BET
protein BRDT.20 Binding mode analysis from the dinaciclib bound crystal structure of BRDT
showed that dinaciclib acts as a KAc mimetic at the bromodomain binding pocket. Notably,
functional groups of dinaciclib that mediate hinge binding in kinases were found to be critical for
binding to the BRDT. Later, work in our lab showed that BRD4 has an inherent propensity to
interact with diverse kinase inhibitors, where various types of functional groups of distinct kinase
inhibitors interacted differently with the KAc binding site (Fig. 1.10).45, 46 These discoveries, and
the possibility of developing an existing kinase inhibitor as a dual BRD-kinase inhibitor to exert a
desirable polypharmacological effect in the clinic accelerated the dual BRD-kinase drug
development efforts.47-49 The first dual BET-PI3K inhibitor SF116 is currently being assessed in
the clinic (clinical trial phase I/II, 2019) as a single agent for various cancers.42, 43
The idea of the polypharmacologic drug for effective cancer treatment is more than a
decade old,50-53 but rationally targeting more than one pathway has remained a considerable
challenge due to the failure in earlier clinical trials using conventional approaches of drug
combinations.54-59 The approach has evolved from drug combination treatment to targeted
polypharmacologic inhibition, where the ability of a targeted inhibitor to hit an off-target is
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exploited for a desired phenotypic effect. For example, lorlatinib, first developed as an ALK
inhibitor with ROS1 as an off-target, has recently been approved by the FDA for ALK mutated
NSCLC with ROS1 as the primary target.60, 61 A major limitation of ATP site-directed kinase
inhibitors are high promiscuity, as the whole kinase superfamily is comprised of diverse classes of
kinases with the common substrate ATP. The ensuing shift in drug discovery paradigm indicates
the necessity of multiple pathways targeted single agent to overcome this barrier.62-64 With the
current set of chemical biology tools, perhaps it is difficult to conceive how to discover and design
such drug molecules. In the last few years, it has been shown that dual inhibition of BET
bromodomains (particularly BRD4) and a subset of kinases by a single chemical molecule can
effectively restrain cancer progression that can be exploited to develop next-generation dual BRDkinase inhibitors.47, 65, 66 However, discovery and development of dual BRD-kinase inhibitor have
been mostly limited to BET bromodomains.
More than 50 small molecule inhibitors of protein kinases have been approved by the FDA
for various diseases signifying the enormous efforts undertaken by the pharmaceutical industry
and academia alike. Innovative strategies and new approaches, deployed in the kinase inhibitor
drug discovery, have significantly advanced our understanding of critical issues in drug
development, and provided a large repertoire of drug-like chemical matters to explore. Discovery
of bromodomain (BRD) inhibition by diverse scaffold-containing kinase inhibitors incorporates a
new concept of dual BRD-kinase inhibition in drug development much aligned to the current
strategy of combination therapy for cancer. In combination therapy, two or more drugs are utilized
to intervene in multiple cancer-driving pathways for better therapeutic response and to minimize
the chance of acquired drug resistance. With a dual BRD-kinase inhibitor as treatment such as dual
BET/JAK2 or dual BET-PI3K inhibitor (Fig. 1.11), one can envision that two tumor survival
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pathways – one pathway through kinase-mediated signaling and another pathway through
bromodomain-mediated epigenetic events – can be tamed in certain types of cancers resulting in
better patient survival, and lower chance of remission and acquired drug resistance. Thus, a
reduced rate of failure associated with cancer chemotherapy can be expected. The understanding
gained through the successful utilization of potential chemical inhibitors developed through this
approach will be useful to transform other areas of research involving different epigenetic
mechanisms. The success of a dual BRD-kinase inhibitor in clinical trials will be a significant leap
in epigenetic drug development, particularly in the bromodomain targeted drug development,
which will also encourage future research on diverse BRDs involved in cancers and other diseases.

FIGURES AND TABLES

Figure 1.1. Cryo-EM structure of canonical nucleosome core (PDB:6ESF).
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Figure 1.2. Schematics of post-translational modifications of the histone tails. (Reused with
copyright permission; see Appendix for copyright permission)
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Figure 1.3. Bromodomain recognizes the acetylated lysine on the histone tail. A) Acetylated
histone bound BRD of BRD4 (PDB:3UVW), BRD is shown as beige surface view, histone peptide
as a green loop, acetylated lysine as yellow sticks and conserved asparagine as magenta sticks. B)
Acetylated lysine of histone tail interacting with the conserved asparagine of BRD4. BRD is shown
as cartoon, and the KAc involving hydrogen bonds are shown as black dotted lines. C) Detail
interaction of KAc in the BRD binding pocket. Structurally conserved waters (numbered 1-6) are
shown as light pink spheres, and hydrogen bonds for the ZA channel water network are shown as
green dotted lines.
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Figure 1.4. Bromodomain family. Multiple BRDs in one protein are shown with numbers in
parenthesis. 61 individual bromodomains (62 including BRD8-2) in 46 different BRD-containing
proteins are classified in eight phylogenetic classes.
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Figure 1.5. Domain maps of the proteins that contain a representative BRD family
members. Protein names with consisting domains are shown on the left, and domain legends are
shown on the right. (Reused with copyright permission; see Appendix for copyright permission)
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Figure 1.7. Chemical structure of the first BRD (BET) inhibitor JQ1.

Figure 1.8. BRD targeting small molecule inhibitors (BRDis). A representative inhibitor is
shown for each class of the BRD family. Drug development status of each BRD class inhibitors is
shown with color-coded dashed lines.
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Figure 1.9. Four phases of bromodomain targeting drug development.
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Figure 1.10. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4)
interacts with diverse kinase inhibitors. (Reused with copyright permission; see Appendix for
copyright permission)
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Figure 1.11. Dual BRD-kinase inhibitors. A) Chemical structure of potent dual BET-JAK2
inhibitor SG3-179.47 B) Chemical structure of dual BET-PI3K inhibitor SF1126 that is in clinical
trial phase I/II.42
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Table 1.1. BRD inhibitors in clinical trials. (Source: www.clinicaltrials.gov; accessed on
03/09/2020).
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CHAPTER 2: DISCOVERY AND CHARACTERIZATION OF DUAL INHIBITORS OF
TAF1 BROMODOMAIN AND ATR KINASE

ABSTRACT

Bromodomain-containing proteins regulate chromatin remodeling and gene transcription
through the recognition of acetylated lysines on histones and other proteins. Bromodomaincontaining protein TAF1, a subunit of general transcription factor TFIID, initiates preinitiation
complex (PIC) formation and cellular transcription. Therefore, TAF1 is a promising target to
develop small molecule inhibitors for the treatment of diseases arising from dysregulated
transcription such as cancer. Here we report the discovery of a dual bromodomain-kinase inhibitor
AZD6738, currently in clinical trial phase I/II as an ATR inhibitor, that binds to the second
bromodomain of TAF1 and shows promising selectivity within the BRD family. High resolution
crystal structures and small angle X-ray scattering (SAXS) derived solution structures of
unliganded BRDs and inhibitor bound complexes revealed that AZD6738 induces large
conformational changes in TAF1 tandem bromodomain leading to the spatial reorientation of the
two bromodomains. Parallel investigation with a known TAF1 inhibitor BAY299 also indicated
large conformational changes upon ligand binding as well as ligand-induced dimerization of the
TAF1 tandem bromodomain. Using the TAF1 inhibitors as chemical probes we showed that BRD
inhibition of TAF1 activates p53 mediated DNA damage response pathway and prevents cancer
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cell growth in a p53 dependent manner. Combined, our study provides a structural framework for
effective TAF1 inhibition to invoke p53 mediated DNA damage signaling in cancer.

INTRODUCTION

Non-BET BRD-containing protein TAF1 (TATA-binding protein associated factor 1) is
the largest subunit of general transcription factor TFIID. TAF1 initiates the formation of preinitiation complex (PIC) for transcription by recognizing the core promoter elements of target
genes.1, 2 In a genomic landscape study, TAF1 has been found to be significantly mutated in uterine
serous carcinoma,3, 4 and TAF1 overexpression has been described as a major factor for the high
mitotic activity in solid tumors.5 Recently, acetyl-lysine recognition function of the bromodomains
of TAF1 has been implicated in AML1-ETO (AE) fusion protein causing acute myeloid leukemia
(AML), a common type of AML occurring from chromosomal translocation (t(8;21)(q22;q22)). 6,
7

Full-length TAF1 protein contains several domains – a TBP (TATA-binding protein)
binding domain, an N-terminal putative kinase domain (KD 1), a domain of unidentified function
(DUF3591), a pseudo-histone acetyltransferase (HAT) domain, a winged-helix (WH) domain, a
zinc knuckle motif (Zf), a tandem bromodomain (BD1 and BD2) and a C-terminal putative kinase
domain (KD 2) (Fig. 2.1).8-11 Through the various domains, TAF1 plays a wide range of regulatory
role in transcription. For example, TAF1 N-terminal TBP binding domain (TAF1TAND1/2) can bind
to Myc oncoprotein and assist Myc-driven gene transcription12 whereas TAF1 bromodomains can
directly interact with diacetylated p53 (K373ac and K382ac) to initiate the transcription of p53
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target genes.13 Besides transcription, TAF1 has been reported to activate Mdm2-mediated p53
degradation leading to G1/S cell cycle transition.14-16 Importantly, inactivating mutation of TAF1
activates p53 and leads to cell cycle arrest in a similar manner to ATR (Ataxia telangiectasia and
Rad3-related protein)-mediated DNA damage response.17
Although deregulation of gene transcription and evolving plasticity are the underlying
cause of ever-increasing drug resistance in cancer, TAF1 remains an underexplored target for the
development of drugs aimed at uncontrolled gene transcription. Studying the functions of TAF1
remained challenging in part due to its complex role in general transcription and overlapping
functions of its multiple putative domains.18-20

Recent advancements in chemical biology and

drug development indicate that targeting the basal transcription machinery and PIC are viable
means to develop promising new drugs (Fig. 2.2).21-25 However, none of the current approaches
addressed the targeted inhibition of TAF1.
Functionally well-validated and structurally characterized domains of a target protein
provide critical impetus for structure-based drug discovery approach. Although TAF1 has a
number of defined and putative domains, only the HAT domain, and tandem bromodomains
(TAF1-T) have been structurally characterized (Fig. 2.1). However, HAT domain of TAF1 is a
pseudo-HAT as it does not share the common architectures found in the other HAT family
members and requires association with TAF7 (Transcription initiation factor TFIID subunit 7) as
an essential structural component (Fig. 2.3).26 Moreover, TAF1 HAT domain is devoid of a
binding pocket, and contains a number of charged residues (Arg864, Arg875 and Lys818) in the
DNA binding winged-helix (WH) domain (Fig. 2.3, Fig. 2.1B). Therefore, the pseudo-HAT
domain of TAF1 is most likely undruggable by small molecules.27 Importantly, among the two
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structurally characterized domains of TAF1, only bromodomains have been proven to be tractable
by small molecule inhibitors.28, 29
Few bromodomain inhibitors of TAF1 have been reported to date, which includes
BAY299, GNE-371 and bromosporine as the most potent ones.29-31 GNE-371 has been reported
as a selective TAF1 BRD inhibitor, whereas BAY-299 is a TAF1 and BRPF2 BRD inhibitor with
8-fold selectivity for TAF1, and bromosporine (BSP) is a pan BRD inhibitor rendering it to be not
useful.29 Activity of the two potent and selective TAF1 BRD inhibitors against cancer cell lines
was weak or not reported, but antiproliferative synergy with the BET inhibitor JQ1 was
demonstrated.30, 31 No TAF1 inhibitor has reached the clinic, and biological effects of inhibiting
the bromodomains of TAF1 have not been reported yet. However, the mechanistic effect of
bromodomain inhibition of TAF1 in cellular processes or cancer relevant pathways are yet to be
understood. Previously, it was shown that TAF1 regulates cell cycle processes, particularly cyclin
A and D1 gene expression, Rb phosphorylation and p21/p27 expression.32, 33 Importantly, recent
studies reported that TAF1 plays important roles in DNA damage repair and p53 pathways
involving direct interaction with acetylated p53 and activation of DNA damage response kinase
ATR .13, 17, 34 However, particular role of the bromodomains of TAF1 in cell cycle regulation, DNA
damage response or p53 pathways are not known.
In this study, screening a commercially available kinase inhibitor library against the tandem
bromodomain of TAF1 we have discovered that AZD6738, a methylmorpholine containing kinase
inhibitor, selectively inhibits the second bromodomain (BD2) of TAF1. Using X-ray
crystallography, small-angle X-ray scattering (SAXS) and a cascade of biophysical and
biochemical binding assays, we have characterized the binding of methylmorpholine containing
several kinase inhibitors along with a known BRD inhibitor to the BRDs of TAF1. Additionally,
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we have utilized these small molecule inhibitors as chemical tools in cancer cell line models to
advance our understanding of the function of non-BET BRDs of TAF1 particularly in p53
mediated DNA damage response pathway.

RESULTS

Establishment of differential scanning fluorimetry (DSF)
DSF is based on the biophysical phenomenon that globular proteins are stabilized upon
ligand binding to the native state, which is dictated by the energetic state of ligand-protein complex
and protein-melting characteristics.35, 36 This phenomenon results in a ligand-dependent shift of
the melting curve of an unliganded globular protein towards higher temperature. The difference
between the mid-points of unliganded and liganded melt curves, designated as thermal shift
(ΔTm), is proportional to the binding affinity (dissociation constant, Kd) of the ligand.37-39 In DSF,
an environmentally sensitive dye (e.g. Sypro Orange) is used as a reporter. Due to the presence of
acetyl lysine binding pocket in the globular domain,40, 41 bromodomains are amenable to DSF.40,
42-46

For the last few years, our lab has been routinely using DSF to identify bromodomain and

extra-terminal domain (BET) inhibitors.47 In preliminary DSF experiments, Bromosporine (BSP),
a pan-bromodomain inhibitor reported as potent TAF1-2 binder and moderate TAF1-1 (first
bromodomain) binder, 29 was used as a positive control. BSP showed ΔTm of 8.6 °C and 4.2 °C
against TAF1-T and TAF1-2, respectively (Fig. 2.4A). Dose response DSF of BSP against TAF1T and TAF1-2 also showed assay sensitivity to ligand-induced stabilization of the bromodomains
of TAF1 (Fig. 2.4B). DSF melt curve for BSP against TAF1-T exhibits two transitions, which is

31

expected as the ~ 31 kDa (molecular mass) TAF1-T construct contains two bromodomains (BD1
and BD2).48 ITC experiment with BSP validated binding to TAF1-T (discussed later). In an
objective to screen small molecule compound libraries, the DSF assay was designed for 384-well
format (Fig. 2.5) and assay robustness was assessed before screening the compound library.
Robustness of the DSF assay was analyzed from the conducted experiment in 384-well
format using 100 μM BSP as positive control and 4 μM of TAF1-T. Signal to noise ratio was high
(S/N = 39.3) with low signal to background ratio (S/B = 1.2) and the calculated coefficient of
variation for all the tested conditions was below 1% ( < 0.5% for optimized condition) (Fig. 2.6).
The assay Z′-factor was 0.85 as calculated for day to day and plate to plate variation using
published analysis method.49 The high Z′-factor, high S/N ratio and excellent signal window (=
37.2) of the control compound gave us confidence that our DSF assay is robust, reproducible and
will be able to detect molecules with a wide range of binding potential.

Discovery of dual TAF1 BRD-kinase inhibitors
TAF1 was reported to be an essential subunit of TFIID and is not considered as an
oncogene. Moreover, recent studies suggest that chemical inhibition of the BRDs of TAF1 alone
is insufficient to prevent cancer cell growth.30 Therefore, we focused our attention to identify small
molecule inhibitors that can inhibit TAF1 and a kinase with the potential to produce synthetic
lethal effect. Crystallization-grade TAF1-T was screened against a library of 418 kinase inhibitors
using DSF. From the screen, two hit compounds – AZD6738, a potent ATR kinase inhibitor that
is in clinical trials,50-52 and BI2536, a potent PLK1 kinase inhibitor, were identified (Fig. 2.7 A-B,
Table 2.1). AZ20, a close analog of AZD6738 and an ATR/mTOR inhibitor,53 was identified in
the library and included for further studies. Both hit compounds were assessed against TAF1-2 by
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DSF and were found to be potential binders. Among the two hits, AZD6738 was the most
promising as it showed thermal shift (ΔTm = 3 - 3.2 °C) for both the TAF1-T and TAF1-2. BI2536
showed small thermal shift (ΔTm = 1.2 – 1.7 °C) for both TAF1-T and TAF1-2 (Fig. 2.7 A-B,
Table 2.1) indicating weak binding potential for TAF1. However, BI2536 was previously reported
as potent inhibitor of BETs 54-56 and, therefore, was not the focus of our study. Follow-up studies
using dose response DSF (Supplementary Fig. S2.2), and direct binding studies by isothermal
titration calorimetry (ITC) and microscale thermophoresis (MST) confirmed that AZD6738 binds
to the TAF1-T/2 with a Kd of 1.7 – 2.8 μM (Fig. 2.7C, Table 2.1 ). Unbiased binding affinity was
also determined for AZD6738 against TAF1-2 by AlphaScreen (by Reaction Biology) and pPCRbased competitive binding assay (BromoScan, by DiscoverX). Both the AlphaScreen IC50 (= 427
nM) and BromoScan Kd (= 175 nM) values showed higher binding affinity compared to the Kd
values determined by ITC and MST (Table 2.1, Supplementary Fig. S2.2). The discrepancy in
binding affinity is presumably due to differences in the assay methodology and the use of different
protein preparations. However, ITC and MST experiments were conducted with crystallization
grade proteins prepared in a uniform buffer condition. Profiling of AZD6738 across a panel of 32
bromodomains by DiscoverX revealed high selectivity for the second bromodomain of TAF1 and
TAF1L (Fig. 2.7D). Five other bromodomains (BRD2-2, BRD3-2, BRD4-2, CECR2 and WDR92) also weakly interacted with AZD6738 (Supplementary Table S2.1).

Two analogs of

AZD6738 – ATR inhibitor AZ20,53 identified from the screen library compounds, and mTOR
inhibitor AZD3147 (Supplementary Fig. S2.1), identified through literature search,57 showed
weak binding potential for TAF1 (Table 2.1) and therefore, were included for further structure
activity relationship (SAR) studies. ATR, ATM and mTOR, the target kinases of the AZD6738,
AZ20 and AZD3147 are considered PI3K-like kinases (PI3KKs).58
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Structural basis of dual TAF1-kinase inhibitor binding to the second bromodomain of TAF1
To elucidate the detailed binding mode of the identified kinase inhibitors to TAF1, we
performed crystallographic studies with two TAF1 constructs, TAF1-2 consisting of BD2 only and
TAF1-T encompassing BD1 and BD2. Compounds AZD6738, AZ20, BI2536 and AZD3147 were
subjected to co-crystallization screening campaigns, and conditions were established that allowed
for the growth of X-ray grade crystals. High resolution co-crystal structures of TAF1-2 determined
between 1.6 and 2.5 Å resolution revealed that AZD6738, its analogue AZ20 and BI2536 bind to
the KAc site of BD2 (Fig. 2.8A-C). All three compounds establish hydrogen bonding (H-bonding)
interactions with the highly conserved Asn1583. (R)-methyl-morpholino warhead of AZD6738
and AZ20 occupies the KAc binding site of TAF1-2 where morpholine oxygen mediates direct Hbonding interaction with the conserved Asn1583 side chain (Fig. 2.8A,B left panel). Comparison
between AZD6738 and AZ20 showed a highly similar binding pattern except for the sulfoximine
group of AZD6738, which establishes two H-bonds at the opposite end of the KAc site with the
main chain amide nitrogen of Asn1533 and the carbonyl oxygen of Pro1531 (Fig. 2.8A, B). These
differences in H-bonding potential explain the considerably weaker binding activity of AZ20 than
AZD6738. However, binding mode of BI2536 to the TAF1-2 KAc binding site is slightly different
(Fig. 2.8C). Although the dihydropteridinone oxygen of BI2536 directly interacts with the side
chain of conserved asparagine (Asn1583) through direct H-bond interaction, it loses significant
interactions with the hydrophobic flank opposite to the WPF (Tryp1526-Pro1527-Phe1528) shelf
allowing the Phe1536 containing ZA loop to move away (Fig. 2.8C, E-iii and F ) . BI2536 remains
stabilized in the binding site through vdW interactions with the WPF shelf and Tyr1589, though it
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cannot access the ZA channel Asn1533 or Pro1531 for H-bonding while the N-methylpiperidine
group of the compound remains solvent exposed.
For comprehensive structural studies, we have also determined the co-crystal structure of
TAF1-2 complexed with the potent inhibitor BSP. BSP shows canonical binding mode in the KAc
site (Fig. 2.8D). Pyrazolopyridazine nitrogen and acetamide oxygen of BSP interacts with the
conserved Asn1583 through two H-bonds, whereas sulfonamide group interacts with the main
chain of asparagine (Asn1533) of ZA loop on the other side of the pocket via an additional Hbond. These H-bond interactions at the two ends of the KAc binding site, and pyrazolopyridazine
ring mediated vdW interactions with WPF shelf (Trp1526-Pro1527-Phe1528) and hydrophobic
flank residues (Val1532-Asn1533-Phe1536-Val1537) of ZA loop stabilize the compound very
well in the narrow KAc binding pocket. To better understand the differences in binding potency
between BSP, AZD6738 and BI2536, we compared the compound binding mode of these three
inhibitors overlaying with unliganded TAF1-2 (PDB:3UV4). Binding of BSP did not cause
perturbation of the protein main chain surrounding the KAc site (Fig. 2.8E-i), and only lead to
conformational changes in the side chains of bulky residues Trp1526, Phe1536 and Tyr1589, most
likely favoring induced fit of BSP in the binding site. In contrast, binding of AZD6738 (Fig. 2.8Eii), results in widening of the binding pocket due to the shifting away of hydrophobic flank in the
ZA loop and movement of the WPF shelf main chain, in addition to the vdW-favorable side chain
conformation of Tyr1589. Whereas, in BI2536 bound structure of TAF1-2 (Fig. 2.8E-iii),
movement of ZA loop hydrophobic flank is more prominent, which makes the binding site
unusually wide and results in weak binding interactions. These structural comparison indicate that
TAF1-2 KAc binding site can tolerate ligand induced perturbation in the flexible hydrophobic
flank of ZA loop, but most likely comes with an unfavorable binding pose. For AZD6738, this
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unfavorable binding is compensated by additional H-bond interactions with the ZA loop residues
(Asn1533 and Pro1531) and vdW-favorable conformations of WPF shelf as well as Tyr1589.
However, similar compensatory mechanism is not observed for BI2536 and therefore, BI2536
binding to TAF1-2 is weaker than AZD6738.
Currently, it is hypothesized that first bromodomain of TAF1 (TAF1-1) is less druggable
than the second one (TAF1-2) 59. There is no potent TAF1-1 inhibitor reported so far. Potent TAF12 inhibitors BSP and BAY299,31 only weakly bind to the TAF1-1 with a Kd of 5.5 μM (by Picaud
et al, 201629) and 4.5 μM (Fig. 2.13), respectively. Newly identified dual BRD-kinase inhibitor
AZD6738 did not show any binding potential for TAF1-1 as assessed by DSF and ITC (data not
shown). Sequence analysis show that sequence homology between the two BRDs of TAF1 (~ 45%
sequence identity and ~ 68% sequence similarity) is relatively low (Supplementary Fig. S2.3) for
the same bromodomain family members. A similar phenomenon was observed in BETs where
sequence homology between the tandem BRDs within a BET protein is lower (36 – 43 % sequence
identity) compared to other BRDs of the same bromodomain family (65 – 74 % sequence identity).
However, structural comparison of the TAF1-1, extracted from unliganded TAF1-T crystal
structure determined in this study, and AZD6738 bound TAF1-2 indicates overall structural
similarity (r.m.s.d. = 0.52) and high structural conservation surrounding the KAc binding sites
(Fig. 2.8G). Importantly, five different residues are in the vicinity of the ligand binding pocket
including the Tyr1403BD1 for Trp1526BD2 of WPF shelf, Val1413BD1 for Phe1536BD2 of the
hydrophobic flank, and Leu1466 BD1 for critical Tyr1589BD2. All three residues show significant
contribution in AZD6738 binding to TAF1-2 through several vdW interactions. Therefore, these
differences in the vicinity of TAF1-1 ligand binding site might explain the difficulty in finding a
high affinity ligand of TAF1-1.
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Methylmorpholine containing PI3KK kinase inhibitors are bona fide binders of TAF1
Previous studies have reported four different conformations of TAF1-T determined from
crystal structures in unliganded states 60, 61 bivalent inhibitor bound state62 and as a complex with
histone chaperone CIA/ASF163 (Supplementary Fig. S2.4). These four conformations indicate
that tandem BRDs of TAF1 connected through a five residue long structured loop, shortest among
all tandem BRD-containing proteins, remain in multiple conformations separated by a small
energy difference. Nevertheless, whether these conformational states are few of the various
allowed low energy conformational states or influenced by ligand binding is not known. To explore
the possibility of ligand binding effect on the conformation of tandem bromodomain, we
determined co-crystal structures of TAF1-T with 3-methyl-morpholine warhead-containing three
PI3KK inhibitors: AZD6738, AZ20 and AZD3147 (Fig. 2.9). All three inhibitors bind only to the
BD2 of TAF1-T. Binding mode of AZD6738 and AZ20 to the TAF1-TBD2 is near identical to that
of TAF1-2 (Fig. 2.9 A-B and Fig. 2.8 A-B) except that Tyr1582TAF1-T(BD2) interacts with the
methyl group of 3-methyl-morpholine warhead inside the pocket through vdW interactions. The
sulfonyl group of AZ20 and AZD3147 (Fig. 2.9B-C) establish only a single H-bond with Asn1533,
while the other sulfonyl oxygen is incapable of direct interaction with Pro1531, and in fact shifts
away but being stabilized by a water mediated H-bond with the main chain amide oxygen of
Pro1531. In AZD3147, opposite stereochemistry of the methylmorpholino moiety and an
additional cyclopropyl group connected to sulfone results in a loss of shape complementarity with
the KAc site of BD2 (Fig. 2.9C). As a result, inhibitor binding is accompanied by substantial
structural changes, particularly of residues Tyr1589 and Phe1536. Comparison of the ligand
positioning in the KAc site of TAF1-TBD2 illustrates that methylmorpholine core of the PI3KK
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inhibitors mediates a H-bond interaction with the side chain of conserved Asn1583BD2 on one side
of the binding pocket and a second H-bond interaction with the main chain of Asn1533BD2 on the
other side (Fig. 2.9D). Thus, the core scaffold occupies the binding pocket and remains stable, and
additional H-bonding interactions, e.g. sulfoximine of AZD6738 with Pro1531, along with
hydrophobic interactions by other functional groups, e.g. cyclopropyl of AZD3147 with Phe1536,
increase the binding potential of the ligands. We have also acquired a 1.7 Å resolution co-crystal
structure of TAF1-2 /1,4-dioxane complex revealing that 1,4-dioxane binds to the KAc site of
TAF1-2 in a canonical manner similar to the morpholino group of AZD6738 (Supplementary
Fig. S2.5). Since 1,4-dioxane is a low molecular weight solvent, we attempted to determine the
possible binding of this compound in BET BRDs but did not yield any bound crystals.
Interestingly, 1,4-dioxane (116.9 mM) showed a thermal shift (∆Tm) of 2.3 °C for TAF1-2 (Table
2.1) but not for BRD4 (data not shown). This also signifies that binding interactions of morpholino
ring or similar dioxane ring are most likely specific for the KAc site of TAF1-2.
Comparison of the binding pattern of AZD6738 in TAF1-TBD2 and that of a close analogue
(PI3K inhibitor) in a mutant PI3Kα kinase domain mimicking ATR64 (Fig. 2.9 E,F) shows that the
methylmorpholine group is critical for binding to the hinge region of the ATP site and to the
conserved asparagine in the KAc site. The pyrrolopyridine group of AZD6738 is solvent exposed
in TAF1 (Fig. 2.9F) while this group interacts with the ATP site residues in the kinase domain of
PI3Kα as well as ATR (Fig. 2.9E). The sulfoximine group is most likely critical for binding to
the KAc site (Fig. 2.9F) while it is partly exposed to solvent in ATR (Fig. 2.9E).
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Inhibitor binding to the TAF1-T stabilizes certain conformations
Comparison of the unliganded and ligand bound structures of TAF1-T determined at 1.50
– 2.25 Å resolution revealed global conformational changes of TAF1-T resulting in distinct “open”
and “closed” states (Fig. 2.10). The complexes of TAF1-T with AZD6738 as well as AZ20 are
the most compact structures, stabilized through inter-domain contacts between the one flank of
BD2 (residues 1533-1535) and the residues of BD1 (residues 1418, 1421 and 1458) (Fig. 2.10-iii),
and through surface interactions between the Zα helix (residues 1558-1559) of BD2 and Bα helix
(residues 1443 and 1447) of BD1. The complex of TAF1-T with AZD3147 exists as a “semiclosed state” (Fig. 2.10-ii). The structural changes appear to be mediated through the linker region
connecting the BD1 and BD2, including a peptide flip around residues 1496 - 1498 (Fig. 2.10-i).
Combined, these findings support inhibitor-induced open-closed transitions in TAF1-T, albeit the
molecular trigger for these changes is not clear yet.
To understand the difference between the ligand bound “closed” conformation (in this
study) and the published “unliganded-closed” conformation,61 we analyzed the two structures in
details (Fig. 2.11). In published “unliganded-closed” conformation, few residues of BD1 loop
region and helix surface (Tyr1418 and Glu1447) interact with the BD2 residues (Lys1534,
Lys1555 and Lys1559) (Fig. 2.11B). However, residues in the N-term flexible loop (residues
1359-1376) outside the BD1 domain mediate additional H-bonds with the C-term residues of BD2.
Notably, the disulfide bridge between the Cys1364 of the extended N-terminus and Cys1619BD2
of the C-terminus most likely imposes an artificial restrain for the BD1 and BD2 to remain in a
“locked” state (Fig. 2.11B), which is not comparable with the structures determined in our study
using reducing agents consistent with in vivo conditions.
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Characterization of inhibitor binding to TAF1-T in solution by SEC-SAXS
To interrogate the conformational changes in solution upon ligand binding, we used SAXS
(small-angle X-ray scattering). SAXS is a uniquely suited structural technique to experimentally
investigate conformational states of macromolecules in solution through the quantitative measure
of radius of gyration and particle shape.

65, 66

Our initial SAXS experiments conducted in batch

mode (data not shown) suffered from concentration dependent aggregation propensity. Therefore,
we employed size exclusion column coupled with SAXS (SEC-SAXS). In-line SEC and coflow
method at the APS Bio-CAT (beamline 18-ID-BIO) ensure X-ray data collection of homogenous
sample devoid of radiation damage 67, 68. Using SEC-SAXS, we have studied TAF1-T alone and
in presence of AZD6738 and BAY299. Experiments with AZD3147 or bromosporine were not
conducted because of poor aqueous solubility in the SAXS buffer (see methods for details).
Consistent measurements of macromolecule parameters across the conducted SEC-SAXS data
collection frames indicated homogenous population (Supplementary Fig. S2.6).
SEC elution profiles of the three samples (TAF1-T in the absence and presence of
AZD6738 and BAY299) show that unliganded TAF1-T and TAF-T complexed with AZD6738
elute as a monomer whereas BAY299 appears to induce dimerization (Fig. 2.12A). SAXS
scattering profile show that in presence of AZD6738 X-ray scattering slightly differs from that of
protein alone, particularly at high q region, which indicates potential conformational changes in
macromolecules due to the presence of AZD6738 (Fig. 2.12B, Supplementary Fig. S2.7).
However, scattering profile of the protein in presence of BAY299 is significantly different
indicating large changes in macromolecule characteristics. For TAF1-T protein in solution, radius
of gyration (Rg), maximum intraparticle distance (Dmax) and estimated molecular mass (volume
of correlation, Vc / Porod’s volume, Vp) were 25.7 Å, ~ 83 Å and 34.9 / 41.2 kDa, respectively
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(Fig. 2.12C-E, Supplementary Fig. S2.6). In presence of AZD6738, all the macromolecule
parameters decreased (Rg = 23.1 Å, Dmax = ~ 74 Å and Vc / Vp = 29.3 / 36.7 kDa). Importantly,
changes in the peak characteristics and pair distance distribution function (P(r)) of
protein/AZD6738 complex compared to protein alone indicate a more compact conformation (Fig.
2.12D). Whereas, in the presence of BAY299 all the macromolecule parameters increased
significantly (Rg = 35.9 Å, Dmax = ~ 125 Å and Vc / Vp = 47.9 / 64.6 kDa), indicating
dimerization. Combined, the linear Guinier plots (Fig. 2.12C), consistency of the changes in Rg,
Dmax, differences in molecular masses from one sample to another (Fig. 2.12E) and globular
characteristics from Kratky plot (Supplementary Fig. S2.7D) indicate conformational differences
between unliganded TAF1-T and in complex with AZD6738 or BAY299. Notably, significant
increase of Rg, Dmax and molecular mass (Fig. 2.12C-E) in the presence of BAY299 corroborates
the observed dimerization of TAF1-T in SEC (Fig. 2.12A).
Ab initio low-resolution envelope of TAF1-T and TAF1-T/inhibitor complexes were
reconstructed from the scattering data using DENSS69 (Fig. 2.12F-H, Supplementary Fig. S2.8A)
as well as DAMMIN70 (Supplementary Fig. S2.8B). Models were built using ab initio envelope
and rigid body fitting (see methods for details) of two bromodomains (BD1 and BD2) for TAF1T, TAF1-T/AZD6738 complex and TAF1-T/BAY299 complex. The resulting model of
unliganded TAF1-T indicates a “twisted” conformation (Fig. 2.12F) unlike those found in any
crystal structures. In this “twisted” conformation, KAc binding sites of the two domains are
positioned far from each other and oriented in an opposite direction. Built model of TAF1T/AZD6738 complex in solution shows two domains of TAF1-T reorient the two KAc sites to face
each other (Fig. 2.12G). This is similar but not identical to the “semi-closed” conformation
observed for AZD3147 (Fig. 2.10). Interestingly, the model generated for TAF1-T/BAY299
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complex suggests dimerization into a larger complex. The large envelope of TAF1-T/BAY299 can
accommodate two molecules of TAF1-T, a “closed” conformation protomer and an apo solution
“twisted” conformation protomer (Fig. 2.12H). However, how the BAY299 induces this
dimerization of TAF1-T in solution could not be deduced from the low-resolution SAXS data.
Unfortunately, BAY299 resisted our extensive co-crystallization attempts with TAF1-T.

Characterization of inhibitor binding interactions with TAF1 by ITC
To investigate the interaction stoichiometry of BAY299 with TAF1-T, we conducted the
ITC experiments on BAY299 with individual BRDs (BD1 and BD2) as well as TAF1-T and
analyzed the thermodynamic parameters derived from ITC. BAY299 binds to BD1 and BD2 with
a Kd of 4.5 μM and 47 nM with an apparent stoichiometry of 1.3 and 0.96, respectively (Fig.
2.13A). However, ITC thermogram of BAY299 interaction with TAF1-T shows a biphasic binding
curve where the first phase of high affinity binding (Kd1 = 9.3 nM) has an approximate
stoichiometry of N = ~3 and the second phase of weak affinity binding (Kd2 = 2.1 μM) has an
approximate stoichiometry of N = ~1. Previously, it has been reported that pan-BRD inhibitor BSP
bind to the both BRDs of TAF1 (Kd = ~ 17 nM for TAF1-2 and Kd = ~ 5 μM for TAF1-1)29.
Therefore, we also conducted ITC for BSP interaction with TAF1-T to investigate whether it also
shows biphasic binding interaction. In ITC experiment, BSP binds to the TAF1-T with Kd of 147
nM and an apparent stoichiometry of N = 1.1 (Fig. 2.13B). Thermodynamic signature analysis
from the ITC data indicates that first phase of the biphasic binding of BAY299(1) is almost
exclusively enthalpy driven and the second phase of the biphasic binding of BAY299(2) is almost
exclusively entropy driven (Fig. 2.13C). In case of binding to the individual bromodomains,
BAY299 binding to TAF1-2 is enthalpy driven and entropically disfavored, and binding to TAF1-
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1 is both enthalpy and entropy contributed. In case of BSP, binding to the TAF1-T comes with a
large entropic unfavourability whereas binding to the TAF1-2 is largely enthalpy driven. For
AZD6738 binding to the TAF1-T and TAF1-2 is both enthalpy-driven, and entropy-assisted,
similar to each other which is expected as it only interacts with the BD2.

Inhibition of TAF1 bromodomain activates p53 and induces DNA damage signaling
Previously, it was demonstrated that at non-permissive temperature TAF1 point mutation
in ts13 cells activates ATR kinase mediated p53 phosphorylation at Ser15 and leads to cell cycle
arrest.17 Therefore, to test the cellular effects of TAF1 bromodomain inhibition, A549 lung tumor
cells were treated with inhibitors for 24 hours and analyzed for p53 pathway markers by western
blot (Fig. 2.14A). The most potent TAF1 inhibitor BAY299 strongly induced p53 and p21 to the
levels similar to those caused by the MDM2 inhibitor Nutlin. AZD6738 also induced modest p53
and p21 increase, consistent with its moderate inhibition of TAF1. Whereas ATR inhibitor AZ20
with weak TAF1 activity did not seem to induce p53 or p21. To determine whether p21 induction
was mediated by p53, HCT116 colon cancer cells with and without p53 were tested for response
to inhibitor (Fig. 2.14B). TAF1 inhibition did not induce p21 in the absence of p53, demonstrating
that p53 activation mediates the induction of p21.
p53 is activated by several mechanisms including DNA damage signaling, ribosomal
stress, and oncogenic stress. TAF1 inhibition caused down regulation of MDMX, which is
suggestive of DNA damage signaling 71. Analysis of DNA damage response (DDR) marker pSer15
level in p53 showed strong induction of Ser15 phosphorylation after TAF1 inhibitor treatment,
similar to the effect of ɣ-radiation (Fig. 2.14C). Furthermore, TAF1 inhibitors did not synergize
with radiation in inducing p53 and p21, suggesting that the two treatments act through similar
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mechanism. Treatment with TAF1 inhibitors caused cell death in A549 cells, and further
synergized with the MDM2 inhibitor Nutlin (Fig. 2.14D). These data suggest that TAF1
bromodomain is involved in DNA damage sensing or repair. Inhibition of TAF1 activates DNA
damage signaling, which in turn activates p53. However, these results do not rule out that TAF1
inhibition can directly affect its binding and phosphorylation of p53.
Anti-proliferative activity of TAF1 inhibitors (TAFi) were determined in A549 lung cancer
cells and HEK293T cells (Fig. 2.14E). In A549 cancer cells, AZ20 is the most active (IC50 = 0.65
μM) among the three TAF1i, followed by BAY299 (IC50 = 0.86 μM) and AZD6738 (IC50 = 2 μM).
In HEK29T cells, AZ20 is also the most active (IC50 = 0.85 μM) among the three TAF1i, but
followed by AZD6738 (IC50 = 1.2 μM) and BAY299 (IC50 = 1.4 μM). Potent PLK1i BI2536 and
ATRi BAY1895344 worked as positive control as they were reported to have potent activity in
various cell lines.72, 73 Notably, HEK293T cells, in which p53 gene is mutated, are less sensitive
to TAF1i BAY299 compared to A549 cells.

Structure-activity relationship studies of dual TAF1 BRD-PI3KK kinase inhibitors
A series of 3(R)-methyl-morpholine ring-containing AZD6738 derivatives were
synthesized by the Lopchuk lab at Moffitt Cancer Center for SAR studies against TAF1 and
ATR/ATM. Among all the derivatives, triazine ring-containing TS1-299 and TS1-252 maintained
the comparable ATR inhibitory activity while the modification abolished the ATM inhibitory
properties making them selective ATR inhibitors over ATM (Fig. 2.15A, B). However, attempted
modification of AZD6738, as seen with all other derivatives, significantly reduced the binding
potential for TAF1 as assessed by DSF (Supplementary Table S2.2). Only TS1-252 showed
moderate binding potential (ΔTm = 1.0 °C) while ZS1-040 (ΔTm = 0.5 °C) showed some binding
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potential above the experimental error of margin (ΔTm ≥ 0.5 °C). Notably, ZS1-024, a racemic
mixture of AZD6738, significantly loses the binding potential showing only ΔTm = 0.9 °C. This
indicates that binding of AZD6738 in the KAc site of TAF1 is very sensitive to ligand shape and
conformation.
To understand the effect of modification of core pyrimidine with a triazine ring in the
starting compound, we have determined the co-crystal structures of TAF1-2 complexed with TS1299 and TS1-252. Both the TS1-299 and TS1-252 bind to the KAc site very similar to the
AZD6738 except that TS1-299 is unable to interact with ZA channel residue Pro1531 through Hbonding and sulfonamide group of TS1-252 interacts with the His1530 through additional two Hbonds (Fig. 2.15B). However, weak binding potential of both the compounds indicate that
electronics of triazine core is not favorable for strong binding to the KAc site of TAF1.

DISCUSSION

Although dysregulated gene transcription is a major contributing factor in cancer, general
transcription machineries and the proteins involved in basal transcription mostly remained elusive
target to develop targeted cancer therapeutics. A major challenge in the drug development
targeting the general transcription is identification of a suitable protein while ensuring that target
protein inhibition translates into specific cellular effect without toxicity. Earlier studies have
reported that TAF1, the largest subunit of TFIID, can be potently inhibited by small molecule
inhibitors via bromodomain. However, TAF1 inhibition alone in cancer cells did not show any
cellular effect, but showed synergistic effect with BRD4 inhibition. At this stage, the mechanistic
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understanding of cellular effect from TAF1 inhibition is missing. In this study, we report the
discovery of first dual TAF1-ATR inhibitor. Using various biophysical methods, we show that
inhibitor binding to the BRD of TAF1 induces large conformational changes in the tandem
bromodomain.
Characterization of these large conformational changes was conducted by SEC-SAXS,
which provides global shape of the macromolecules at 23 – 37 Å resolution. Inherently, SAXS
method is highly sensitive to protein aggregation. Therefore, to avoid protein aggregation
propensity and ensure ligand saturation, protein sample was loaded at 6 mg/mL (< 200 μM ) in
SEC-SAXS experiment for estimated maximum concentration of 50 μM in the elutes. SAXS
scattering profile, radius of gyration (Rg) from Guinier analysis and the Pair distance distribution
function P(r) (Fig. 2.12B-D, Supplementary Fig. S2.7) show that presence of AZD6738 reduces
the size and alters the shape of TAF1-T/AZD6738 complex in solution whereas presence of the
BAY299 significantly increases the size of TAF1-T/BAY299 complex in solution, which is
congruent with SEC profile. For ab initio shape reconstruction from the SAXS data, we used both
the newly developed program DENSS and well-known program DAMMIN to check the bias of
certain algorithm, and the reconstructed ab initio electron density maps by DENSS and ab initio
bead model by DAMMIN matches with each other (Supplementary Fig. S2.8). Rigid body model
building with the individual BRDs using phenix.dock_in_map or Chimera map fitting produced a
new “twisted” conformation for unliganded TAF1-T in solution and an unique dimeric state for
TAF1-T/BAY299 complex. Although BAY299 binding-induced TAF1-T dimerization is
confirmed by SEC chromatogram profile and a general understanding of the dimer shape can be
achieved, at this resolution the protomer contacts cannot be deduced from the SAXS model. Most
likely due to this dimerization, ITC thermogram of BAY299 with TAF1-T results in a distinct
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biphasic binding curve. This biphasic binding interactions and change in heat capacity were
consistent across various titrant concentrations (not shown), which eliminates the possibility of
aggregation effect during titration. Moreover, the biphasic interaction characteristics (with two
stoichiometry, N1 = ~3 and N2 = ~1) and thermodynamic signatures of BAY299 with TAF1-T are
different from that of AZD6738 and BSP, thus suggesting a distinct binding mode of BAY299
with TAF1-T. It is possible that fused-ring of benzo[de]isoquinoline containing BAY299
(Supplementary Fig. S2.1) can place itself in between the two molecules of TAF1-T to stabilize
the dimeric state. In that case, first phase of BAY299 binding interaction with stoichiometry N =
~3 can be attributed to a combined effect from saturation binding to the BD2, weak unsaturation
binding to the BD1 and saturation binding to a third unknown site perhaps at the interphase of two
molecules of TAF1-T. Similarly, the second phase with stoichiometry N = ~1 can be attributed to
the continuation of weak binding of BAY299 to the BD1 reaching the saturation.
Our structural studies indicate that unliganded TAF-T can remain in an “open” or “twisted”
conformation and certain ligand binding induces the reorientation of two domains to adopt a “semiclosed” and “closed” conformations. It is possible that unliganded protein transitions between the
“open” and “closed” states, and inhibitor binding merely stabilizes a certain conformation for
crystal lattice formation. Importantly, different conformational states of TAF1-T and switching of
the conformational states upon ligand binding could regulate important cellular functions,
particularly nucleosome dynamics and transcription initiation. Previously, it was shown that a
different “semi-closed” conformation of TAF1-T (named double bromodomain, DBD) without
engaging its bromodomains binds to histone chaperone CIA/ASF-1 (Supplementary Fig. S2.4D)
for site specific histone eviction.63 Based on the earlier studies and current advancements in the
understanding of transcription initiation mechanism,1,
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74

it is possible that a “semi-closed”

conformation of TAF1-T in complex with CIA/ASF-1 can bind to acetylated lysine on histone tails
and shuttle histone chaperone CIA/ASF-1 to the histone tetramer complex (H3-H4)2 for
nucleosome remodeling and accessing the initiator/promoter site of target genes. During the
dynamic nucleosome remodeling process TAF1-T might tolerate “semi-closed” to “closed”
conformation to allow binding of TBP, and TFIID complex formation through its NTDs (Nterminal domains), and initiate the PIC formation.27 During the transcription initiation, TFIID
undergoes enormous rearrangement,27 which could lead to TAF1-T “open” or “twisted”
conformation, decoupling of TAF1 from histone and switch TFIID from transcription initiation to
active transcription state.
Our study also shows that TAF1 inhibition triggers p53 activation through Ser15
phosphorylation and intervenes p53 mediated DNA damage signaling pathways. In our parallel
radiation and drug treatment experiment for DDR pathway study (Fig. 2.14C), ATRi treatment
also increases p53 Ser15 phosphorylation nearly equal to the level of radiation treatment. Increased
p53 Ser15 phosphorylation is expected for ionizing radiation, but how ATRi treatment induces the
p53 Ser15 phosphorylation warrants further investigation. Since there are significant cross-talks
among ATM, ATR and DNA-PKcs,58 a possible explanation is that inhibition of ATR by AZ20 or
AZD6738 could activate ATM and DNA-PKcs, which can phosphorylate p53 at Ser15.
In cell proliferation assays, AZD6738 showed weaker antiproliferative potential than AZ20
in both the studied cell lines (A549 and HEK293T). Moreover, both AZD6738 and AZ20 were
weaker anti-proliferative agents compared to the different ATR inhibitor BAY1895344. In
previous studies, AZ20 and AZD6738 were reported as equipotent ATR inhibitors in vitro (Kd =
5 nM vs 4 nM) and in cellulo (IC50 = 61 nM vs 74 nM).75, 76 Our data combined with published
results indicate that TAF1 inhibition might antagonize the effect of ATR inhibition. In an earlier
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study, it was demonstrated that at non-permissive temperature TAF1 point mutation in ts13 cells
activates ATR kinase mediated p53 phosphorylation at Ser15, and leads to G1 cell cycle arrest.17
Additionally, a second line of investigation showed that blockade of active transcription by
deactivating the elongating RNA pol II triggers ATR kinase mediated p53 phosphorylation at
Ser15. 77 Therefore, it is possible that TAF1 and active transcription machinery work as a regulator
for the downstream process of ATR activation in DNA damage response pathway, which could
also explain the observed antagonistic effect of concomitant inhibition of TAF1 and ATR in cellproliferation assays. Combined, the study shows differential cellular effects of TAF1 or ATR
inhibition alone from simultaneous inhibition.

EXPERIMENTAL SECTION

Protein expression and purification
The expression plasmid for human TAF1 (Uniprot ID P21675) 2nd bromodomain (residues
1501-1635) and tandem bromodomain (residues 1373-1635) was from Addgene (plasmid 39117
and 39118, respectively). DNA sequences encoding the human TAF1 1st bromodomain (residues
1373-1499) was cloned in-frame of a modified pET28a vector providing an N-terminal hexahistidine tag followed by a Tobacco Etch Virus (TEV) cleavage site. The encoded bromodomain
proteins were expressed in the BL21 (DE3) strain of E. coli.
Plasmids were transformed into E. coli cells and grown at 37 °C in LB medium (Fisher
Scientific) containing carbenicillin (0.1 mg/mL). At OD600 of 0.6, the culture was cooled down
to 18 °C and induced with 0.1 mM IPTG. After 18 h growth, the culture was harvested by
centrifugation at 6,000 × g for 25 min and stored at -80 °C. Harvested cell pellets were re49

suspended in 50 mM Na/K phosphate buffer (pH 7.4) containing 150 mM NaCl, 40 mM imidazole,
0.01% w/v lysozyme and 0.01% v/v Triton X-100 at 4 °C for 1 h, subjected to sonication and the
lysate was clarified by centrifugation (30,000 × g for 45 min at 4 °C). Proteins were purified by
FPLC at 4 °C using columns and chromatography materials from GE Healthcare. The lysate was
subjected to an immobilized Ni2+ affinity chromatography column equilibrated with 50 mM Na/K
phosphate buffer (pH 7.4) containing 150 mM NaCl and 40 mM imidazole using a gradient from
40 to 500 mM of imidazole. Fractions containing the target protein were combined and incubated
for 2 – 16 h with TEV protease at 4 °C, and the cleaved His6-tag was removed by a second Ni2+
affinity column. BRDs were purified to homogeneity by size exclusion chromatography using
Superdex 75. The elution buffers were 20 mM HEPES/150 mM NaCl/1 mM DTT (pH 7.5) for
TAF1-2, 50 mM HEPES/3000 mM NaCl/1 mM DTT (pH 7.5) for TAF1-1, and 50 mM HEPES/2
mM DTT (pH 7.5) for TAF1-T. BRDs eluted as monomeric proteins and were of crystallization
grade quality (> 95% purity as judged by SDS-PAGE). BRD-containing fractions were combined,
concentrated to 15 - 20 mg/ml and aliquots were flash-frozen in liquid N2 and stored at -80 °C.

Differential scanning fluorimetry (DSF)
Compound library screening and thermal shift determination by DSF was conducted as
described before.78 Briefly, DSF experiments were carried out in Applied Biosystem QuantStudio
6 Flex (compound library screening) and StepOnePlus (thermal shift determination) real-time PCR
system (Thermo Fisher Scientific) using sealed 384-well or 96-well plates, assayed in
quadruplicate.

To obtain robust fluorescence signals, the assay was optimized regarding

concentration of protein (4 μM for screening, 4.5 μM for thermal shift determination) and the
fluorescence dye SYPRO Orange (Invitrogen, Thermo Fisher Scientific) (5.5X for screening and
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5X for thermal shift determination). For library screening, dilutions of compound in assay buffer
(50 mM HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 1% DMSO) were prepared using a Mosquito
liquid dispenser (TTP Labtech Ltd). Protein in assay buffer including fluorescence dye was mixed
with 100 μM compound and 2% DMSO in 20 μL reaction volumes. Reaction mixtures were heated
from 25 °C to 95 °C at 1 °C/min with fluorescence readings every 0.5 °C at 610 nm. The observed
thermal shift (∆Tm) was recorded as the difference between the Tm of sample and DMSO reference
wells.

Isothermal titration calorimetry (ITC)
All experiments were conducted using an ITC200 microcalorimeter from Malvern
Panalytical (Spectris PLC). BRDs were buffer exchanged (Table 2.2) using PD10 columns (GE
life sciences) before the experiments and concentrated to ~ 10 mg/mL. Experiments were carried
out in ITC buffer while stirring at 750 rpm in reverse titration method. The microsyringe (40 μL
load volume) was loaded with a solution of protein sample (250-350 μM protein in ITC buffer)
and was inserted into the calorimetric cell (0.2 ml cell volume), which was filled with the solution
of compounds (20-25 μM in ITC buffer). All titrations were conducted using an initial control
injection of 0.3 μl followed by 25 -38 identical injections (1.52 or 1 μl per injection) with a duration
of 3.04 or 2 sec (per injection) and a spacing of 150 sec between injections. The ratio of titrants in
the titration experiments were optimized to ensure complete saturation of the titrant (protein or
compounds) in cell before the final injection thus facilitating the estimation of baseline for each
injection. Experimental data were corrected by subtracting the heats of dilution determined from
independent titrations. The collected data were analyzed using MicroCal™ Origin software
provided with the ITC instrument to determine the enthalpies of binding (ΔH) and binding
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constants (KB) as previously described (Wiseman et. al)

79.

Thermodynamic parameters were

calculated using the basic equation of thermodynamics (ΔG = ΔH - TΔS = -RTlnKB, where ΔG,
ΔH and ΔS are the changes in free energy, enthalpy and entropy of binding, respectively). In all
cases a single binding site model was used. Dissociation constants and thermodynamic parameters
are shown in Table 2.2.

Microscale thermophoresis (MST)
His6-TAF1 BD2 was labeled using the RED-NHS kit (NanoTemper Technologies)
according to the manufacturer’s instructions. Experiments were performed on the Monolith™
NT.115Pico instrument using the RED detector. For labeling, a protein concentration of 20 nM
and a buffer containing 50 mM HEPES pH7.5, 150 mM NaCl, 0.05% Tween20 and 0.5 mM TCEP
were used. After 30 minutes incubation with labeling reagent, the protein-label mix was
centrifuged for 10 min at 20,000 rpm and then transferred to a new tube leaving 20 μL of solution
at the bottom of centrifuge tube. A three-fold 15-point dilution series of compounds were prepared
starting at 500 μM compound concentration and one point with solvent in a buffer containing 50
mM HEPES pH7.5, 150 mM NaCl, 0.05% Tween20, 5% v/v DMSO and 0.5 mM TCEP. Labeled
TAF1-2 was added to the compound dilution tubes. After 5-10 min incubation, the protein and
compound samples were centrifuged using benchtop centrifuge and then loaded into NT.115 Series
Standard Treated Capillaries. The MST experiment was performed using LED Power of 20% or
40 %, and MST Power of 40% or 80% with thermophoresis occurring over 30 seconds. Initially,
Kd values were determined with the MO.Affinity Analysis Software v2.1 from Nanotemper and
final Kd values from independent experiments were determined and plotted with Graphpad Prism.
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Crystallization and X-ray crystallography
All crystallization experiments were performed at 18 °C. Aliquots of purified BRDs were
set up for crystallization using mosquito crystallization robot (TP Labtech). Initially, coarse
screens were set up using Greiner 3-well plates at three different concentrations of precipitant to
protein (200+400 nl, 300+300 nl, 400+200 nl) per condition. Conditions producing crystals were
further optimized and scaled up for the manual set up of 2 µl drops. For co-crystallization,
compound was either pre-mixed with protein on ice or added to protein-reservoir solution drops
to achieve final concentrations of 0.5-2.5 mM compound and 5–10 % DMSO (Supplementary
Table S2.4). Crystals were cryoprotected using the well solution supplemented with ethylene
glycol (15-30%) and flash frozen in liquid nitrogen. X-ray diffraction data were collected at -180
°C at the beamlines 22-ID and 22-BM, SER-CAT, or beamlines 23-ID, GM/CA, Advanced Photon
Source, Argonne National Laboratories, and in the Moffitt Chemical Biology Core using CuKα
X-rays generated by a Rigaku Micro-Max 007-HF X-ray generator, focused by mirror optics and
equipped with a Rigaku CCD Saturn 944 system. Data were reduced and scaled with XDS 80 or
DIALS81 and Aimless82. PHASER83 was employed for molecular replacement using PDB entry
3UV4 as search model for TAF1-2 and 3UV5 for TAF1-T. Refinement was carried out with
PHENIX83 and model building was performed with Coot.84 Initial models for the small molecule
ligands were generated using MarvinSketch (ChemAxon, Cambridge, MA) with ligand restraints
from eLBOW of the PHENIX83 suite. All structures were validated by MolProbity. Figures were
prepared using PyMOL (Schrödinger, LLC) or UCSF Chimera. Data collection and refinement
statistics are shown in supplementary table S2.5, 2.6. The coordinates and structure factors are in
process to be deposited with the PDB.
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SAXS data collection
Small angle X-ray scattering (SAXS) data collection was performed at BioCAT (beamline
18ID at the Advanced Photon Source, Lemont, IL) with in-line size exclusion chromatography
(SEC-SAXS). Experiments were conducted at room temperature in 50 mM HEPES (pH7.5), 5%
v/v ethylene glycol, 2.5% v/v DMSO and 2 mM DTT. 300 μL of samples were loaded onto the
Superdex 200 Increase 10/300 column (GE Life Sciences) and eluted with a flow rate of 0.7
mL/min. The elute from the SEC passed through the UV cell of size exclusion chromatogram and
reached the SAXS quartz capillary flow cell, where sample was exposed to X-ray for data
collection. SEC column to X-ray beam dead volume was approximately 0.1 mL. Sample scattering
intensity was recorded on a Pilatus3 1M (Dectris) detector placed 3.5 m from the sample
and a wavelength of λ = 1.03320164497, which yields range of momentum transfer (scattering qrange) 0.004 < q < 0.4 Å-1 (q = 4𝛑sin𝛉/ λ, where 2𝛉 is the scattering angle). 0.5 second exposures
were used with 0.5 second interval during the elution. Data were reduced at the beamline using
BioXTAS RAW 1.6.1.85 The buffer scattering was determined by averaging frames from the SEC
eluent of pre and post-peak, which contained baseline levels of integrated X-ray scattering,
UV absorbance and conductance. The frame intensities were corrected by subtracting the buffer
contribution. The corrected frames were investigated by radius of gyration, Rg derived by the
Guinier approximation I(q) = I0 exp (-q2Rg2/3) with the limits q*Rg < 1.3. Final q versus I(q) data
sets were generated by averaging frames in the region of least Rg variation, automatically selected
by the BioXTAS RAW 1.6.4

85

program, and merging. These merged SAXS data with q range

0.0002 – 0.35 Å-1 were used to generate the forward scattering (I0), Guinier plots and radius of
gyration (Rg), volumes-of-correlation (Vc), Porod’s corrected volume (Vp), Pair distribution
function P(r), and normalized Kratky plots. The P(r) functions were further assessed and computed
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manually with the program GNOM86 for smooth reaching to X-axis (Log(I(q) = → 0). The
molecular mass (Vc and Vp) was computed according to published methods.87, 88 All the data
analysis were done by using BioXTAS RAW 1.6.4 85 and Graphpad Prism was used for graphical
representation. As a quality measure, the Guinier plots (Fig. 2.12C) indicate aggregation free
samples.

SAXS solution structure modeling
Ab initio shape models of TAF1-T constructs were generated using electron density map
generation program DENSS69 and bead modeling program DAMMIN70. Multiple runs were
performed to generate 20 starting models and the final ab initio shape was reconstructed by
averaging and refining the starting models. Resolution and quality of the ab initio shape model
generated by DENSS are given in supplementary table S2.3. The low resolution electron density
map generated by DENSS69 and the bead model with an average core volume of 20 starting model
computed by DAMFILT in ATSAS suit89 are shown in supplementary fig. S2.8.
The 1.6 Å resolution TAF1-T/AZ20 crystal structure was used to generate BD1 and BD2
rigid body starting model with truncation of the N-term and C-term flexible residues. The BD2
and BD1 rigid body domains were fitted into the DENSS generated electron density map by
phenix.dock_in_map in PHENIX83 suite or Chimera90. N-term and C-term loop residues were built
by aligning the high-resolution crystal structures of the corresponding protein/inhibitor complexes.
The loop region connecting the two domains were modelled by ModLoop91. The flexible residues
on the N-term (1371 -1376) and C-term (1631 – 1635) those were not visible in high resolution
crystal structures were not modeled in the final models. BAY299 in the KAc site of BD1 was
modeled by overlaying with BD2 KAc site. Reconstructed model fitting was iteratively evaluated
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against experimental SAXS data by Crysol 3.0

92

to find the best fitted models that satisfy good

map fitting as well as fitting to the experimental SAXS data. The computed Rg, molecular mass
and goodness of fit of the final models are given in supplementary table S2.3.

Cell culture and p53 pathway biomarker analysis by western blot
A549, HCT116, HCT116 p53-/- and HEK293T cells were maintained in Dulbecco
modified Eagle medium with 10% fetal bovine serum. All cell lines used in this study were
obtained from the ATCC. For western blotting, cells were lysed in lysis buffer (50 mM Tris-HCl
[pH 8.0], 5 mM EDTA, 150 mM NaCl, 0.5% NP40, 1 × protease inhibitor cocktail), centrifuged
for 10 min at 14,000 × g and the insoluble debris discarded. Cell lysate (10–50 µg of protein) was
fractionated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred
to Immobilion P filters (Millipore). The filter was blocked for 1 h with phosphate-buffered saline
containing 5% nonfat dry milk and 0.1% Tween20, incubated with primary and secondary
antibodies, and the filter was developed using the Supersignal reagent (Thermo Scientific). The
following antibodies were produced in Jiandong Chen lab at Moffitt Cancer Center: MDM2 was
detected using monoclonal antibody 3G9, MDMX was detected with monoclonal antibody 8C6 or
a rabbit polyclonal antibody. The following antibodies were purchased from commercial sources:
Actin (Sigma, A5441), p53 DO-1 (BD Pharmingen, 554293), p21 (BD Pharmingen, 556430), and
phosphor-p53 Ser15 (Cell Signaling, 9284).

Cell proliferation assay by CellTiter Blue
Mammalian cells were seeded in 96-well plates at approximately 1,500 cells per well (0.1
mL). Seeded cells were allowed to settle and attach to the plate surface for 20 hours. Before dosing,
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cell media was removed for replenishing with fresh media containing desired drug concentration.
A three-fold 9-point dilution series of compounds were prepared starting at 10 μM compound
concentration and one point with vehicle in the culture media with 0.1% DMSO. Cells were
incubated with the compounds for 72 hours in hexaplicates per drug concentration. After 72 hours
of drug treatment, 15 μL of CellTiter Blue reagent (Promega) was added to each well, followed by
orbital shaking for 5 minutes and incubation for 3 hours at 37 oC. Plate fluorescence was recorded
in a Wallac EnVision 2103 Multilabel Reader (PerkinElmer) using excitation and emission filters
of 570 and 615 nm, respectively. Growth inhibition data were analyzed with the Prism 8.4
(GraphPad).

Kinase activity ELISA assay
ATM and ATR kinase with C-terminal FLAG tag were transiently expressed in HEK293T
cells, immunoprecipitated with M2-agarose beads (Sigma), and eluted with 250 µg/mL FLAG
peptide diluted in kinase buffer (25 mM HEPES [pH 7.5], 50 mM NaCl, 10 mM MgCl2, 10 mM
MnCl2, 1 mM DTT, 5% glycerol, 0.05% NP40). ELISA plates were coated with GST-1-90-p53 in
PBS (0.25 µg/well in 50 μL) for 18 hrs at 4˚C. The plates were washed 4 times with PBS containing
0.1% Tween-20 (PBST), blocked with 0.3 mL PBST containing 1% BSA for 15 min at RT, and
washed 2 times with kinase buffer. The phosphorylation reaction in each well contained 50 μL
kinase buffer, 3 μM ATP, compounds form prepared dilution series, and 0.125 μL purified ATM
or ATR kinase. The plates were incubated at RT for 1 hr with gentle shaking and washed 4 times
with PBST followed by 2 times with PBS. To detect phosphorylation of immobilized GST-1-90p53, 50 μL/well of anti-pS15 antibody diluted 1:650 in PBST with 5% nonfat dry milk was added.
The plates were incubated for 1 hr at RT and washed 4 times with PBST. The plates were further
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incubated with 50 μL HRP-anti-rabbit IgG diluted in PBST containing 5% nonfat dry milk for 1
hr at RT, washed 4 times with PBST, and washed 2 times with PBS. TMB substrate (75 µL/well,
SeraCare) was added and incubated at RT for 1-5 min. The chromogenic reaction was terminated
by addition of 100 μL 0.12 N HCl, and absorbance was measured at 450 nm using a
spectrophotometer.
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FIGURES AND TABLES

Figure 2.1. Full length TAF1 protein is a multi-domain protein. A) Domain map of human
TAF1. B) Cryo-EM and crystal structure-based hybrid model of TAF1 HAT domain bound to
DNA (PDB:5FUR). C) Crystal structure of TAF1-T. (A-C) TBP BD, TATA binding protein
binding domain; HAT, Histone acetyl transferase; BD1/2, Bromodomain 1 or 2; KD1/2, Kinase
domain 1 or 2; WH, Winged-helix domain, Zf, Zinc finger knuckle.
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Figure 2.2. Current strategies to modulate transcription using small molecule inhibitors that
target the basal transcription machinery and pre-initiation complex.
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Figure 2.3. Pseudo-HAT domain of TAF1. A) TAF1 HAT domain consisting the TAF1 (beige),
TAF7 (cyan) and WH domain (PDB:4RGW). (B-D) Overall architecture of the three HAT family
members – B) p300 HAT of P300/CBP family (PDB:5LKU), C) GCN5L HAT of GNAT family
(PDB:1Z4R) and D) NuA4 HAT of MYST family (PDB:5J9W).
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Figure 2.4. DSF with bromosporine (BSP) for TAF1-T and TAF1-2. A) ∆Tm of BSP for
TAF1-T and TAF1-2. B) Dose response curve of BSP for TAF1-T and TAF1-2. C) Chemical
structure of bromosporine (BSP).
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Figure 2.5. Compound library screening workflow by DSF.
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Figure 2.6. Performance of DSF assay for TAF1-T with or without bromosporine (BSP). A)
Plot of melting temperature (Tm) of TAF1-T with BSP or DMSO for each well. Solid horizontal
lines indicate arithmetic means, dashed lines indicate three standard deviation (SD) from mean. B)
Table of calculated plate statistics to assess the assay robustness. Z′-factor was calculated
(3𝜎 + 3𝜎 )
according to the equation: Z ′ = 1 − | 𝜇𝑐+ − 𝜇 𝑐−| , where σc+ is standard deviation for BSP, σc- is
𝑐+

𝑐−

standard deviation for DMSO, μc+ is mean for BSP and μc- is mean for DMSO.
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Figure 2.7. Dual TAF1 BRD-kinase inhibitors were identified and validated by biophysical
assays. A) DSF thermal shift curves of the hits identified from a kinase inhibitor library, for TAF1T (left) and TAF1-2 (right). DMSO, BSP and AZ20 worked as reference, positive control and
negative control, respectively. B) Chemical structures of the hits AZD6738 and BI2536, and the
AZD6738 analog AZ20. C) Binding affinity (Kd) determination for AZD6738 against TAF1 by
ITC and MST (see supplementary fig. S2.2 for Kd determination by ITC, MST and BromoScan).
D) Selectivity profile of AZD6738 (20μM) in BRD family (32 individual BRDs, assessed by
DiscoverX).
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Figure 2.8. Structural basis of inhibitor binding to TAF1-2. A) Co-crystal structures of TAF12 bound to AZD6738 B) Same as (A) for AZ20. C) Same as (A) for BI2536. (A-D) TAF1 protein
is shown as cartoon representation, compounds and interacting residues are shown as yellow and
beige sticks, respectively. Hydrogen bond and vdW interactions are shown as black and green
dashed lines, respectively. Schematics of inhibitor interactions with the KAc site are shown beside
the respective structures where black dashed lines, green dashed lines and green curves indicate
H-bonds, π-π or π-σ interactions and vdW interactions, respectively. (figure continued to next
page)

67

Figure 2.8. (continued) D) Same as (A) for bromosporine (BSP). E) Structural changes in the KAc
site of TAF1-2 upon ligand binding. i) BSP (green) bound TAF1-2 overlayed with unliganded
TAF1-2 (cyan) (PDB:3UV4), ii) same as (i) for AZD6738 (yellow) and iii) same as (i) for BI2536
(orange). F) Conformations of the bound inhibitors (BSP, AZD6738 and BI2536) in the KAc site
of TAF1-2. G) Differences in the KAc sites of BD1 (light blue) and AD6738 bound BD2 (beige)
of TAF1. (E-G) Conserved asparagine (N1583) is shown in magenta.
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Figure 2.9. Methylmorpholine containing PI3KK kinase inhibitors are bona fide binders of
TAF1. Binding mode of the PI3KK inhibitors in the co-crystal structures of A) AZD6738 bound
TAF1-T, B) AZ20 bound TAF1-T and C) AZD3147 bound TAF1-T.(A-C) Schematics of inhibitor
interactions with the KAc site are shown beside the respective structures where black dashed lines,
green dashed lines and green curves indicate H-bonds, π-π or π-σ stacking and vdW interactions,
respectively. (figure continued to next page)
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Figure 2.9. (continued) D) Hydrogen bond potentials of methymorpholine containing three PI3KK
inhibitors in the KAc site of TAF1-T. Black dashed lines indicate H-bond (distance < 3.3 Å) and
red dashed lines indicate distance between two atoms. Distances (Å) are shown beside the dashed
lines. E) Binding mode of a PI3K⍺ inhibitor, an AZD6738 analog, in ATR mimicking PI3K⍺
mutant (PDB: 5UK8) (left) and binding mode of AZD6738 in PI3K⍺ kinase elucidated by docking
the AZD6738 in PI3K⍺ kinase domain. F) Differential binding mode of AZD6738 in TAF1 from
crystal structure.
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Figure 2.10. Inhibitor binding to TAF1-T stabilizes conformationally flexible BRDs in
different conformations. Conformational states of TAF1-T in the crystal structures of i)
unliganded, ii) AZD3147 bound, and iii) AZD6738 or AZ20 bound complexes. Distances (Å)
between the two domains are shown as black dashed lines, (inset) hydrogen bond interactions
between the two domain residues (shown as black dashes) at the inter-domain interface, and (inset
below unliganded TAF1) conformational changes of the residues in the linker region in three
different states.
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Figure 2.11. Structural comparison of the “closed” conformation of TAF1-T (this study) with
a previously reported “unliganded-closed” conformation of TAF1-T. A) (Left) Surface view
and the interface of BD1 and BD2 of TAF1-T in AZD6738 bound “closed” conformation and
(right) cartoon representation showing the interacting residues at the interface of BD1 and BD2 of
TAF1-T. Hydrogen bonding interactions and salt bridges between the residues of BD1 and BD2
are shown in the inset below. B) Same as (A) for published “unliganded-closed” conformation of
TAF1-T (PDB: 1EQF). (A-B) BD1 in cyan, BD2 in beige, linker region in green, interface residues
of BD1 interacting with BD2 are in deep blue, interface residues of BD2 interacting with BD1 are
in light pink, AZD6738 is shown as yellow stick-ball representation, hydrogen bond interactions
or salt bridges (d < 3.3A) are shown as black dashed lines.
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Figure 2.12. Inhibitor binding to TAF1-T in solution results in conformational changes as
well as dimerization. A) Overlay of SAXS in-line analytical size exclusion column (SEC)
chromatograms of TAF1 in absence of and in presence of the inhibitors (AZD6738 and BAY299).
B) SAXS profiles of TAF1-T in absence of and in presence of 250 μM AZD6738 and 13.3 μM
BAY299. C) Guinier analysis for radius of gyration (Rg) determination. D) Pair distance
distribution p(r) function of TAF1-T in absence of and in presence of the inhibitors. E)
Macromolecule particle parameters – Rg, maximum intraparticle distance Dmax, and estimated
molecular mass (volume of correlation, Vc and Porod’s volume, Vp) for TAF1-T determined from
SEC-SAXS. F) Ab initio envelope for TAF1-T in absence of inhibitors generated from SAXS data
(left) and the fitted model of TAF1-T in the envelope (see supplementary table S2.3 for further
details). G) same as (F) for TAF1-T in presence of AZD6738. H) same as (F) for TAF1-T in
presence of BAY299.
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A
TAF1-2 / BAY299

TAF1-1 / BAY299

Kd = 4.5 μM
N = 1.3

TAF1-T / BAY299

Kd1 = 9.26 nM
N1 = ~ 3
Kd2 = 2.1 μM
N2 = ~ 1.1

Kd = 46.7 nM
N = 0.96

B
TAF1-2 / BSP

TAF1-T / BSP

Kd = 146.7 nM
N = 1.1

Kd = 52.6 nM
N = 0.9

C

Figure 2.13. Kd determination of the bromodomain inhibitors for TAF1 by ITC. A) ITC
thermograms of BAY299 interaction with TAF1. B) Same as (A) for BSP. C) Thermodynamic
signature analysis for the studied inhibitors with TAF1-T, TAF1-2 and TAF1-1.
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Figure 2.14. Inhibition of TAF1 BRD activates p53, induces DNA damage signaling and
cooperates with MDM2 inhibitor to induce cell death. A) A549 lung tumor cells treated with
indicated compounds (10 µM, 24 hrs) were analyzed for p53 pathway markers by western blot.
The MDM2 inhibitor Nutlin served as positive control. B) HCT116 colon tumor cells with and
without p53 were treated with TAF1 inhibitor and gamma radiation for 8 hrs. P53 pathway markers
were analyzed by western blot. C) A549 lung tumor cells treated with indicated compounds (10
µM, 5 hrs) were analyzed for p53 pathway markers by western blot. Phosphorylation of p53 at
Ser15 was determined using a phosphorylation-specific antibody. D) A549 cells were treated with
MDM2i Nutlin and TAF1i combination for 24 hrs. Cell death was documented by photography.
E) TAF1 BRD inhibition attenuates the antiproliferative effect of ATR inhibitors. A549 (left) and
HEK293T (right) cells were treated with inhibitors for 72 hrs followed by growth inhibition
determination using CellTiter-Blue. F) Determined cell growth inhibitory potential of TAF1i and
dual TAF1-ATRi. PLK1i BI2536 and ATRi BAY1895344 served as control compounds.
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Figure 2.15. SAR of dual TAF1 BRD-PI3KK kinase inhibitors. A) In vitro inhibitory activity
of the AZD6738 analogs against ATR (left) and ATM (right). B) Chemical structures of triazine
ring containing dual TAF1 BRD-PI3KK kinase inhibitors. C) Binding mode of TS1-299 in the
KAc site of TAF1-2. i) Ligand interactions, ii) a schematic of inhibitor interactions with the KAc
site residues and iii) overlay of TS1-299 and AZD6738 (orange) in the KAc site of TAF1-2. D)
Same as (C) for TS1-252. (C, D) Black dashed lines indicate H-bonds (distance < 3.3 Å) and green
dashed lines indicate vdW interactions. (C, D-ii) Green dashed lines and green curves indicate ππ or π-σ stacking and vdW interactions, respectively.
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Table 2.1. Binding potential of the studied inhibitors for TAF1.

Table 2.2. ITC experiment conditions and thermodynamic parameters of inhibitor
interaction with TAF1.

Table 2.3. SAR of dual TAF1 BRD-PI3KK kinase inhibitors for ATR and ATM.
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SUPPLEMENTARY INFORMATION
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Figure S2.1. Chemical structures of AZD3147, BAY299, Bromosporine, PI3K⍺ inhibitor
and 1,4-dioxane, which were used in the experiments or included in the analysis.

Figure S2.2. Validation of hits and binding affinity determination. A) Dose response DSF of
AZD6738 (0– 0.4mM) for TAF1-T and TAF1-2. B) IC50 determination of AZD6738, AZ20 and
bromosporine against TAF1-2 by AlphaScreen (Reaction Biology Corporation). C) Kd
determination of BAY299 against TAF1-2 by MST. D) Kd determination of AZD6738 (left) and
AZ20 (right) against TAF1-2 by BromoScan (DiscoverX). (C-D) Excluded outliers are shown in
gray or light colors.
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Figure S2.3. Sequence alignment of BD1 and BD2 of TAF1. Conserved asparagine (N1460BD1
and N1583BD2) and critical WPF shelf region are shown with red dotted lines. Dissimilar residues
at the vicinity of KAc sites are marked with asterisk below the sequence and the dissimilar residues
that directly interact with inhibitors are marked with double asterisk. Between and BD1 and BD2,
sequence identity 44.6 %, similarity 67.9 % and gaps 0.9 %.

Figure S2.4. Known four conformational states of TAF1-T. A) Unliganded TAF1-T (residues
1359-1638, PDB: 1EQF). B) Unliganded TAF1-T (residues 1373-1635, PDB: 3UV5). C) TAF1T bound to bivalent inhibitor UNC-4512 (residues 1359-1638, PDB: 6FIC). D) TAF1-T in
complex with CIA/ASF1 (residues 1342-1629, PDB: 3AAD). (A-D) BD1 shown in cyan, linker
region shown in green, BD2 shown in beige, (C) bound UNC-4512 shown as yellow sticks and
(D) CIA/ASF1 histone chaperone protein shown in light brown.
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Figure S2.5. Structure analysis of TAF1 bound AZD6738 and its related analogs. A) Overlay
of TAF1-2 bound AZD6738 and AZ20. B) Overlay of TAF1-2 bound AZD6738 and TAF1-TBD2
bound AZD3147. C) H-bond and VDW interactions of 1,4-dioxane in the KAc site of TAF1-2.
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Figure S2.6. Two-dimensional plots of SEC-SAXS frames for TAF1-T in with or without the
inhibitors (AZD6738 and BAY299). Integrated intensity on left Y axis and calculated particle
parameters on the right Y axis. A) TAF1-T, B) TAF1-T with AZD6738 and C) TAF1-T with
BAY299.

Figure S2.7. SAXS profile. A) SAXS profile (upper panel) and residual value plot (lower panel)
of curve fitting for TAF1-T. B) same as (A) for TAF1-T with AZD6738. C) same as (A) for TAF1T with BAY299. D) Normalized Kratky plot for the subjected experimental samples.
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Figure S2.8. Ab initio shapes reconstructed from SAXS data. A) Reconstructed ab initio
electron density maps generated from SAXS data by DENSS for TAF1-T (left), TAF1-T +
AZD6738 (middle) and TAF1-T + BAY299 (right). B) ab initio bead model and averaged core of
20 bead models generated from SAXS data by DAMMIN for TAF1-T (left), TAF1-T + AZD6738
(middle) and TAF1-T + BAY299 (right).
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Table S2.1. Selectivity profiling of AZD6738 against 32 bromodomains (by DiscoverX).

83

Table S2.2. SAR of dual TAF1 BRD-PI3KK kinase inhibitors for TAF1-2.
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Table S2.3. Calculation for DENSS electron density maps and ab initio models. Calculated
values for DENSS generated ab initio electron density maps reconstructed from SAXS data and
evaluation of TAF1-T (and inhibitor bound complex) models fitted in the ab initio low-resolution
envelope by Crysol 3.0 program in ATSAS. Resolution (Å) of ab initio electron density map was
calculated from Fourier shell correlation = 0.5 (FSC0.5) of DENSS. χ2 values for the models
calculated by Crysol 3.0 program (ATSAS suit) show goodness of the fit.
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Table S2.4. Co-crystallization conditions for TAF1-T and TAF1-T with small molecule
inhibitors.
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Table S2.5. Crystallographic table for TAF1-T.

Table S2.6. Crystallographic table for TAF1-2.
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CHAPTER 3: SMALL MOLECULE INHIBITORS OF THE BRD7/9 BROMODOMAINS

PART I: AN ADVANCED TOOL TO INTERROGATE BRD91

Abstract
Selective inhibitors of bromodomain-containing protein 9 (BRD9) may have therapeutic
potential in the treatment of human malignancies and inflammatory diseases. A selective small
molecule inhibitor that is well tolerated and has proper pharmacokinetic properties is required to
explore the function of BRD9 in diseases. BI-9564 (2) is a cell permeable and non-cytotoxic BRD9
inhibitor provided to the scientific community to explore BRD9 biology and determine potential
as a drug target.

Bromodomains are highly conserved epigenetic “reader” modules that specifically
recognize N-acetylated lysine (KAc) residues on histones and other proteins. Bromodomaincontaining proteins modulate numerous functions including gene transcription and chromatin
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remodeling and play fundamental roles in cell proliferation and division. A number of BRDcontaining proteins, particularly those of the bromodomain and extraterminal (BET) family, have
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been linked to tumorigenesis and inflammatory diseases. The landmark discoveries of potent small
molecule inhibitors of BET bromodomains1, 2 provided chemical tools for the first time to explore
the function of proteins, such as BRD4, in disease states. Since then several BET inhibitors have
entered clinical trials for oncology and cardiovascular indications. More recently, novel inhibitors
targeting non-BET bromodomains for which the physiological functions are not well understood
have been reported.3 Such inhibitors are valuable probes to unravel the function of bromodomains
outside the BET family, the relevance of these proteins in certain disease states, and their potential
as drug targets. In this issue of Journal of Medicinal Chemistry, Martin et al. report the
development of a selective, in-vivo active BRD9 inhibitor with promising potential as a chemical
probe 4.

BRD9 is a subunit of the mammalian SWI/SNF chromatin remodeling complex but its
biological function is unknown. High prevalence of mutations of SWI/SNF subunits in human
tumors5 and overexpression of BRD9 in several cancers suggests BRD9 as a potential target for
cancer drugs.6 Martin et al. describe the structure-guided development of 2 (BI-9564), from hit
compounds identified by fragment based and virtual screening to the design of potent BRD9
inhibitors. Various methods and techniques were applied to demonstrate binding activity and to
determine the structural basis of inhibition, target engagement in the cell and target selectivity
through profiling against panels of bromodomains, kinases and GPCRs. Inhibitor 1 displayed
binding and inhibitory potential against BRD9 with low nanomolar K d and IC50 values, similar to
the previously reported BRD9 inhibitors LP997, 288 and I-BRD99 (Fig. 3.1). Key interactions of
the BRD9-2 complex are hydrogen bonding with Asn100, a conserved bromodomain residue
critical for the interaction with KAc residues, π-stacking with Tyr106, T-stacking with Phe44 and
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CH-π interactions with Ile53 (Fig. 3.2A). Importantly, 2 is > 10-fold more selective for BRD9 over
the highly homologues bromodomain BRD7, which has been implied as a tumor suppressor and
is down-regulated in cancer cells.10 The high similarity of the KAc binding site across
bromodomain containing proteins presents a formidable challenge in the development of selective
inhibitors. Most potent BRD4 inhibitors target all members of the BET family with similar
potency, irrespective of the high chemical diversity among the pharmacophores and warheads
identified to date. It is equally challenging to develop intra-family selective inhibitors of
bromodomains from other branches on the phylogenetic tree, such as BRD9 and BRD7, which
exhibit high sequence and structure similarity of the KAc sites.

Of the BRD9 inhibitors reported to date4, 7-9, 11, 12, 2 is the most comprehensively studied.
Structure-activity relationship studies elegantly identified a hot spot in the KAc site of BRD9
around residue Phe47 that responds to variations of the dimethoxyphenyl moiety with large effects
on selectivity (Fig. 3.2A-D). Inhibitor 1 (BI-7273), an isomer of 2, displayed subnanomolar
binding potential for BRD9, but inhibited BRD7 to the same extent and therefore lacked
selectivity. While the o-methoxy of 2 attracts the side chain of Phe47, the m-methoxy of 1 pushes
Phe47 away. Notably, Phe47 adopts the same conformation in complex with all BRD9 inhibitors
except 1 (Fig. 3.2E, F). Inhibitors 1 and 2 showed no inhibitory activity against BET
bromodomains, due to the structural differences of the KAc binding sites imposing steric
hindrance. CECR2 was the only in-vitro off-target identified outside the BRD9/BRD7 subfamily,
but cellular inhibition of CECR2 was not observed by FRAP assay. Studying the effect of 1 and 2
in parallel may provide information on synergistic or antagonistic effects of BRD9-BRD7
inhibition in malignant and normal cell lines, patient samples, and/or in vivo models. What sets 2
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apart from other reported BRD9 inhibitors is the evaluation of in vivo properties including
pharmacokinetic profiling, demonstration of efficacy in cell lines and in a disseminated mouse
model of AML. Significantly, 2 will be made available to the broad scientific community,
providing an invaluable resource to align and streamline biological studies by different laboratories
on the effect of BRD9 inhibition in diverse disease models. Growing evidence suggests that
targeting bromodomains with selective small molecule inhibitors is a viable strategy to control
epigenetic events. While most kinase inhibitors drastically disrupt vital signaling pathways or cell
cycle events, inhibitors of bromodomains outside the BET family may exert more subtle responses
over a longer period. Recent reports on strong synergistic action of kinase and BET bromodomain
inhibitors for a variety of cancers13-15 suggests that inhibitors of bromodomains outside the BET
family may synergize with other drugs as well. Compounds such as 2 are perfectly suited to
determine the function of BRD9 and its potential as a drug target.
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PART II: STRUCTURAL BASIS OF INHIBITOR SELECTIVITY IN THE BRD7/9
SUBFAMILY OF BROMODOMAINS2

Abstract
Inhibition of the bromodomain containing protein 9 (BRD9) by small molecules is an
attractive strategy to target mutated SWI/SNF chromatin remodeling complexes in cancer.
However, reported BRD9 inhibitors also inhibit the closely related bromodomain containing
protein 7 (BRD7), which has different biological functions. The structural basis for differential
potency and selectivity of BRD9 inhibitors is largely unknown due to the lack of structural
information on BRD7. Here, we biochemically and structurally characterized diverse inhibitors
with varying degrees of potency and selectivity for BRD9 over BRD7. Novel co-crystal structures
of BRD7 liganded with new and previously reported inhibitors of five different chemical scaffolds
were determined alongside BRD9 and BRD4. We also report the discovery of first-in-class dual
bromodomain-kinase inhibitors outside the BET family targeting BRD7 and BRD9. Combined,
the data provide a new framework for the development of BRD7/9 inhibitors with improved
selectivity or additional polypharmacologic properties.

Introduction
Bromodomains (BRDs) are evolutionary conserved epigenetic reader modules that
recognize N-acetylated lysine (KAc) residues on histones and other proteins.16, 17 BRD-containing
__________________
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proteins have important functions in gene transcription and chromatin remodeling, gene splicing,
protein scaffolding and signal transduction.18 BRD-containing proteins, particularly those of the
bromodomain and extra-terminal (BET) family, have been linked to tumorigenesis and
inflammatory diseases, and several BET inhibitors are in clinical trials for oncology and nononcology indications.19 More recently, inhibitors targeting non-BET bromodomains for which the
physiological functions are less understood, have been the subject of intense efforts in academia
and pharmaceutical industry alike.20
The BRD-containing proteins BRD7 and BRD9 recognize acetylated lysines on histone H3
(H3Ac).16 Although they contain a structurally similar single bromodomain (62 % sequence
identity), the cellular functions of full-length BRD7 and BRD9 are remarkably different. BRD9
is a component of ncBAF (noncanonical BRG1/BRM-associated factor), a subtype of the BAF
complex, while BRD7 is a component of PBAF (polybromo-associated BAF) complex.21
Importantly, BRD9 has an essential role in a number of cancers such as acute myeloid leukemia
(AML), synovial sarcoma and malignant rhabdoid tumor (MRT).22-24 In contrast, BRD7 is a
potential tumor suppressor10 with critical functions in oligodendrocytes progenitor cell
differentiation25 and spermatogenesis.26
BRD9 has attracted attention as a druggable subunit of mSWI/SNF chromatin remodeling
complexes, various subunits of which are mutated in nearly 20% of all human cancers.5 To target
mSWI/SNF complexes in cancer, few small molecule inhibitors of the acetyl-lysine binding site
(KAc site) of BRD9 have been reported to date.4, 7, 9, 27, 28 These inhibitors showed varying degrees
of selectivity across bromodomains in general and within the BRD9/BRD7 subfamily in particular.
As the role of BRD7 in human biology is not fully understood, off-target inhibition of BRD7 by
non-selective BRD9 inhibitors bears the risk of unwanted pleiotropic effects. Recently, proteolysis

102

targeting chimeras (PROTACs), dBRD9 and VZ185, have been developed using the potent
BRD7/9 inhibitor BI-7273 as a warhead. While dBRD9 induced the selective degradation of
BRD9 over BRD7, VZ185 showed concomitant degradation of BRD9 and BRD7.29, 30
An obstacle to the rational design of inhibitors selective for BRD9 is the limited structural
information on BRD7. Specifying the binding interactions of an inhibitor in closely related
proteins is crucial for the development of selective inhibitors. Here, we applied a multifaceted
approach towards the characterization of diverse small molecule inhibitors with varying degrees
of potency and selectivity for BRD7 and BRD9. We report the discovery of first-in-class dual
bromodomain-kinase inhibitors outside the BET family targeting BRD7 and BRD9. TG003, a
Cdc2-like kinase (Clk2) inhibitor31, sunitinib, a multi-targeted tyrosine kinase inhibitor32, and PF477736, an inhibitor of cell cycle checkpoint kinase 1 (Chk1)33 were identified as moderately
active BRD7/9 inhibitors with Kd values between 4 and 17 µM. Novel crystal structures of BRD7,
BRD9 and BRD4 liganded with new and known inhibitors were determined, the information of
which provides a structural basis for the differential potency and selectivity of BRD7/9 inhibitors.
Combined, the data afford a new framework for the structure-based design of inhibitors with
improved selectivity or additional polypharmacologic properties.

Results
Structure-activity relationship of reported BRD9 inhibitors
To address inhibitor selectivity over BRD7, structure-activity relationship (SAR) studies
were performed with five previously reported BRD9 inhibitors (Fig. 3.3A). Binding studies by
differential scanning fluorimetry (DSF) and isothermal titration calorimetry (ITC) showed
significant correlation between the data sets for both BRD7 and BRD9 (Fig. 3.3B, C,
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Supplementary Table S3.1, Supplementary Figs. S3.1, S3.2). For BRD9, the thermodynamic
parameters of protein-inhibitor interactions were predominantly enthalpy driven and accompanied
by entropic penalty (Fig. 3.3D). By contrast, BRD7 showed neutral or favorable entropic
contributions upon interaction with all inhibitors. The isomers BI-7273 and BI-9564 have been
reported as potent BRD7/9 inhibitors, BI-7273 lacking selectivity and BI-9564 being 12 times
more selective for BRD9.4, 28 Our data using crystallization-grade proteins support a different
notion with BI-7273 being the most potent (Kd = 9 nM) and selective inhibitor of BRD9 among
the compounds tested (Fig. 3.3C). This finding may explain the recent use of BI-7273 rather than
BI-9564 as a warhead in the development of BRD9-targeting proteolysis targeting chimera
(PROTAC).29 BI-9564 shared with TP-472 similar activity and selectivity values, I-BRD9 and
bromosporine were the least selective inhibitors.
While several co-crystal structures of BRD9 with inhibitors have been determined
previously, the structure of BRD7 was described only in an unliganded state by NMR.34 Recently,
the Structural Genomics Consortium deposited a crystal structure of BRD7 liganded with BI-9564
in the PDB (5MQ1), albeit without context. Although the bromodomains of BRD7 and BRD9
share 62 % sequence identity, BRD7 is temperature-sensitive with a melting temperature of Tm =
31 °C, whereas BRD9 shows the temperature stability typical of BET bromodomains (Tm = 46 °C)
(Fig. 3.3B). The temperature sensitivity of BRD7 may explain the difficulties in obtaining X-ray
crystals caused by protein denaturation during lengthy crystallization experiments. Therefore,
purification of BRD7 was performed expeditiously, resulting in highly homogeneous protein that
readily formed X-ray grade crystals in unliganded and several liganded states using different
crystallization conditions (Supplementary Tables S3.2, S3.3). The overall structures of the
bromodomains of BRD7 and BRD9 are highly similar (r.m.s.d. = 0.63 Å), residues within the KAc
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site are identical and 6 differing residues are located in the vicinity of the KAc site (Fig. 3.4A).
Distances between the opposing flanks of the KAc site are similar for both proteins (Fig. 3.4B).
Co-crystal structures were determined for BRD7 liganded with BI-7273 (Fig. 3.4C) and
BI-9564 (Fig. 3.4F) showing the same binding mode as previously determined in BRD9 4 (Fig.
3.4D, G). The naphthyridinone oxygen of both compounds establishes a single H-bond with
BRD7N211 or BRD9N216. However, the dimethoxyphenyl moieties of BI-7273 and BI-9564, which
establish multiple hydrophobic van-der-Waals (VDW) interactions with KAc site residues, adopt
slightly different positions (Fig. 3.4E, H). These differences appear to be caused by steric
hindrance with residue F160 of BRD9. In BRD7, the main and side chain conformations of the
equivalent residue F155 differ from BRD9 presumably due to alanine vs. glycine as preceding
residues (BRD7A154 and BRD9G159). In the absence of structural information on BRD7-inhibitor
complexes, it was previously suggested that differences in the side chain conformation of
BRD9F163 and the equivalent residue BRD7F158 determine the potency and selectivity of BI-9564.4,
28

However, comparison of BRD9 and BRD7 inhibitor complexes suggests that this residue adopts

multiple conformations even in different monomers comprising the asymmetric unit. Additionally,
the finding that BI-7273 is more potent and selective for BRD9 than BI-9564 (Fig. 3.4C) suggest
that the hydrophobic VDW interactions observed between BRD9F163 and BI-9564 are less
significant.
Novel co-crystal structures were also obtained for BRD7 with I-BRD9 (Fig. 3.5A), TP472 (Fig. 3.5D) and bromosporine (Fig. 3.5G) as well as for BRD9 with TP-472 (Fig. 3.5E).
Crystal structures of BRD9 liganded with I-BRD9 and bromosporine have been determined
previously9, 35, but we included a new data set of the BRD9-IBRD9 complex determined at higher
resolution (1.5 Å) for structural comparison with BRD7 (Fig. 3.5B). All three inhibitors showed
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the same principal interaction pattern, but slightly different conformation and positioning in the
respective KAc sites (Fig. 3.5C, F, I). These differences were not as pronounced as with BI-7273
and BI-9564 (Fig. 3.4E, F) and likely reflect the decreased selectivity of these compounds for
BRD9 over BRD7 particularly of I-BRD9 and bromosporine (Fig. 3.3C). TP-472 undergoes a
significant shift towards the critical asparagine in the KAc site of BRD9, likely strengthening Hbonding activity and explaining the observed increased selectivity for BRD9.
To further evaluate the structure-activity relationship of BRD9 inhibitors, we attempted
co-crystal structure determination with the first bromodomain of BRD4, a member of the
evolutionary distant BET family of bromodomain-containing proteins. BI-7273, BI-9564 and TP472 showed weak binding potential for the first bromodomain of BRD4 (BRD4-1) by DSF
corresponding to Kd values above 10 µM (data not shown). Novel co-crystal structures were
determined for BRD4 liganded with these inhibitors showing the same principal interactions of
the respective warheads with the critical asparagine side chain in the KAc site (BRD4N140) (Fig.
3.6). However, all three inhibitors undergo significant conformational changes upon binding to
BRD4, primarily caused by steric hindrance with the side chain of Trp81, which comprises the
WPF shelf characteristic of all BET bromodomains. The methoxyphenyl ring of BI-9564 rotates
180° to accommodate the ortho and meta methoxy groups, while the double-meta position of the
methoxy groups in BI-7273 forces the ring to rotate away from Trp81 due to steric hindrance (Fig.
3.6A, B). TP-472 and bromosporine undergo the largest conformational changes upon binding to
the BRD4 vs. BRD7 (Fig. 3.6C, D). The conformational changes of BI-7273, BI-9564 and TP472 suggest a loss of shape complementarity with the KAc site of BRD4, resulting in weak binding
potential. By contrast, the changed binding pose of bromosporine suggests a gain in shape
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complementarity, reflected by a substantial increase of binding potential for BRD4-1 (Kd = 42
nM35) over BRD7 (Kd = 390 nM).

Discovery of dual BRD7/9-kinase inhibitors
Although BRD9 has an essential role in malignant transformation by modulating the
functions of the BAF complex, it is not considered an oncogene. In cancer, altered BAF complexes
complement driver oncogenes such as PIK3CA, KRAS, c-Myc or ATR.23, 27, 36, 37 While BRD9
inhibition alone may be insufficient to elicit robust anti-cancer activity, the concomitant inhibition
of BRD9 and a kinase crucial for the survival of cancer cells may exert synergistic lethal effects.
We explored the potential of kinase inhibitors to interact with BRD7 and BRD9 by screening a
commercial library of 418 compounds against BRD9 using DSF. Three kinase inhibitors, TG003,
a Cdc2-like kinase (Clk2) inhibitor31, sunitinib, a multi-targeted tyrosine kinase inhibitor32, and
PF-477736, an inhibitor of cell cycle checkpoint kinase 1 (Chk1)33 were identified as potential hits
(Fig. 3.7A). These inhibitors showed small but reproducible temperature shifts against both BRD9
and BRD7 (Fig. 3.7B). The highest temperature shift was 2.1 °C as compared to 13.6 °C for
positive control BI-7273, suggesting relatively weak binding potential of kinase inhibitors for
BRD9. ITC binding studies established that BRD7 and BRD9 interact with TG003 in the low
micromolar range (Kd = 4 and 16 µM, respectively) (Fig. 3.7C). qPCR-based competition assays
confirmed that all three inhibitors bind to BRD7 and BRD9 with Kd values between 5 and 17 uM,
except sunitinib which was significantly less active against BRD9 (Fig. 3.7D).
Co-crystal structures of BRD7 and BRD9 liganded with TG003 show canonical H-bonding
interactions of the propanone moiety with the conserved asparagine residue (BRD7 N211 and
BRD9N216) (Fig. 3.8A, B). Several VDW interactions with residues of the flanks hold the inhibitor
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in place, of which π-stacking interactions between the ring system of TG003 and the side chain of
BRD7Y217 and BRD9Y222 are most prominent. The only difference between the KAc sites in the
unliganded and liganded states is a slight movement of this tyrosine towards the inhibitor.
Superposition of the two structures revealed almost identical positioning of the inhibitor in BRD7
and BRD9 (Fig. 3.8C). A co-crystal structure was also obtained for BRD9 liganded with sunitinib,
which binds to the KAc site in a non-canonical manner through H-bonding of the pyrrole amine
group with the main chain carbonyl oxygen of F160 (Fig. 3.8D). Thus, TG003 and sunitinib show
significantly different binding modes in the KAc site of BRD9 (Fig. 3.8E). Inhibitor PF-477736
resisted co-crystallization attempts due to low aqueous solubility.
A comparative analysis of the binding interactions in kinases and bromodomains was
performed using available co-crystal structures of TG003 in CLK238 and sunitinib in ITK39.
TG003 and sunitinib are Type I inhibitors that bind to the ATP site of kinases through H-bonding
interactions with main chain atoms of the hinge region. For TG003, the methoxy oxygen is the
hinge-binding group in CLK238 while it is solvent exposed in BRD9 (Fig. 3.8F). The propanone
group which is critical for binding to the KAc site in BRD7/9 is in H-bonding distance to a lysine
residue in CLK2, but this interaction is probably less significant for kinase inhibitory activity.
Thus, the functional groups primarily responsible for binding to the ATP and KAc sites are
different and positioned opposite to each other. Substitution of the methoxy group likely renders
the TG003 pharmacophore less active against CLK2 while maintaining activity against BRD7/9.
Similarly, modifications of the propanone moiety would reduce or eliminate binding potential for
BRD7/9 while maintaining activity against kinases. Sunitinib establishes multiple H-bonding
interactions with the hinge region of ITK through its indolinone and pyrrole moieties (Fig. 3.8G)39.

108

As the pyrrole amine also establishes the only H-bond in the KAc site, the simultaneous inhibition
of kinases and BRD7/9 is inherent to the sunitinib pharmacophore.

Discussion
As with kinase inhibitors targeting the ATP site, a major challenge in the development of
selective BRD inhibitors is the high similarity of the KAc site across bromodomain-containing
proteins. Known BRD9 inhibitors also inhibit the closely related BRD7, an unwanted off-target
due to its tumor suppressor properties.10, 40, 41 Previously, the structure-based design of reported
BRD9 inhibitors relied on co-crystal structure information of BRD9, but lacked structural details
on BRD7. We report the first crystal structures of BRD7 in unliganded and liganded states with
inhibitors of five different chemical scaffolds. New co-crystal structures were also determined of
BRD9 and BRD4. The data provide a comprehensive picture of the differences in binding
interactions of BRD9 inhibitors within and outside the BRD7/9 subfamily. Combined with
biochemical data from direct binding studies, a structural basis for the potency and selectivity of
diverse BRD7/9 inhibitors could be established. Although the KAc sites of BRD7 and BRD9 are
composed of identical residues, small differences in the overall structures of the bromodomains
appear to affect the conformation and positioning of inhibitors upon binding. The observed
differences in binding pose are caused by steric hindrance with surrounding, mostly nonpolar
residues. These changes may reflect loss or gain in shape complementarity of low energy
conformations of an inhibitor with the KAc site, resulting in differential binding potency for BRD7
and BRD9.
Several kinase inhibitors that also inhibit bromodomains have been identified for BRD4
and other BET bromodomains.42-44 Our discovery of first-in-class dual kinase-BRD7/9 inhibitors
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suggest that the biological activity of kinase inhibitors in development (TG003 and PF-477736)
and in clinical use (sunitinib) may in part be caused by concomitant inhibition of BRD7 and BRD9.
However, the bromodomain-kinase inhibitors identified in this work are significantly more potent
against the respective kinase targets than against BRD7 or BRD9. TG300 inhibits Clk1 and Clk4
with IC50 values of 20 and 15 nM, respectively31, about 250 times that of BRD7 (Fig. 1). Sunitinib
inhibits multiple tyrosine kinases with IC50 values below 10 nM32, about 1,000 times that of BRD7,
and PF-477736 inhibits Chk1 with a Ki of 0.49 nM33, about 20,000 times that of BRD7. In order
to exert a meaningful synergistic action of kinase and bromodomain inhibition in the cell, the
binding affinity of these inhibitors for BRD7 and/or BRD9 is insufficient. The structural data of
this work provide a new framework for the development of more potent dual kinase-BRD7/9
inhibitors based on the chemical scaffolds identified and beyond. Recent studies on potent BRD9
inhibitors against several cancer cell lines found only weak antiproliferative effects.4, 22, 27 While
inhibition of BRD9 alone may lack efficacy, the simultaneous inhibition of kinases of specific
signaling events could be beneficial in anti-cancer therapy.

EXPERIMENTAL SECTION

Protein expression and purification
The expression plasmid for BRD9 (Uniprot ID Q9H8M2) bromodomain (residues 134239) was from Addgene (plasmid 39012). DNA sequences encoding the human full length BRD7
(Uniprot ID Q9NPI1) were custom synthesized by GeneArt (Thermo Fisher Scientific) and BRD7
bromodomain (residues 129-250) were cloned in-frame of a modified pET15b vector providing an
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N-terminal hexa-histidine tag followed by a Tobacco Etch Virus (TEV) cleavage site. The encoded
bromodomain proteins were expressed in the BL21 (DE3) strain of E. coli.
Plasmids were transformed into E. coli cells and grown at 37 °C in LB medium (Fisher
Scientific) containing carbenicillin (0.1 mg/mL). At OD600 of 0.6, the culture was cooled down to
18 °C and induced with 0.1 mM IPTG. After 18 h growth, the culture was harvested by
centrifugation at 6,000 × g for 25 min and stored at -80 °C. Harvested cell pellets were resuspended in 50 mM Na/K phosphate buffer (pH 7.4) containing 100 mM NaCl, 40 mM imidazole,
0.01% w/v lysozyme and 0.01% v/v Triton X-100 at 4 °C for 1 h, subjected to sonication and the
lysate was clarified by centrifugation (30,000 × g for 45 min at 4 °C). Proteins were purified by
FPLC at 4 °C using columns and chromatography materials from GE Healthcare. The lysate was
subjected to an immobilized Ni2+ affinity chromatography column equilibrated with 50 mM Na/K
phosphate buffer (pH 7.4) containing 100 mM NaCl and 40 mM imidazole using a gradient from
40 to 500 mM of imidazole. Fractions containing the target protein were combined and incubated
for 2 – 16 h with TEV protease at 4 °C, and the cleaved His 6-tag was removed by a second Ni2+
affinity column. BRDs were purified to homogeneity by size exclusion chromatography using
Superdex 75. The elution buffers were 50 mM HEPES/100 mM NaCl/1 mM DTT (pH 7.5) for
BRD7 and 20 mM HEPES/150 mM NaCl/2 mM DTT (pH 7.5) for BRD9. BRDs eluted as
monomeric proteins and were of crystallization grade quality (> 95% purity as judged by SDSPAGE). BRD-containing fractions were combined, concentrated to 10 - 15 mg/ml and aliquots
were flash-frozen in liquid N2 and stored at -80 °C.
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Isothermal titration calorimetry (ITC)
All experiments were conducted using an ITC200 microcalorimeter from Malvern
Panalytical (Spectris PLC). BRD7 and BRD9 were buffer exchanged (Supplementary Table
S3.1) using PD10 columns (GE life sciences) before the experiments and concentrated to 6-10
mg/mL. Experiments were carried out in ITC buffer while stirring at 750 rpm, either in normal
titration method (BRD7) or reverse titration method (BRD9). The microsyringe (40 μL load
volume) was loaded with a solution of protein sample (150-300 μM protein in ITC buffer for
BRD9) or compound sample (150-600 μM compound in in ITC buffer for BRD7) and was inserted
into the calorimetric cell (0.2 ml cell volume), which was filled with the solution of compounds
(10-30 μM in ITC buffer) or protein (15-50 μM in ITC buffer). All titrations were conducted using
an initial control injection of 0.3 μl followed by 30 or 20 identical injections (1.58 or 2 μl per
injection) with a duration of 3.16 or 4 sec (per injection) and a spacing of 150 sec between
injections. The ratio of titrants in the titration experiments were optimized to ensure complete
saturation of the titrant (protein or compounds) in the cell before the final injection thus facilitating
the estimation of baseline for each injection. Experimental data were corrected by subtracting the
heats of dilution determined from independent titrations (protein into buffer for BRD9 or
compound into buffer for BRD7). The collected data were analyzed using MicroCal™ Origin
software provided with the ITC instrument to determine the enthalpies of binding (ΔH) and binding
constants (KB) as previously described (Wiseman et. al)

45.

Thermodynamic parameters were

calculated using the equation ΔG = ΔH - TΔS = -RTlnKB, where ΔG, ΔH and ΔS are the changes
in free energy, enthalpy, and entropy of binding, respectively. In all cases a single binding site
model was used. Dissociation constants and thermodynamic parameters are shown in Fig. 1C, D.
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Differential scanning fluorimetry (DSF)
DSF experiments were carried out in Applied Biosystem QuantStudio 6 Flex (compound
library screening) and StepOnePlus (thermal shift determination) real-time PCR system (Thermo
Fisher Scientific) using sealed 384-well or 96-well format plates, assayed in quadruplicate. To
obtain robust fluorescence signals, the assay was optimized regarding concentration of protein (4
μM for screening, 4.5 μM for thermal shift determination) and the fluorescence dye SYPRO
Orange (Invitrogen, Thermo Fisher Scientific) (5.5X for screening and 5X for thermal shift
determination). For library screening, dilutions of compound in assay buffer (50 mM HEPES pH
7.5, 150 mM NaCl, 2 mM DTT, 1% DMSO) were prepared using a Mosquito liquid dispenser
(TTP Labtech Ltd). Protein in assay buffer including fluorescence dye was mixed with 100 μM
compound and 2% DMSO in 20 μL reaction volumes. Reaction mixtures were heated from 25 °C
to 95 °C at 1 °C/min with fluorescence readings every 0.5 °C at 610 nm. The observed thermal
shift (∆Tm) was recorded as the difference between the Tm of sample and DMSO reference wells.

Crystallization and X-ray crystallography
All crystallization experiments were performed at 18 °C. Aliquots of purified BRD7 and
BRD9 were set up for crystallization using mosquito crystallization robot (TP Labtech). Initially,
coarse screens were set up using Greiner 3-well plates at three different concentrations of
precipitant to protein (200+400 nl, 300+300 nl, 400+200 nl) per condition. Conditions producing
crystals were further optimized and scaled up for the manual set up of 2 µl drops. For cocrystallization, compound was either pre-mixed with protein on ice or added to protein-reservoir
solution drops to achieve final concentrations of 1-2 mM compound and 5–10 % DMSO
(Supplementary Table S3.2). Crystals were cryoprotected using the well solution supplemented
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with ethylene glycol (15-30%) and flash frozen in liquid nitrogen. X-ray diffraction data were
collected at -180 °C at the beamlines 22-ID and 22-BM, SER-CAT, Advanced Photon Source,
Argonne National Laboratories, and in the Moffitt Chemical Biology Core using CuKα X-rays
generated by a Rigaku Micro-Max 007-HF X-ray generator, focused by mirror optics and equipped
with a Rigaku CCD Saturn 944 system. Data were reduced and scaled with XDS 46 or DIALS47 and
Aimless48. PHASER49 was employed for molecular replacement using PDB entry 3HME as search
model for both BRD9 and BRD7. Refinement was carried out with PHENIX 49 and model building
was performed with Coot.50 Initial models for the small molecule ligands were generated using
MarvinSketch (ChemAxon, Cambridge, MA) with ligand restraints from eLBOW of the
PHENIX49 suite. All structures were validated by MolProbity. Fig.s were prepared using PyMOL
(Schrödinger, LLC). Data collection and refinement statistics are shown in Supplementary Table
S3.3. The coordinates and structure factors have been deposited with the PDB.

KEYWORDS
Drug design, polypharmacology, kinase inhibitors, protein crystallography, isothermal
microcalorimetry, differential scanning fluorimetry
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PDB ID Codes
6PPA (apo), 6V1E (BI-7273), 6V1F (BI-9564), 6V1H (bromosporine), 6V17 (I-BRD9), 6V0Q
(TG003) and 6V16 (TP-472) for BRD7. 6UZF (apo), 6V14 (TP-472), 6V0X (sunitinib), 6V1B (IBRD9) and 6V0S (TG003) for BRD9. 6V1K (BI-7273), 6V1L (BI-9564), 6V0U (bromosporine)
and 6V1U (TP-472) for BRD4-1.
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FIGURES AND TABLES

Figure 3.1. Structures of BI-95464 (2) and BI-7273 (1) in comparison with previously
reported BRD9 inhibitors. The atoms labeled magenta directly interact with Asn100, the blue
highlighted methoxy moiety in BI-9564 determines increased selectivity for BRD9 over BRD7.
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Figure 3.2. Co-crystal structures reveal a subsite critical to the selectivity of inhibitors for
BRD9. (A, B) Detailed interaction patterns of the isomers BI-9564(2) and BI-7273(1) in the KAc
site of BRD9. Black dotted lines indicate H-bonding, green dotted lines VDW and π interactions,
and cyan spheres are water molecules. The arrow denotes the conformational change of Phe47 in
a subsite that appears to modulate BRD9 selectivity. (C-F) Surface presentations of structurally
aligned BRD9 complexes with BI-9564(2) (PDB: 5F1H), BI-7273(1) (PDB: 5EU1), I-BRD9
(PDB: 4UIW) and LP99 (PDB: 5IGN), respectively.
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Figure 3.3. Binding potential of inhibitors for BRD7 and BRD9. A) Chemical structures of
reported BRD9 inhibitors studied herein. B) Melting temperature shifts of BRD7 and BRD9 in the
presence of 100 µM inhibitor. C) ΔTm values determined by DSF and Kd values determined by
ITC and data correlation for BRD9 (blue) and BRD7 (red). For statistical analysis, r is the
Pearson’s correlation coefficient; asterisks indicate the significance of the two-tailed P value (α =
0.05). For graphical expression, data were fitted to semilogarithmic lines. D) Thermodynamic
parameters of inhibitor interactions with BRD9 (upper panel) and BRD7 (lower panel). ITC
conditions and thermograms are shown in Supplementary Table S3.1 and Figs. S3.1, S3.2.
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Figure 3.4. Differences in the overall structures of BRD7 and BRD9 affect the binding poses
of BI-7273 and BI-9564. A) Superposition of the crystal structures of BRD7 (beige) and BRD9
(cyan) in the unliganded state (PDB: 6PPA, 6UZF). Differing residues (red arrows) are located
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outside the KAc site, the critical asparagine residue (BRD7 N211 and BRD9N216) is drawn in
magenta. B) Comparison of the unliganded KAc sites of BRD7 and BRD9. Distances between
the flanks of the binding site are indicated as orange dotted lines (in Å). C) Co-crystal structure of
BRD7 with BI-7273 along with a schematic presentation of the binding interactions (PDB: 6V1E).
D) Same as C) for BI-7273 in BRD9 (PDB: 5EU1). E) Superposition of both structures. F) Cocrystal structure of BRD7 with BI-9564 (PDB: 6V1F) and G) of BRD9 with BI-9564 (PDB:
5F1H). H) Superposition of both structures. BRD7 residues are shown in beige and BRD9 residues
in cyan. H-bonding interactions are indicated as black dotted lines, VDW hydrophobic interactions
as green curved lines and π-stacking interactions as green dotted lines. Crystallization conditions
and data collection and refinement statistics are shown in Supplementary Tables S3.2, S3.3. 2FoFc and Fo-Fc omit electron density maps are shown in Supplementary Figs. S3.3, S3.4.
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Figure 3.5. Binding modes of I-BRD9, TP-472 and bromosporine in BRD7 and BRD9. A)
Co-crystal structure of I-BRD9 in BRD7 (PDB: 6V17) and B) in BRD9 (PDB: 6V1B). C)
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Superposition of both structures. D – F) Same as A – C) for TP-472 (PDB: 6V16 and 6V14). G –
I) Same as A – C) for bromosporine (PDB: 6V1H and 5IGM). Except for the BRD9-bromosporine
complex, all structures were determined experimentally (Supplementary Table S3.3). 2Fo-Fc and
Fo-Fc electron density maps are shown in Supplementary Figure S3.3, S3.4.
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Figure 3.6. Binding modes of BRD7/9 inhibitors in BRD4. A) Co-crystal structure of BI-7273
with BRD4-1 (PDB: 6V1K) and superposition with the BRD7/BI-7273 complex (PDB: 6V1E).
B) Same as A) for BI-9564 (PDB: 6V1L and 6V1F). C) same as A) for TP-472 (PDB: 6V1U and
6V16). D) Same as A) for bromosporine (PDB: 6V0U and 6V1H). All structures were determined
experimentally. Residues of BRD4 are shown in green and of BRD7 in beige. Inhibitor liganded
with BRD4 is shown in yellow and liganded with BRD7 in orange. 2Fo-Fc and Fo-Fc electron
density maps are shown in Supplementary Figure S3.5.
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Figure 3.7. Discovery of BRD7/9-kinase inhibitors. A) Chemical structures of kinase inhibitors
identified as ligands of BRD7 and BRD9. B) DSF temperature derivative plots for BRD7 and
BRD9 in the presence of 100 µM inhibitor. C) ITC thermograms of TG003 interaction with BRD7
and BRD9. D) Dissociation constants determined by qPCR assay (performed by DiscoverX) (N =
2).

124

Figure 3.8. Structural basis of BRD7/9 inhibition by kinase inhibitors. A) Co-crystal structure
of TG003 in BRD7 (PDB: 6V0Q) and B) in BRD9 (PDB: 6V0S). C) Superposition of both
structures. D) Co-crystal structure of BRD9 liganded with sunitinib (PDB: 6V0X). E)
Superposition of TG003 (yellow) and sunitinib (orange) bound to the KAc site of BRD9. F)
Comparison of the binding mode of TG003 in the ATP site of CLK2 (PDB: 6FYI) (left panel) and
the KAc site of BRD9 (right panel). The kinase hinge region is colored in orange and other kinase
residues are colored in pink. G) Comparison of the binding mode of sunitinib in the ATP site of
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ITK (PDB: 3MIY) (left panel) and the KAc site of BRD9 (right panel). 2Fo-Fc and Fo-Fc electron
density maps are shown in Supplementary Figs. S3.3, S3.4.
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SUPPLEMENTARY INFORMATION

Figure S3.1: ITC thermograms of BRD9-inhibitor complexes.
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Figure S3.2: ITC thermograms of BRD7-inhibitor complexes.

128

Figure S3.3. Electron density maps of inhibitors bound in the KAc site of BRD7. The 2Fo-Fc
density map upon refinement with ligand is shown in blue (contoured at 1σ). The Fo-Fc density
map upon refinement omitting the ligand is shown in red (contoured at 2σ).
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Figure S3.4. Electron density maps of inhibitors bound in the KAc site of BRD9.
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Figure S3.5. Electron density maps of inhibitors bound in the KAc site of BRD4.
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Table S3.1: ITC experimental conditions and thermodynamic parameters of inhibitor
interaction with BRD9 and BRD7.

Protein

BRD9

BRD7

[P]
[L]
Temperature
Kd
Ligand
Assay buffer
(µM)
(µM)
(K)
(nM)
150
BI7273
15
9.43 ± 1.6
150
BI9564
15
46.5 ± 4.6
50 mM HEPES (7.4),
150
I-BRD9
10
37 ± 2.1
150 mM NaCl, 0.05%
298.15
150
TP472
10
82 ± 4.8
Tween20
150 Bromosporine 15
113.5 ± 5.2
340
TG003
25
16,000 ± 2,400
15
15
50
15
15
25

BI7273
BI9564
I-BRD9
TP472
Bromosporine
TG003

200
200
20 mM Bis-Tris (6.4),
600
150 mM NaCl, 0.05%
200
Tween20
400
200
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283.15

121.1 ± 4.6
418.4 ± 29.9
147.7 ± 13.9
555.6 ± 26.98
392.2 ± 13.3
4,200 ± 350

1.02
1.01
1.12
1.00
0.96
1.05

ΔH
TΔS
ΔG
(kcal/mol)
-16.00 5.04 -10.96
-15.28 5.28 -10.00
-7.81 -2.33 -10.14
-13.10 3.43 -9.67
-11.10 1.63 -9.47
-7.48 0.94 -6.54

1.02
0.95
1.01
0.93
0.99
0.97

-7.03
-6.65
-1.66
-7.21
-6.13
-6.60

N

-1.94
-1.61
-7.19
-0.89
-2.27
-0.37

-8.97
-8.27
-8.85
-8.10
-8.41
-6.97

Table S3.2. Crystallization conditions for BRD9, BRD7 and BRD4.

Protein

Protein buffer

[ Protein ]
mg/mL

Ligand

Apo
0.02 M HEPES (pH7.5),
0.15 M NaCl, 2 mM DTT

10

TG003

BRD9

0.05 M HEPES (pH 7.5),
0.1 M NaCl and 1 mM
DTT

BRD7

BRD4

0.05 M Na/K phosphate
(pH 7.4), 0.1M NaCl, 1
mM DTT

0.01 M HEPES (pH 7.5),
0.1M NaCl, 1 mM DTT

6

13.5

10

[ Ligand ] Crystallization conditions
mM
0.05 M (NH4 )2 SO4 , 0.05 M Bis-Tris (pH 6.5),
NA
30% Pentaerythritol ethoxylate (15/4
EO/OH)
0.2 M Li2 SO4 , 0.1 M HEPES (pH 7.5), 25%
2
w/v PEG 3,350

I-BRD9

1

0.1 M KSCN, 30% w/v PEG MME 2,000

Sunitinib

2

TP-472

1

0.2 M NaCl, 0.1 M Bis-Tris (pH 5.5), and
25% PEG 3350

Apo

NA

BI9564

1

BI7273

1

I-BRD9

1

TP-472

1

TG003

2

Bromosporine

1

BI7273

1

BI9564

1

TP472

1

Bromosporine

1
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0.05 M (NH4 )2 SO4 , 0.05 M Bis-tris (pH 6.5),
and 30 % Pentaerythritol ethoxylate
0.05 M (NH4 )2 SO4 , 0.1 M Bis-tris (pH 6.5),
and 30 % Pentaerythritol ethoxylate

0.1 M (NH4 )2 SO4 , 0.05 M Bis-tris (pH 6.5),
and 30 % Pentaerythritol ethoxylate

0.2 M (NH4 )2 SO4 , 0.1 M Tris (pH 8.5), and
25% PEG 3350

Table S3.3. X-ray data and refinement statistics.

Protein

BRD7

Inhibitor

Apo

BI7273

BI9564

Bromosporine

I-BRD9

TG003

TP-472

PDB ID

6PPA

6V1E

6V1F

6V1H

6V17

6V0Q

6V16

Ligand code

N/A

5SW

5U6

BMF

H1B

EAE

QMG

Data reduction
Space group

Unit cell
dimensions

C 2 2 21

C 2 2 21

C 2 2 21

C 2 2 21

P 21 21 21

P 1 21 1

P 1 21 1

a

71.30

71.73

71.49

71.43

41.10

59.97

47.08

b

99.36

108.49

108.71

109.02

64.75

36.78

33.50

c

37.83

36.12

36.65

36.90

96.11

118.96

76.56

α

90

90

90

90

90

90

90

β

90

90

90

90

90

101.77

98.45

γ
Resolution range (Å)
Unique reflections

90

90

90

90

90

90

90

31.67 - 1.77

54.24 - 2.3

32.32 - 2.0

19.92 - 1.93

38.59 - 2.05

35.07 - 1.69

46.57 - 1.9

(1.833 - 1.77)

(2.383 - 2.3)

(2.072 - 2.0)

(1.999 - 1.93)

(2.123 - 2.05)

(1.75 - 1.69)

(1.968 - 1.9)

13498 (1339)

6584 (653)

10019 (983)

11158 (1071)

16494 (1428)

56784 (5698)

18694 (1811)

Rmeas (% )

6.6 (35)

7.3 (36.4)

4.6 (33.2)

4.2 (35.2)

4.933 (31.48)

6.3 (32.1)

4.99 (12.9)

Completeness (% )

99.87 (100)

99.88 (99.85)

99.74 (99.9)

99.43 (99.81)

98.71 (88.53)

98.49 (99.35)

98.2 (95.17)

I/σI

20.3 (6.1)

20.6 (5.74)

28.8 (6.5)

19.8 (6.8)

9.1 (3.93)

Rwork (% )

17.77 (22.64)

20.8 (26.64)

21.71 (24.57)

20.09 (25.11)

20.89 (28.64)

17.97 (20.12)

18.82 (23.3)

19.71 (28.33)

24.94 (37.47)

24.88 (21.79)

23.46 (32.56)

24.14 (30.25)

21.51 (24.28)

22.16 (26.93)

a

Rfree (% )
Wilson B (Å2)

24.7 (4.9)
7.86 (2.31)
Structure refinement

20.0

27.6

30.2

31.6

32.6

19.7

22.5

all

27.0

32.9

37.9

43.1

46.1

28.8

31.5

protein

25.8

32.9

37.7

43.1

46.4

28.0

31.4

ligand

57.1

33.3

43.6

46.5

42.5

26.7

20.0

solvent

33.5

30.7

37.3

37.6

33.5

35.2

33.3

rmsdb bond lengths (Å)
rmsd angles (deg)

0.003

0.003

0.003

0.010

0.008

0.012

0.004

Average B (Å²)

Ramachandran

0.48

0.56

0.58

0.97

0.91

1.64

0.93

favored (%)

99.13

99.15

98.26

99.13

100.00

99.78

99.10

allowed (%)

0.87

0.85

1.74

0.87

0.00

0.22

0.90

outliers (%)

0

0

0

0

0

0

0

Values in paranthesis are for the highest resolution bins.
a

Rfree is Rcryst calculated for randomly chosen unique reﬂections, which were excluded from the refinement.

b

rmsd = root-mean-square deviation from ideal values.
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Table S3.3 continued

Protein

BRD9

Inhibitor

Apo

TP-472

Sunitinib

I-BRD9

TG003

PDB ID

6UZF

6V14

6V0X

6V1B

6V0S

Ligand code

N/A

QMG

B49

H1B

EAE
P 21 21 2

Data reduction
Space group

Unit cell
dimensions

P 21 21 21

P1

P 21 21 2

P 1 21 1

a

34.27

23.27

32.53

56.99

74.63

b

55.51

33.86

112.06

38.50

123.01

c

58.41

37.68

30.82

60.92

31.69

α

90

104.10

90

90

90

β

90

102.10

90

108.99

90.0

γ

90

105.91

90

90

90

40.24 - 1.75

30.85 - 1.7

31.24 - 1.5

30.01 - 1.5

35.71 - 2.4

(1.813 - 1.75)

(1.761 - 1.7)

(1.554 - 1.5)

(1.554 - 1.5)

(2.486 - 2.4)

Unique reflections

11749 (1142)

11089 (1047)

18319 (1758)

39482 (3932)

12054 (1169)

Rmeas (% )

6.8 (64.4)

2.6 (10.1)

1.24 (27.88)

5.3 (66.7)

3.848 (0.3321)

Completeness (% )

99.91 (99.83)

98.35 (92.49)

97.24 (95.39)

97.83 (98.65)

99.54 (99.15)

I/σI

23.96 (3.27)

30.9 (8.12)

23.79 (3.4)
Structure refinement

12.83 (1.98)

39.45 (8.33)

Rwork (% )

17.66 (23.13)

14.82 (16.94)

19.74 (22.84)

17.38 (24.01)

19.24 (28.24)

Rfree (% )

22.23 (32.06)

17.33 (29.04)

22.25 (28.69)

19.59 (27.9)

23 (27.21)

17.1

13.3

25.1

19.1

56.3

all

18.8

17.6

38.3

30.2

79.4

protein

16.6

16.6

37.9

29.3

79.6

ligand

36.9

13.6

36.9

23.5

67.5

solvent

29.1

24.8

41.6

36.4

63.3

0.007

0.005

0.006

0.011

0.009

Resolution range (Å)

2

Wilson B (Å )

Average B (Å²)

rmsd bond lengths (Å)
rmsd angles (deg)
Ramachandran

0.62

0.72

0.77

1.07

1.24

favored (%)

100.00

100.00

100.00

99.55

98.65

allowed (%)

0.00

0.00

0.00

0.45

1.35

outliers (%)

0

0

0

0

0
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Table S3.3 continued

Protein

BRD4

Inhibitor

BI7273

BI9564

Bromosporine

TP-472

PDB ID

6V1K

6V1L

6V0U

6V1U

Ligand code

5SW

5U6

BMF

QMG

Space group

P 21 21 21

P 21 21 21

P 21 21 21

P 21 21 21

a

37.51

41.94

38.85

37.50

b

46.59

51.29

42.99

44.42

c

78.81

52.51

79.07

78.31

α

90

90

90

90

β

90

90

90

90

γ

90

90

90

90

Data reduction

Unit cell
dimensions

39.4 - 1.75

32.47 - 2.1

29.1 - 1.4

29.37 - 1.73

(1.813 - 1.75)

(2.175 - 2.1)

(1.45 - 1.4)

(1.792 - 1.73)

Unique reflections

14506 (1426)

6960 (668)

26633 (2604)

14180 (1387)

Rmeas (% )

7 (37.5)

15.3 (57.1)

5.6 (37)

7.9 (32.4)

Completeness (% )

99.95 (99.93)

99.7 (99.85)

99.37 (98.56)

99.59 (99.93)

I/σI

22.57 (5.76)

Rwork (% )

17.56 (18.06)

17.12 (17.84)

16.8 (19.08)

16.83 (16.43)

Rfree (% )

21.39 (25.53)

22.6 (20.87)

18.63 (20.36)

19.86 (18.22)

Wilson B (Å2)

13.4

11.7

11.0

13.1

all

18.0

15.4

18.2

17.0

protein

17.1

15.3

17.3

16.1

ligand

12.5

17.5

10.6

18.4

solvent

24.7

16.8

26.9

26.1

rmsd bond lengths (Å)

0.006

0.008

0.006

0.006

rmsd angles (deg)

0.83

1.02

0.89

0.84

favored (%)

99.20

96.69

98.39

99.19

allowed (%)

0.80

3.31

1.61

0.81

outliers (%)

0

0

0

0

Resolution range (Å)

Average B (Å²)

Ramachandran

19.7 (8.12)
23.25 (5.67)
Structure refinement
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25.8 (14.4)

Table S3.4. Compound information

Compound

Vendor

Purity*

Product Information

Selleck

> 99%

https://www.selleckchem.com/products/bi-7273.html

> 99%

https://www.selleckchem.com/products/bi-9564.html

Name
BI7273

Chemicals
BI9564

Selleck
Chemicals

I-BRD9

Selleck

99%

Chemicals
TP472

Tocris

https://www.selleckchem.com/products/i-brd9gsk602.html

> 98%

https://www.tocris.com/products/tp-472_6000

> 99%

https://www.selleckchem.com/products/bromosporine.

Biosciences
Bromosporine

Selleck
Chemicals

TG003

Selleck

html
> 99%

https://www.selleckchem.com/products/tg003.html

> 99%

https://www.selleckchem.com/products/sunitinib.html

> 99%

https://www.selleckchem.com/products/pf-

Chemicals
Sunitinib

Selleck
Chemicals

PF477736

Selleck
Chemicals

477736.html
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CHAPTER 4: DEVELOPMENT OF DUAL BET-KINASE INHIBITORS

ABSTRACT

Inhibition of BET BRDs by small molecule inhibitors has emerged as a promising
therapeutic strategy to treat atherosclerotic cardiovascular diseases and cancers. However, BET
inhibitors are being used as a combination therapy in clinical trials, mostly in phase II, for sustained
and effective pharmacological benefits. Similar to the combination therapy, dual BET-kinase
inhibitors can provide synergistic pharmacological benefits by intervening in two disease
contributing pathways. In the first part of this chapter, we report the development of dual BETJAK2 inhibitor lead compounds as potential drug candidates for testing in preclinical disease
models. From the crystallographic studies and DSF binding assay, inhibitors were identified that
equipotently inhibit BRD4 and JAK2, one of which has preferential activity for JAK2 within the
JAK family of protein kinases. In the second part of this chapter, studying a set of
PLK1/ERK5/LRRK2 inhibitors against the BET BRDs we showed that tetrahydropteridinone and
pyrimidodiazepinone scaffold containing kinase inhibitors are dual BET-PLK1/ERK5 inhibitors.
Correlation studies with DSF and other binding assays establish that DSF can be used as a standalone assay to determine binding potential, and predict the binding affinity of small molecule
inhibitors for BETs. Combined, these studies offer dual BET-JAK2 lead compounds for preclinical
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investigation and provide a structural basis for developing a dual BET-PLK1/ERK5 inhibitor for
synergistic pharmacological benefit.

INTRODUCTION

Bromodomain and extraterminal domain or so-called BET proteins are a group of BRDcontaining proteins (BRD2, BRD3, BRD4 and BRDT) of the BRD family II that contain two BRDs
(BD1 and BD2 in tandem) in the N-terminus and an extraterminal domain (ET) in the C-terminus
(Fig. 4.1).1 Among the four BET family members, BRD4 and BRDT contain an additional Cterminal motif (CTM) that is absent in BRD2 and BRD3. Across the BETs, both the bromodomain
show high sequence homology as the inter-BET sequence identity for BD1 and BD2 are > 73%
and > 65%, respectively. However, inter-domain sequence conservation between the BD1 and
BD2 among the BETs are relatively low (sequence identity 36 – 43% only) (Fig. 4.1).2 Although
the individual BRD maintains a highly conserved bromodomain structural fold, large sequence
variations between the BD1 and BD2 even within the closely related family members indicate their
potentially distinct cellular and biological functions. A growing number of evidence showed that
BD1 of the BET proteins are largely involved in acetyl-lysine recognition on histones and thus
regulate epigenetic mechanisms whereas BD2 can recognize acetyl-lysine on histones as well as
on other proteins, and also mediate sequence specific DNA binding interactions indicating its
distinct role in the cellular processes than BD1.3-5 The ET domain and CTM are thought to play
role in BET biology through protein-protein interactions,6 but their precise functions are not clear
yet.
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A number of first-generation BET inhibitors, which potently inhibit the BET BRDs, are
currently being assessed in the clinic (Fig. 4.2). Phase I clinical trials with those inhibitors showed
a wide range of promising outcome and the recorded toxicities were satisfactory across the board,
but with moderate effectiveness.7, 8 Promising candidates are currently being studied in phase I,II
and phase III in combination therapy with a second drug such as JAK inhibitor, androgen blocker
and HMG-CoA inhibitor. A recurrent theme arising in the BRD drug development is that BRD
mediated transcriptional regulation via epigenetic process is somewhat independent of wellstudied signaling pathways in cancer and inflammatory diseases such as PD-1/PD-L1 and JAK2
signaling. The discovery of BRD inhibition by the clinical kinase inhibitor dinaciclib opened up
the opportunity to connect two distinct cellular processes with a dual inhibitor.9 Importantly, this
discovery led to significant efforts from academia and industry alike to validate the hypothesis that
kinase inhibitors those are in clinic or in preclinical stage can also inhibit BRD mediated epigenetic
events.10 In a follow up study our lab has reported that diverse kinase inhibitors can bind to the
KAc site of BRD4, particularly the potent pan-JAK kinase family inhibitor TG101209, its derivate
TG101348 (Fedratinib), a selective JAK2 inhibitor, and potent PLK1 inhibitor BI2536.11
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PART I: DEVELOPMENT OF DUAL BET-JAK2 INHIBITORS

Results and discussion

SAR study for hit to lead development
The SAR study for hit to lead development being reported here started with the hit
compound TG101209 and its early derivative compound 5 or SG3-179 (Table 1).12 In earlier
studies our lab has reported that diaminopyrimidine core scaffold of TG101209 (and TG101348)
mediates critical binding interactions both in BRD4 KAc site and JAK2 kinase hinge binding site
(Fig. 4.3). Therefore, the objective of this study was to develop a set of dual BET-JAK2 inhibitor
lead compounds with varying kinase inhibitory activity while improving or maintaining the
binding potency for BRD4 for studying in animal models. Encouraging early phase clinical data
of JAK2 inhibitors with various selectivity for the JAK kinase family members and recent FDA
approval of Baricitinib, Upadacitinib and Fedratinib show that JAK inhibitors with a wide range
of selectivity profiles are effective drug against one or multiple diseases with various JAK kinase
signaling. Therefore, developed inhibitors with a varied range of selectivity for JAK family
members but with added inhibition of BRD4 will be valuable drug candidate for myeloproliferative
diseases, particularly the nonresponsive subtypes of myelofibrosis (MF) and polycythemia vera
(PV). Towards the objective of this study, a number of diaminopyrimidine scaffold containing
derivatives were synthesized in collaboration with Nicholas Lawrence lab at Moffitt Cancer Center
and binding potential for BRD4 were assessed by DSF (See Fig. 4.4) for studied derivatives).
Based on the DSF data and co-crystal structure derived structural data, structure-guided approach
was used for lead optimization (Table 4.1).
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Modification of solvent exposed groups
We first focused on the partially solvent exposed C ring of the core and various substitution
in that ring to test whether modification can introduce new binding interactions of the compounds
with the KAc pocket surrounding residues without affecting the activity of the A/B ring core.
Among the various modifications of R3 (Fig. 4.4), N-methyl piperazine and N-methyl piperidine
showed the highest potency (∆Tm). Importantly, piperazine containing compounds showed poor
metabolic stability in the liver microsomal stability assay. Therefore, we focused mostly on the
piperidine group containing compounds. In the co-crystal structure, binding mode of the piperidine
containing one of the most potent compound MA9-060 (∆Tm = 14.6 °C and Kd = 43.5 nM by ITC,
see Table 4.1 and Supplementary Fig. S4.1) show the very same principle binding mode of the
core of the compound in the KAc site of BRD4 as was observed with TG101209 (Fig. 4.5A and
Fig. 4.3A). A pyrimidine nitrogen and an amine nitrogen of the diaminopyrimidine core interacts
with the conserved Asn140 through H-bonding and the second amine group connecting the A and
B ring mediates the third H-bond interaction with the amide oxygen of Pro82 main chain.
However, MA9-060 contains a reverse sulfonamide compared to TG101209, which allows the
extended tert-butyl group to place on the hydrophobic WPF-shelf for critical vdW interactions
with the WPF shelf residues as well as the Ile146 of the C⍺ helix of the BRD4. The residues on
the hydrophobic flank of BRD4 allow multiple hydrophobic interactions with the A, B, C ring
system. Thus, compound remains highly stabilized upon binding to the KAc site of BRD4. In the
C ring, N-methyl-piperidine in meta position in MA9-062 (Fig. 4.5B) instead of para position in
MA9-060 reduces the binding potential of MA9-062 (∆Tm = 11.2 °C), most likely due to small
rotation of the fluorobenzene ring (ring C) close to the Leu94 and Leu92 producing an unfavorable
orientation in the hydrophobic space. Interestingly, substitution with (N-ethoxy)pyrrolidine at the
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para position of ring C slightly increased the binding potential of compound MA9-169 (∆Tm =
15.1 °C). In MA9-169 bound structure (Fig. 4.5C), the orientation of the core and the fluorine
substituted C ring are identical to the optimum binding pose observed in MA9-060 and sulfone
group mediates two water mediated H-bonds with the main chain of Asp145. The flexible
ethoxypyrrolidine bends towards the hydrophobic flank residues and interacts with Leu94 through
vdW interactions. However, ethoxypyrrolidine group remains completely solvent exposed
indicating that potential vdW interactions are most likely transitional. We also tested a MA9-60
analogue with a pyridine C ring where the pyridine nitrogen is closest to the conserved Asn140
with the idea that electronegative nitrogen in the ring system could strengthen H-bonding
interactions with Asn140 (Fig. 4.5D). However, the derived compound PN1-064 did not show
higher potency (∆Tm = 13.7 °C) than MA9-060, though the pyridine nitrogen interacts with the
Ans140 and Asp144 through a surface water mediated H-bonding. Moreover, replacement of the
C ring with a pyrimidine heterocycle in MA10-174 to MA10-179 series nearly abolished the
binding potential for BRD4 (∆Tm = 0.9 – 2.8 °C) (Table 4.1). These modifications indicate that
pyridine C ring negatively affects the optimum inhibitor interactions with the KAc site and the
compensation from water mediated H-bond was marginal whereas pyrimidine C ring is not
tolerated in the KAc site at all. Thus, various modification on the solvent exposed groups on a
benzene C ring largely maintained the binding potency for BRD4.

Modification of core pyrimidine ring
Multiple diaminopyrimidine heterocycle containing epidermal growth factor receptor
(EGFR) family kinase inhibitors are FDA approved drugs13. Additionally, diaminopyrimidine
containing kinase inhibitors were reported to inhibit FMS-like tyrosine kinase 3 (FLT3), a well-
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validated drug target for acute myeloid leukemia (AML) and other hematologic malignancies 14.
Since TG101209 and its first generation derivatives, including SG3-179, are also
diaminopyrimidine compounds and showed inhibition of FMS-like tyrosine kinase 3 (FLT3) 12,
we wanted to modify the pyrimidine ring of the core with a pyridine to avoid the possibility of
adversely inducing myelosuppression from FLT3 inhibition. Importantly, diaminopyridine
scaffold containing dual BET-kinase inhibitors would also be new chemical matter inhibiting two
protein targets. However, diaminopyridine containing SY3-005 significantly loses its binding
potential for BRD4 (∆Tm = 6.1 °C). A similar trend was also observed consistently with other
diaminopyridine derivatives such as MA9-037 (∆Tm = 6.6 °C), SY3-016 (∆Tm = 5.5 °C), SY3030 (∆Tm = 6.3 °C), MA9-024 (∆Tm = 4.1 °C) and MA9-036 (∆Tm = 6.9 °C) (Tabel 1). Co-crystal
structure of BRD4/ SY3-005 shows that SY3-005 binds in the KAc site of BRD4 in a very similar
fashion as observed for MA9-060 (Fig. 4.6). Although diaminopyridine derivatives interact with
BRD4 similarly as diaminopyrimidine derivatives (Fig. 4.6B), significantly reduces H-bond
potential indicating that the electronic state of pyridine vs pyrimidine is unfavorable. Notably,
these pyridine containing compounds also showed significantly weaker inhibitory activity for
JAK2 and FLT3 (data collected by the Lawrence lab).

Modification of functional groups interacting with WPF-shelf
The hydrophobic WPF-shelf conserved in BETs as well as some other BRDs plays a
critical role in inhibitor binding and stabilization of the BRD-inhibitor complexes. Significance of
the WPF-shelf vdW interactions are well-understood from the binding of SR3-169 to BRD4. SR3169 is an MA9-060 analog where the sulfonamide group is replaced with a methyl-sulfone (Fig.
4.7). This small change in the compound structure results in significant reduction in binding
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potency (∆Tm = 9.9 °C, Table 1). Solved co-crystal structure of BRD4/SR3-169 show that SR3169 binds to the KAc site of BRD4 in a near identical fashion as MA9-060 except that the tertbutyl sulfone is slightly shifted over the WPF-shelf, most likely due to the difference in C–S bond
length in methylsulfone (-CH2-S(O)2-) of SR3-169 in contrast to N–S bond length in sulfonamide
(-NH-S(O)2-) of MA9-060.

Modification of the methyl group in ring A
KAc binding site of the BRD4 is a deep pocket which remains occupied by 5-6 structurally
conserved water molecules while small molecule inhibitor binds to the upper side of the pocket.
Perturbation of such intricate network of bound water molecules usually comes with a large
energetic unfavourability. Based on computational studies it was hypothesized that displacing
those water molecules by the polar functional groups of a bound inhibitor could improve the
binding potency for bromodomain.15 To test the hypothesis, we designed a number of derivatives
where the methyl group of diaminopyrimidine ring (called A-methyl from onward) was substituted
with various polar functional groups, and studied their structure activity relationship. However,
any modification in place of A-methyl significantly reduces the binding potential for BRD4. As
example, PN1-50, a derivative of MA9-060, where A-methyl is substituted with -CF3 showed low
∆Tm (=10.4 °C). BRD4/PN1-50 structure (Fig. 4.8A) shows that although placement of PN1-50
in the KAc site of BRD4 is identical to that of MA9-060, bulky -CF3 group positioned inside the
pocket pushes the Phe83 away and does not allow the Pro82 of WPF-shelf to interact with
diaminopyrimidine nitrogen through H-bond (distance, d = ~3.7Å) (Fig. 4.8A,B). Substitution of
the A-methyl with an electron rich heterocycle ring system N-methyl pyrazole in PN1-145 severely
affects the binding potential for BRD4 (∆Tm =7.2 °C). BRD4/PN1-145 crystal structure shows
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that binding pose of PN1-145 in the KAc site is slightly different than MA9-060 (Fig. 4.8D).
Although pyrazole nitrogen interacts with Met105 deep inside the pocket through a water-bridged
H-bond, placement of methyl pyrazole inside the pocket leads to a slight rotation of the whole
compound and does not allow H-bonding with Pro82 (distance, d = ~3.6Å). Moreover, methyl
pyrazole displaces two structurally conserved water molecules at the bottom of the KAc site, which
most likely perturbs the stability of KAc site leading to significant loss of binding potential. Effect
of KAc site water perturbation becomes clear when we compare the binding of PN1-145 with that
of MA9-060 (Fig. 4.8D) where four structurally conserved water molecules form extensive Hbond network with the polar group of KAc site residues. Importance of KAc pocket water network
become more evident in BRD4 bound PN1-134 structure (Fig. 4.8E). In PN1-134, A-methyl group
is substituted with a polar acetamide group. Overall binding pose of PN1-134 is very same as PN1145 and slightly different than MA9-060 except that smaller acetamide functional group does not
displace any structurally conserved water molecules rather it interacts with all four water
molecules through H-bonding. Although PN1-34 maintains the overall binding pose in the KAc
site and shows extensive H-bonding with KAc site water molecules, due to lack of H-bonding with
the WPF-shelf Pro82 and unfavourability of the polar group acetamide at the depth of KAc site it
shows slightly weaker binding potential (∆Tm =13.8 °C) than MA9-060.

Most potent inhibitor MA9-169 and PN2-122
Among all the tested compounds with diaminopyrimidine scaffold MA9-169 and PN2-122
showed the highest potency with ∆Tm = 15.1 °C and 15.2 °C, respectively. Both the MA9-169 and
PN2-122 (Fig. 4.5C and Fig. 4.9A) are close analogue of MA9-060 (Fig. 4.5A). MA9-169
contains the same solvent exposed group as Fedratinib (Table 4.1) whereas PN2-122 contains a
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meta difluoro substitution on the partially solvent exposed C ring. Binding pose of PN2-122 is
identical to MA9-060 except that an additional fluorine in the meta position of C ring nicely
complements the shape above the conserved asparagine (Fig. 4.9B). We have consistently
observed that all meta-difluoro substitution in the C ring has slightly higher potency compared to
its exact analogue with meta-fluoro substitution. Since the solvent exposed flexible methylpiperidine group can easily rotate or freely move in the solvent, this may cause an applied torsional
force on the C ring. Difluoro-benzene ring in that particular position most likely works as a restrain
to prevent such compound movement and contributes to stable binding of the compound in the
KAc site.

Structural basis of the preferential selectivity of the dual BET-JAK2 inhibitors for BRD4 vs JAK2
We have assessed the promising BET/JAK2 inhibitors for their binding potential and
selectivity against JAK2 family members (by Reaction Biology or DiscoverX). Among all the
derivatives, MA9-086 showed preferential selectivity for JAK2 (Kd = 1 – 10 nM) compared to
JAK1/3 (Kd = 180/400 nM) and Tyk2 (Kd = 65 nM) whereas both the MA9-060 and PN2-122
maintained the potency for JAK2 but with less selectivity (JAK2 Kd = 1 – 10 nM; JAK1/3 Kd =
195/270 nM; and Tyk2 Kd = 65 nM). We determined the crystal structure of BRD4 with MA9086 and JAK2 JH1 kinase domain with MA9-086 and PN2-123 (unpublished data on JAK2 by
Ryan Davis, Schonbrunn lab). MA9-086 showed slightly lower binding potential (∆Tm =13.5 °C)
than PN2-122 (∆Tm =15.2 °C). Structural comparison of the BRD4 bound complexes of these two
compounds (Fig. 4.10A) show that five-membered fused ring with sulfonamide nitrogen and B
ring rigidifies the compound MA9-086 on WPF shelf. WPF shelf Trp81, as seen in PN2-122 bound
state (gray), moves away to avoid steric clashes with five membered ring as well as methyl group
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as shown with an arrow in Fig. 4.10A. This small structural changes in the critical WPF shelf
comes with a slight reduction of binding potency of MA9-086 for BRD4. Interestingly, this fused
ring sulfonamide allows two additional H-bond interactions in JAK2 kinase at the opposite site of
hinge binding region (Fig. 4.10B). Comparison of the JAK2 bound PN2-123 with MA9-086
indicate that conformational differences between flexible sulfonamide and fused ring sulfonamide
most likely results in reduced binding potency of MA9-086 for other JAK kinase family members
producing a preferential selectivity for JAK2.

BET/JAK2 inhibitor leads
Based on our structure-guided design focusing on BRD4 and binding potential assessment
against JAK2 family members, PN2-122, MA9-060 and MA9-086 were selected as potential lead
compounds to be studied in cell line modes and animal models. We have tested the early lead
compounds of this series ( named SG3-179 and MA4-22-2)12, where they equipotently inhibited
the other BET BRDs. Therefore, these inhibitors are BET inhibitors in general. Dual BET/JAK2
inhibitors PN2-122 and MA9-060 will be useful to simultaneously intervene BRD4 mediated Myc
signaling pathway and JAK family kinase mediated STAT3, IL-6, IL2/4 and IFNɣ signaling
pathway (Fig. 4.11). To study the effect of preferential JAK2 inhibition in myeloproliferative
diseases over the other JAK family members MA9-086 will be a useful candidate for preclinical
studies.
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EXPERIMENTAL SECTION

Protein expression and purification
The expression plasmid for human BRD4 (Uniprot ID O60885) 1st bromodomain
(residues 44-168) was from Addgene (plasmid 38942). The encoded bromodomain proteins were
expressed in the BL21 (DE3) strain of E. coli.
Plasmids were transformed into E. coli cells and grown at 37 °C in LB medium (Fisher
Scientific) containing carbenicillin (0.1 mg/mL). At OD600 of 0.6, the culture was cooled down
to 18 °C and induced with 0.1 mM IPTG. After 18 h growth, the culture was harvested by
centrifugation at 6,000 × g for 25 min and stored at -80 °C. Harvested cell pellets were resuspended in 50 mM Na/K phosphate buffer (pH 7.4) containing 150 mM NaCl, 40 mM imidazole,
0.01% w/v lysozyme and 0.01% v/v Triton X-100 at 4 °C for 1 h, subjected to sonication and the
lysate was clarified by centrifugation (30,000 × g for 45 min at 4 °C). Proteins were purified by
FPLC at 4 °C using columns and chromatography materials from GE Healthcare. The lysate was
subjected to an immobilized Ni2+ affinity chromatography column equilibrated with 50 mM Na/K
phosphate buffer (pH 7.4) containing 150 mM NaCl and 40 mM imidazole using a gradient from
40 to 500 mM of imidazole. Fractions containing the target protein were combined and incubated
for 2 – 16 h with TEV protease at 4 °C, and the cleaved His6-tag was removed by a second Ni2+
affinity column. BRD4 were purified to homogeneity by size exclusion chromatography using
Superdex 75. The elution buffers were 10 mM HEPES/100 mM NaCl/1 mM DTT (pH 7.5). BRD4
eluted as monomeric proteins and were of crystallization grade quality (> 95% purity as judged by
SDS-PAGE). BRD-containing fractions were combined, concentrated to 15 mg/ml and aliquots
were flash-frozen in liquid N2 and stored at -80 °C.

155

Differential scanning fluorimetry (DSF)
DSF experiments were carried out in Applied Biosystem StepOnePlus (thermal shift
determination) real-time PCR system (Thermo Fisher Scientific) using 96-well format plates,
assayed in quadruplicate. To obtain robust fluorescence signals, the assay was optimized regarding
concentration of protein (4.5 μM for thermal shift determination) and the fluorescence dye SYPRO
Orange (Invitrogen, Thermo Fisher Scientific) (5.5X for screening and 5X for thermal shift
determination). For thermal shift determination, dilutions of compound in assay buffer (50 mM
HEPES pH 7.5, 150 mM NaCl, 2 mM DTT, 20% DMSO) were prepared. Protein in assay buffer
including fluorescence dye was mixed with 100 μM compound and 2% DMSO in 20 μL reaction
volumes. Reaction mixtures were heated from 25 °C to 95 °C at 1 °C/min with fluorescence
readings every 0.5 °C at 610 nm. The observed thermal shift (∆Tm) was recorded as the difference
between the Tm of sample and DMSO reference wells.

Isothermal titration calorimetry (ITC)
ITC experiment was conducted using an ITC200 microcalorimeter from Malvern
Panalytical (Spectris PLC). BRDs were buffer exchanged in 50 mM HEPES pH 7.4, 150 mM NaCl
using PD10 columns (GE life sciences) before the experiments and concentrated to ~ 10 mg/mL.
Experiments were carried out in ITC buffer while stirring at 750 rpm in reverse titration method.
The microsyringe (40 μL load volume) was loaded with a solution of protein sample (150-350 μM
protein in ITC buffer) and was inserted into the calorimetric cell (0.2 ml cell volume), which was
filled with the solution of compounds (20-25 μM in ITC buffer). All titrations were conducted
using an initial control injection of 0.3 μl followed by 25 identical injections (1.52 μl per injection)
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with a duration of 3.04 sec (per injection) and a spacing of 150 sec between injections. The ratio
of titrants in the titration experiments were optimized to ensure complete saturation of the titrant
(protein or compounds) in cell before the final injection thus facilitating the estimation of baseline
for each injection. Experimental data were corrected by subtracting the heats of dilution
determined from independent titrations. The collected data were analyzed using MicroCal™
Origin software provided with the ITC instrument to determine the enthalpies of binding (ΔH) and
binding constants (KB) as previously described (Wiseman et. al) 16. Thermodynamic parameters
were calculated using the basic equation of thermodynamics (ΔG = ΔH - TΔS = -RTlnKB, where
ΔG, ΔH and ΔS are the changes in free energy, enthalpy and entropy of binding, respectively). In
all cases a single binding site model was used.

Crystallization and X-ray crystallography
All crystallization experiments were performed at 18 °C. Aliquots of purified BRDs were
set up for crystallization using mosquito crystallization robot (TP Labtech). Initially, coarse
screens were set up using Greiner 3-well plates at three different concentrations of precipitant to
protein (200+400 nl, 300+300 nl, 400+200 nl) per condition. Conditions producing crystals were
further optimized and scaled up for the manual set up of 2 µl drops. For co-crystallization,
compound was either pre-mixed with protein on ice or added to protein-reservoir solution drops
to achieve final concentrations of 0.5-2.5 mM compound and 5–10 % DMSO. An optimum cocrystallization condition consisting 100 mM Tris HCl (pH 8.5)/25% PEG 3,350, and 200 mM
ammonium sulphate or ammonium acetate or lithium chloride was used for most of the inhibitors.
Crystals were cryoprotected using the well solution supplemented with ethylene glycol (15-30%)
and flash frozen in liquid nitrogen. X-ray diffraction data were collected at -180 °C at the
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beamlines 22-ID and 22-BM, SER-CAT, or beamlines 23-ID, GM/CA, Advanced Photon Source,
Argonne National Laboratories, and in the Moffitt Chemical Biology Core using CuKα X-rays
generated by a Rigaku Micro-Max 007-HF X-ray generator, focused by mirror optics and equipped
with a Rigaku CCD Saturn 944 system. Data were reduced and scaled with XDS17 or DIALS18 and
Aimless19. PHASER20 was employed for molecular replacement using PDB entry 4O74 as search
model for BRD4. Refinement was carried out with PHENIX 20 and model building was performed
with Coot 21. Initial models for the small molecule ligands were generated using MarvinSketch
(ChemAxon, Cambridge, MA) with ligand restraints from eLBOW of the PHENIX 20 suite. All
structures were validated by MolProbity. Figures were prepared using PyMOL (Schrödinger,
LLC). The coordinates and structure factors of the structures are in process to be deposited with
the PDB.

PART II: CHARACTERIZATION OF DUAL BET-PLK1/ERK5 INHIBITORS

Results and discussion

Identification of dual BET-PLK1/ERK5 kinase inhibitor scaffolds
Motivated by the previous reports from our lab and the SGC (Structural Genomics
Consortium) that PLK1 inhibitors BI2536 and Volasertib strongly bind to BRD4, 11, 22 we tested
the binding potential of other available PLK1 inhibitors against BRD4. Our preliminary testing by
DSF showed thermal shift (∆Tm) of 8.2 °C by the pyrimidodiazepinone ring containing Ro3280
(Table 1). Based on this discovery and PLK1 related literature review, we identified similar
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scaffold-containing LRRK2-IN-1, a LRRK2 kinase inhibitor, and ERK5-IN-1 and XMD8-92, two
ERK5 kinase inhibitors, as potential BRD4 binders. 23, 24 In the DSF assay, they indeed showed
∆Tm of 6.4 – 8.5 °C with BRD4 indicating moderate to strong binding (Table 1). Chemical
structures of these six kinase inhibitors (Fig. 4.13) are classified into two classes of scaffold groups
– tetrahydropteridinone containing BI2536 and Volasertib, and pyrimidodiazepinone containing
Ro3280, LRRK2-IN-1, ERK5-IN-1 and XMD8-92 (Fig. 4.14). Using various biophysical and
biochemical methods, we further investigated the binding of these newly identified potential dual
BET-PLK1/ERK5 inhibitors along with few other known BET inhibitors including the SG3-179,
JQ1 and bromosporine (Fig. 1).

Characterization of dual BET-PLK1/ERK5 inhibitor binding to BET BRDs
We characterized the binding of these potential dual BET-PLK1/ERK5 inhibitors against
BRD4-1 and BRDT-1 using DSF, ITC, MST and qPCR-based competition binding assay
(BROMOscan® by DiscoveX). In ITC, these inhibitors showed a wide range of binding potency
against BRD4-1/BRDT-1 (Kd = 4.2 μM – 42 nM) whereas in MST and qPCR assay, the measured
binding affinities were somewhat different (Table 1). Therefore, to understand the variability
among the four different binding potential determination methods, we analyzed the correlation of
the binding potentials determined by these methods. Fig. 4.15, A–C demonstrates the significant
correlation of thermostability and binding affinity as independently determined by direct binding
assays using ITC, MST and qPCR applied for both BRD4-1 and BRDT-1. However, qPCR assay
performed by DiscoverX overestimates the binding affinity (Fig. 4.15D, E and Table 4.2), while
MST and ITC using crystallization grade proteins showed a nearly perfect relationship (Fig. 4F).
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Combined, the data demonstrate that BRDT-1 is about an order of magnitude less sensitive to these
inhibitors than BRD4-1.
In our correlation studies, ∆Tm from DSF correlated reasonably well with the Kd
determined by all three binding affinity determination assays. Therefore, we wanted to assess DSF
thermal shift assay for all 8 BET BRDs (from 4 different BET subclass members) and establish
the DSF as a benchmark assay for inhibitor binding potential determination due to its simplicity
and higher throughput capacity. Fig. 4.16, A-B show that thermal shift (∆Tm) from DSF and direct
binding affinities (Kd) by ITC of the kinase inhibitors follow a similar trend across the BETs.
Moreover, DSF ∆Tm and ITC Kd correlates well within BD1 or BD2 (Fig. 4.16C). From the
correlation, an equation was derived to predict the binding affinity Kd p from ∆Tm. Based on that
equation calculated predicted affinity Kd p matches to the experimental Kd fairly well except for
the two most potent ones (SG3-179 and JQ1) in some cases. This discrepancy is due to the
sensitivity of the ITC instrument, which is limited to around 30 – 50 nM, and therefore, compounds
with Kd lower than 50 nM could not be accurately measured by ITC.
In the DSF versus ITC benchmark study, we noticed that binding affinity of the inhibitors
were considerably weaker for both BRDT-1 and BRDT-2. To investigate the possible reason of
this phenomenon, we determined the binding affinity of these inhibitors for BRDT tandem
bromodomain (BRDT-T) construct comprising the both bromodomains. Interestingly, we found
that all the studied inhibitors bind to BRDT-T with higher affinity and stoichiometry N = ~2, but
for individual BRDT-1/2 the stoichiometry is N = ~1. Moreover, in case of BI2536, Ro3280 and
LRRK2-IN-1, binding potency against BRDT-T was 2 –16 fold higher than individual domains.
These data indicate synergism in binding between two bromodomains in BRDT-T compared to
that of individual bromodomains.
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Structural basis of dual BET-PLK1/ERK5 inhibitor binding to BET BRDs
We have obtained 28 new crystal structures of these kinase inhibitors, along with potent
BETi SG3-179 and bromosporine, complexed with various BET BRDs (Fig. 4.17). Binding mode
of the PLK1/ERK5 kinase inhibitors maintain the principle binding mode in the KAc site as
observed in BRD4 (Fig. 4.18). In BI2536 and Volasertib bound BRD4-1 crystal structures (Fig.
4.18), tetrahydropteridinone carbonyl directly interacts with the conserved asparagine Asn140
through H-bond and the aminopyrimidine nitrogen mediate H-bonds with structurally conserved
water molecules in the ZA channel, while the hydrophobic residues surrounding the binding pocket
including WPF-shelf (81-83), Val87 ,Leu92, Leu94, Tyr97, Tyr139 and Ile146 stabilize the
compound in the KAc site through a network of vdW interactions. Similar binding pattern is
observed for Ro3280 except that pyrimidodiazepinone, instead of pteridinone, carbonyl forms Hbond with Ans140. In benzopyrimidodiazepinone containing LRRK2-IN-1, ERK5-IN-1 and
XMD8-92, the observed binding modes were slightly different than the previous two scaffolds.
Diazepinone carbonyl seven member ring directly forms H-bond with Asn140 while benzene ring
fused to the diazepinone extensively interacts with the Ty139, Tyr97 and Leu94 through π-π and
π-σ interactions. However, the solvent exposed groups of the three compounds orient outside the
pocket with remarkable difference from each other. Since both the LRRK2-IN-1 and ERK5-IN-1
show significantly higher potency (Kd = 183 nM and 213 nM, respectively) compared to XMD892 (Kd = 735 nM), the bulky methylpiperazinyl-piperidine that is solvent exposed plays important
role for improved binding to the KAc site of BRD4. Similar overall binding pattern was observed
for other BETs as well (data not shown).
To better understand the conformational flexibility of the closely related kinase inhibitors
in the KAc site of BETs, we analyzed the compound positioning of these inhibitors (excluding
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XMD8-92 due to its smaller size and significantly weak binding) in BRD4-1 and BRDT-1. Fig.
4.19 shows that solvent exposed groups of the compounds markedly differ from each other in both
the KAc sites of BRD4-1 and BRDT-1, though the core scaffold of the compound is tightly placed
inside the binding pocket. Importantly, the conformation of the least potent inhibitor among the
group is always in opposite side outside of the pocket than the most potent one. However, the core
scaffold of the compounds is loosely aligned with each other in the KAc site of BRDT compared
to BRD4, which indicates a distinct nature of weaker interaction with BRDT. This could possibly
explain why binding interactions of the potent BET inhibitors are significantly weaker for BRDT
compared to all other BETs.
We also compared the relative flexibility of a kinase inhibitor across the BET BRDs (Fig.
4.20). Although conformation of the solvent exposed groups as well as the linker group of
tetrahydropteridinone derivatives (BI2536 and Volasertib) widely varies, the core scaffold of the
compound remains tightly positioned in the KAc site (Fig. 4.20B). Conformation of Ro3280 was
the least varied one among all the inhibitors, yet conformation of the solvent exposed group is
different for one BET from the others (Fig. 4.20). In ERK5-IN-1 and XMD8-92, conformational
variability of the bound ligand across BETs was most prominent (Fig. 4.20B). Importantly, for
both the ligand, the whole compound shifts and rotates inside the KAc binding site, which will
render some conformations very unfavorable for binding to certain BRD indicating possible
selectivity for a bromodomain within the BETs. The effect of conformational variability in the
kinase inhibitors becomes clearer when we compare the conformation of potent BET inhibitor
SG3-179 and bromosporine. SG3-179 and bromosporine bind to the BETs with an affinity range
of Kd = 38 – 158 nM (this study) and Kd = 50 – 172 nM25, respectively. Diaminopyrimidine core
of SG3-179 in the KAc site tightly aligns with each other in the three BET BRD bound structures
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(Fig. 4.21A). Whereas the whole bromosporine compound in the KAc site of five BETs perfectly
aligns onto each other (Fig. 4.21B). Combined, our study shows that conformational flexibility of
the solvent exposed groups of the studied dual BET-PLK1/ERK5 inhibitors in coordination with
the KAc site interacting core scaffold determines the binding potency and preferential selectivity
among the BET BRDs.

Cellular activity of dual BET-PLK1/ERK5 kinase inhibitors
To assess the dual inhibition of BET BRDs and PLK1/ERK5, Norbert Berndt and Suzie
Lee in our lab studied the inhibitors in MM1.S cancer cells. In cell proliferation assay, combined
inhibition of PLK1 and BRD4 produced higher antiproliferative effect (Fig. 4.22). The
antiproliferative potency (GI50 below 1 μM) for the compounds are BI2536 < Volasertib < Ro3280
< JQ1 < ERK5-IN-1 < LRRK2-IN-1 (Fig. 4.22A). Whereas in HEK293T antiproliferative effects
of the compounds corresponds to mostly PLK1 inhibitory potency as the antiproliferative potency
(GI50 below 1 μM) for the compounds are BI2536 < Volasertib < Ro3280 < JQ1 (Fig. 4.22B). As
expected, PLK1 inactive LRRK2-IN-1 did not show potent cell killing potential like Ro3280
though it near equipotently inhibits BRD4. Interestingly, inhibition of ERK5 kinase had some
antiproliferative effect on MM1.S cells, but very little to none on the HEK293T cells. In the BRD4
and PLK1 cellular pathway marker (c-Myc/p21Cip1 and pTCTP, respectively) analysis (Fig.
4.22A-C), compound treatment showed dose dependent c-Myc downregulation and p21Cip1
upregulation as BRD4 inhibitory effect and TCTP phosphorylation at Ser46 as PLK1 inhibitory
effect. In the c-Myc level assessment experiment in MM1.S cell line, we observed that ERK5-IN1 potently downregulated c-Myc level with higher potency than BI2536 (Fig. 4.22A), though its
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BRD4 inhibitory potency was much weaker than BI2536. We reason that this could be due to
ERK5 inhibition mediated instability and degradation of c-Myc as reported by a recent study.26

EXPERIMENTAL SECTION

Protein expression and purification
The expression plasmids for human BET bromodomain were from Addgene (see
supplementary Table S4.1 for details) or the DNA sequences encoding the BRDs were custom
synthesized by GeneArt (Thermo Fisher Scientific) and cloned in-frame of a modified pET15b or
pET28a vector providing an N-terminal hexa-histidine tag followed by a Tobacco Etch Virus
(TEV) cleavage site. The encoded bromodomain proteins were expressed in the BL21 (DE3) strain
of E. coli. Large scale E. coli growth, protein production and purification were conducted as before
(see protein expression and purification method of the experimental section in part I of this chapter,
see supplementary Table S4.1 further details).

Differential scanning fluorimetry (DSF)
DSF was conducted with the BET-PLK1/ERK5 inhibitors as described before ((see DSF
method of the experimental section in part I of this chapter).

Isothermal titration calorimetry (ITC)
ITC experiment was conducted using an ITC200 microcalorimeter from Malvern
Panalytical (Spectris PLC). BRDs were buffer exchanged in 50 mM HEPES pH 7.4, 150 mM NaCl
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using PD10 columns (GE life sciences) before the experiments and concentrated to ~ 10 mg/mL.
Experiments were carried out in ITC buffer while stirring at 750 rpm in reverse titration method.
The microsyringe (40 μL load volume) was loaded with a solution of protein sample (150-400 μM
protein in ITC buffer) and was inserted into the calorimetric cell (0.2 ml cell volume), which was
filled with the solution of compounds (10-40 μM in ITC buffer) (see supplementary Table S4.2
for more details). All titrations were conducted using an initial control injection of 0.3 μl followed
by 19 identical injections (2.0 μl per injection) with a duration of 4 sec (per injection) and a spacing
of 150 sec between injections. The ratio of titrants in the titration experiments were optimized to
ensure complete saturation of the titrant (protein or compounds) in cell before the final injection
thus facilitating the estimation of baseline for each injection. Experimental data were corrected by
subtracting the heats of dilution determined from independent titrations. The collected data were
analyzed using MicroCal™ Origin software provided with the ITC instrument to determine the
enthalpies of binding (ΔH) and binding constants (KB) as previously described (Wiseman et. al)
16.

Thermodynamic parameters were calculated using the basic equation of thermodynamics (ΔG

= ΔH - TΔS = -RTlnKB, where ΔG, ΔH and ΔS are the changes in free energy, enthalpy and
entropy of binding, respectively). In all cases a single binding site model was used. Dissociation
constants and thermodynamic parameters are shown in Table 4.3.

Crystallization and X-ray crystallography
All crystallization experiments were performed at 18 °C. Aliquots of purified BRDs were
set up for crystallization using mosquito crystallization robot (TP Labtech). Initially, coarse
screens were set up using Greiner 3-well plates at three different concentrations of precipitant to
protein (100+200 nl, 200+200 nl, 200+100 nl) per condition. Conditions producing crystals were
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further optimized and scaled up for the manual set up of 2 µl drops. For co-crystallization,
compound was either pre-mixed with protein on ice or added to protein-reservoir solution drops
to achieve final concentrations of 0.5-2.5 mM compound and 5–10 % DMSO. For crystal soaking,
harvested crystals were transferred to 50 µl drop of harvesting buffer containing 0 – 1 mM
compound and 0 – 5% DMSO for two days. Crystals were cryoprotected using the well solution
supplemented with ethylene glycol (15-30%) and flash frozen in liquid nitrogen. X-ray data
collection on the crystals and structure solution was conducted as described before in part I of this
chapter. Figures were prepared using PyMOL (Schrödinger, LLC). The coordinates and structure
factors with the following PDB ID were deposited to PDB and rest are in process of deposition.

ANCILLARY INFORMATION

Key words
Dual BET-kinase inhibitor, BET, bromodomain, kinase, bivalent inhibitor, SAXS,
ternary complex, myeloproliferative disease, cancer

PDB ID codes
5V67: BRD4-1/Volasertib, 5VBR: BRDT-1/Volasertib, 5VBq:BRDT-1/BI2536, 5VBP:
BRD4-1/Ro3280, 5VBO: BRD4-1/LRRK2-IN-1, 4O74: BRD4-1/BI2536 (published11), 5F63:
BRD4-1/SG3-179 (published12).
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FIGURES AND TABLES

Figure 4.1. Domain maps of bromodomain and extraterminal domain (BET) proteins. BD1,
Bromodomain 1; BD2, Bromodomain 2; ET, Extraterminal domain; CTM, C-terminal motif.
Sequence identity within the BD1 (> 73%) or BD2 (> 65%) among the BETs are given inside the
common domain boundary shown as dashed gray lines, and the range of sequence identity (36 43%) between BD1 and BD2 is shown below.
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Figure 4.2. First generation BET inhibitors (BETis). A) Potent BRD4 inhibitor JQ1. B) BETis
in clinical trial phase I/II and phase III in combination with other drugs.

168

Figure 4.3. Binding mode of diaminopyrimidine scaffold-containing kinase inhibitor
TG101209 in BRD4 and JAK2. A) In the KAc site of BRD4-1, TG101209 directly interacts with
the side chain of conserved Asn140 (magenta) and the main chain of Pro82 through H-bonds
(PDB: 4O76). B) In the hinge binding site of JAK2, TG101209 interacts with the main chain of
Leu932 (orange) through direct H-bond (PDB: 4JI9). (A-B) H-bonding interactions are shown as
black dotted lines, and the water molecules are shown as light pink spheres. C) Schematics of the
interactions of TG101209 with BRD4 and (right) defining the A, B, C ring system containing
diaminopyrimidine core scaffold.
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Figure 4.4. Studied derivatives of the core scaffold. Color coded functional group for a given
substitution position showed the highest potency among the tested functional groups.
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Figure 4.5. Modification on the solvent exposed groups of the inhibitors largely maintains
the binding potential for the KAc site of BRD4. A) Binding mode of MA9-060 in the KAc site
of BRD4. Chemical structure of the compound is shown below the complex structure. B) Same as
(A) for MA9-062. C) Same as (A) for MA9-169. D) Same as (A) for PN1-064.
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Figure 4.6. Binding mode of diaminopyridine containing inhibitor in BRD4-1. A) Binding
interactions of SY3-005 in the KAc site of BRD4-1. B) Differential binding of SY3-005 compared
to MA9-060.
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Figure 4.7. Modification of the sulfonamide with alkyl sulfone in SR3-169 loses the critical
vdW interactions with WPF-shelf of BRD4. A) Binding mode of SR3-169 in the KAc site of
BRD4. B) Overlay of BRD4 bound SR3-169 and MA9-060 (orange).
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Figure 4.8. Modifications of the methyl group on ring A positioned inside the KAc site of
BRD4 perturb the WPF-shelf. A) Binding mode of PN1-50 in BRD4. B) Differential binding
mode of MA9-060 in BRD4 compared to PN1-50. C) Removal of structurally conserved water
molecules in the KAc site of BRD4 by PN1-145. D) KAc pocket waters in MA9-060 bound BRD4.
E) H-bond interactions of PN1-134 with the conserved water molecules in BRD4.
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Figure 4.9. Potent inhibitor PN2-122 binding in BRD4. A) Binding mode of PN2-122in the
KAc site of BRD4. Chemical structure of the compound is shown beside the structure. B) Shape
complementarity of PN2-122 in the KAc site of BRD4. BRD4 is shown as electrostatic surface
representation ranging from blue (+2 kT/e) to red (−2 kT/e) and PN2-122 is shown in yellow as
space filling model. Negatively and positively charged surfaces are indicated in red and blue,
respectively.
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Figure 4.10. Structural basis of the preferential selectivity of the dual BET-JAK2 inhibitors
for BRD4 vs JAK2. A) Overlay of BRD4 bound MA9-086 with PN2-122 (gray). B) Binding
mode of MA9-086 in the JH1 kinase domain of JAK2. D) Overlay of JAK2 bound MA9-086 with
PN2-123 (magenta). Chemical structures of MA9-086, PN2-122 and PN2-123 are shown beside
the structures for reference.
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Figure 4.11. Dual BET/JAK2 lead compounds. A) Chemical structure and binding affinities of
equipotent potent dual BET/JAK2 inhibitors. B) Chemical structure and binding affinities of potent
dual BET/JAK2 inhibitor with preferential selectivity for JAK2.
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Figure 4.12. Summary of SAR of BET/JAK2 inhibitors for BRD4.
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Figure 4.13. Chemical structures of the studied kinase and BET inhibitors.
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A

B

Figure 4.14. Dual BET-PLK1/ERK5 inhibitor scaffolds. A) Tetrahydropteridinone scaffold and
its derivatives. B) Pyrimidodiazepinone scaffold and its derivatives.

180

Figure 4.15. Binding potentials of kinase inhibitors for BRD4-1 and BRDT-1 determined by
different methods correlate well. (A - C) Correlation of thermostability and dissociation
constants determined by MST, ITC or qPCR. (D - F) Correlation of dissociation constants with
each other. For statistical analysis, r is the respective Pearson’s correlation coefficient; asterisks
indicate the significance of the two-tailed P value (α = 0.05). For graphical purposes, data were fit
to semilogarithmic (A-C) or log-log lines (D-F). The dotted line indicates an idealized 1:1
relationship between the respective dissociation constants.

181

Figure 4.16. DSF benchmarking against ITC. A) Thermal shift (∆Tm) chart of the studied
inhibitors for BET BRDs. Braille representation of ∆Tm for individual BRDs are shown at the
right. B) Same as (A) for binding affinity (Kd) data. C) Correlation of DSF ∆Tm and ITC Kd and
equation for Kd prediction from DSF. D) Chart for the predicted Kd from DSF and ratio of
predicted Kd p to experimental Kd.
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Figure 4.17. Crystal structures of various BET BRDs bound to the PLK1 kinase inhibitors.
PDB IDs are given below the structure for the published ones. (continued to next page)
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Figure 4.17. (continued) Crystal structures of various BET BRDs bound to the PLK1 kinase
inhibitors. PDB IDs are given below the structure for the published ones.
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Figure 4.18. Co-crystal structures of kinase inhibitors with BRD4-1. Shown are the binding
interactions of inhibitor (yellow) with residues of the KAc site (grey) and water molecules (cyan
spheres). Black dotted lines indicate potential hydrogen bonding interactions (d = 2.2 – 3.5 Å)
while green dotted lines indicate potential hydrophobic van-der-Waals (vdW) interactions (d = 3.3
– 4.0 Å). The conserved asparagine residue is highlighted in magenta. The blue mesh around the
inhibitor is the 2Fo-Fc electron density contoured at 1σ.
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A
Color labels
Yellow: BI2536
Cyan: Volasertib
Light pink: Ro3280
Green: ERK5-in-1
Pink: LRRK2-in-1
Most potent
Least potent

BI2536
Volasertib

B

BI2536

ERK5-in-1

Figure 4.19. Conformational freedom and constraints of kinase inhibitors in the KAc site of
BRD4-1 (A) and BRDT-1 (B).
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A

Tetrahydropteridinone core scaffold

BI2536

Volasertib

Light Pink: BRD2-1
Deep blue: BRD2-2
Blue: BRD3-1
Beige: BRD3-2
Gray: BRD4-1
Red: BRD4-2
Green: BRDT-1
Cyan: BRDT-2
Most potent (in group)
Least potent (in group)

B

Pyrimidodiazepinone core scaffold
Ro3280

ERK5-IN-1

LRRK2-IN-1

Figure 4.20. Conformational freedom and constraints of kinase inhibitors across BETs. A)
conformations of tetrahydropteridinone core scaffold containing BI2536 and Volasertib. B)
conformations of Pyrimidodiazepinone core scaffold containing Ro3280, ERK5-IN-1 and
LRRK2-IN-1.
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A

B
Light Pink: BRD2-1
Deep blue: BRD2-2
Purple blue: BRD3-1
Beige: BRD3-2
Grey: BRD4-1
Red: BRD4-2
Green: BRDT-1
Cyan: BRDT-2

Figure 4.21. Conformational freedom and constraints of potent BRD inhibitors. A)
conformations of SG3-179 bound to BETs. B) conformations of bromosporine bound to BETs.
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Figure 4.22. Cellular activity of dual BET-kinase inhibitors. (A) Growth inhibitory activity of
compounds against MM1.S cells (left panel, 72 h drug exposure, cell-titer blue assay) and effect
on c-Myc and p21 levels (right panel, 6 h drug exposure, immunoblotting). (B) Same as (A) using
HEK293T cells. (C) Levels of phospho-TCTP (PLK1i biomarker) were assessed in parallel with
BRD4i biomarkers to assess dual BRD4-PLK1 inhibitory activity in MM1.S cells (6h drug
exposure, immunoblotting).
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Table 4.1: List of compounds studied for SAR.

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

11 ± 0.1

PDB : 3MXF

SG3-179

13.9 ± 0.2

PDB : 5F63

3

Fedretinib (SG4-094B3)

9.2 ± 0.1

PDB : 4PS5

4

PN1-048.MSA**

6.6 ± 0.1

1.9

5

PN1-064

13.7 ± 0.1

1.5

6

PN1-118

11.6 ± 0.1

1.32

7

PN1-119**

2.4 ± 0.1

1.876

8

PN1-132**

12.9 ± 0.1

1.32

9

PN1-134

13.8 ± 0.2

1.32

10 MA3-072

9.4 ± 0.1

1.5

11 MA4-144-2***

0.6 ± 0.1

1.85

12 MA4-146-2**

3.3 ± 0.4

1.81

13 MA9-037.bisformate

6.6 ± 0.3

1.8

14 MA9-060

14.2 ± 0.1

1.55

15 MA9-062

11.2 ± 0.1

1.45

SI Compoud Name

Chemical
Structure

1

JQ1

(+) ve Control

2
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

16 MA9-086

13.5 ± 0.1

1.2

17 MA9-169.MSA

15.1 ± 0.1

1.7

18 MA9-177.MSA

12.9 ± 0.1

1.65

19 PN1-145

7.2 ± 0.2

1.5

20 PN1-50.MSA*

10.4 ± 0.1

1.8

21 PN2-118

13.1 ± 0.1

1.4

22 PN2-122

15.2 ± 0.1

1.5

23 SR3-169

9.9 ± 0.3

1.9

24 SR4-008

8.5 ± 0.2

1.65

25 SY3-005

6.1 ± 0.1

1.73

26 SY3-016

5.5 ± 0.1

1.5

27 PN1-101**

13.6 ± 0.1

ND

28 PN1-102

11.4 ± 0.2

ND

29 PN1-117

12.7 ± 0.1

ND

30 MA10-148.MSA

7.6 ± 0.1

ND

SI Compoud Name

Chemical
Structure
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

31 MA10-149.MSA

6.2 ± 0.2

ND

32 MA10-174

0.9 ± 0.2

ND

33 MA10-175

1.6 ± 0.2

ND

34 MA10-176

1.4 ± 0.2

ND

35 MA10-178

2.8 ± 0.2

ND

36 MA10-179.MSA

1.4 ± 0.1

ND

37 MA11-002

4.2 ± 0.1

ND

38 MA11-003

8.1 ± 0.1

ND

39 MA11-006

11 ± 0.1

ND

40 MA11-007

13.7 ± 0.1

ND

41 MA11-009.MSA

1.2 ± 0.1

ND

42 MA11-012*

3.9 ± 0.2

ND

43 MA11-016.MSA

13.6 ± 0.1

ND

44 MA11-016**

14.9 ± 0.1

ND

45 MA11-017

14.4 ± 0.1

ND

SI Compoud Name

Chemical
Structure
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

46 MA11-017.MSA

13.9 ± 0.1

ND

47 MA11-022.MSA*

10 ± 0.1

ND

48 MA11-032

5.1 ± 0.1

ND

49 MA11-035

5.2 ± 0.1

ND

50 MA11-102

8.7 ± 0.2

ND

51 MA11-103

5.2 ± 0.2

ND

52 MA11-104.MSA

7.3 ± 0.1

ND

53 MA3-066

8.2 ± 0.1

ND

54 MA3-066.MSA

7.7 ± 0.4

ND

55 MA3-072.MSA

9.3 ± 0.6

ND

56 MA4-022-2B3

12.1 ± 0.2

ND

57 MA4-144-2.MSA**

0.3 ± 0.1

ND

58 MA4-146-2.MSA**

3.7 ± 0.3

ND

59 MA9-024

4.1 ± 0.2

ND

60 MA9-036

6.9 ± 0.2

ND

SI Compoud Name

Chemical
Structure

193

Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

61 MA9-042

6.1 ± 0.1

ND

62 MA9-050

12.7 ± 0.1

ND

63 MA9-060B2.MSA

14.7 ± 0.1

ND

64 MA9-064

8.9 ± 0.1

ND

65 MA9-064.MSA

8.9 ± 0.1

ND

66 MA9-168.MSA

12.6 ± 0.1

ND

67 MA9-176.MSA

10.9 ± 0.1

ND

68 MA9-60B2.MSA

14.8 ± 0.1

ND

69 PN1-004.MSA**

5.1 ± 0.1

ND

70 PN1-005.MSA**

6.4 ± 0.2

ND

71 PN1-006.MSA**

6.7 ± 0.2

ND

72 PN1-007.MSA**

4.7 ± 0.2

ND

73 PN1-037.MSA**

6.8 ± 0.1

ND

74 PN1-038.MSA**

-0.5 ± 0.4

ND

75 PN1-039.MSA**

2.6 ± 0.2

ND

SI Compoud Name

Chemical
Structure
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

76 PN1-040.MSA**

1.7 ± 0.3

ND

77 PN1-138

7.6 ± 0.2

ND

78 PN1-140

9.6 ± 0.2

ND

79 PN2-064

1.1 ± 0.4

ND

80 PN2-080

12.7 ± 0.2

ND

81 PN2-081.MSA

12.3 ± 0.1

ND

82 PN2-084.HCl

14.5 ± 0.1

ND

83 PN2-089.MSA

12.9 ± 0.1

ND

84 PN2-091

11.5 ± 0.1

ND

13 ± 0.1

ND

86 PN2-103

12.4 ± 0.1

ND

87 PN2-104

12.5 ± 0.1

ND

88 PN2-116.MSA

12.2 ± 0.1

ND

89 PN2-117

11.1 ± 0.1

ND

90 PN2-123

14.8 ± 0.1

ND

SI Compoud Name
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

91 PN2-124

13.5 ± 0.1

ND

92 PN2-128.MSA

12.8 ± 0.1

ND

93 PN2-129.MSA

12.8 ± 0.1

ND

94 PN2-173

12.3 ± 0.1

ND

95 PN2-174

13.4 ± 0.1

ND

96 PN2-175

12.6 ± 0.1

ND

97 PN3-052

13.5 ± 0.1

ND

10 ± 0.1

ND

99 PN3-074

14.1 ± 0.1

ND

100 PN3-075

15.3 ± 0.1

ND

101 PN3-076

13.9 ± 0.1

ND

102 PN3-099.MSA

12.3 ± 0.2

ND

103 PN3-10.MSA

5.2 ± 0.1

ND

104 PN3-100.MSA

14.4 ± 0.1

ND

105 PN3-108.MSA

12.9 ± 0.1

ND

SI Compoud Name
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

7.9 ± 01

ND

107 PN3-115

10.2 ± 0.1

ND

108 PN3-117

10.3 ± 0.1

ND

109 SR3-159

8.4 ± 0.1

ND

110 SR3-162

7 ± 0.2

ND

111 SR3-167

9.3 ± 0.2

ND

112 SR4-018

2.8 ± 0.1

ND

113 SR5-156

8.7 ± 0.1

ND

114 SR5-158

7 ± 0.2

ND

115 SY3-016.MSA

4.9 ± 0.3

ND

116 SY3-026

2.3 ± 0.2

ND

117 SY3-030

6.3 ± 0.2

ND

118 SY3-032

2.6 ± 0.2

ND

119 SY3-034

10.7 ± 0.2

ND

120 SY3-036

3 ± 0.2

ND

SI Compoud Name

106 PN3-114.MSA

Chemical
Structure
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Table 4.1: List of compounds studied for SAR. (continued)

∆Tm
[ Avg. ± SEM ]
(°C)

Crystal structure
[ Resolution ]
(Å)

121 SY3-038

12.4 ± 0.1

ND

122 SY3-039

6.8 ± 0.1

ND

123 SY3-040

11.2 ± 0.1

ND

124 SG4-032

12.9 ± 0.1

ND

125 MA4-103

10.3 ± 0.1

ND

126 MA5-016-1**

12.9 ± 0.1

1.6

127 MA5-118

11.3 ± 0.1

1.5

SI Compoud Name

Chemical
Structure
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Table 4.2. Binding potential of kinase inhibitors for BRD4-1 and BRDT-1 and inhibitory
activity against liquid and adherent cell lines.
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Table 4.3. Binding affinities of dual BET/PLK1/ERK5 inhibitors for BET bromodomains
determined by ITC.

Protein

BRD4-1

[P]
(µM)

250

260

BRD4-2

260
250
260
300
310

BRD2-1

300
310
300

BRD2-2

300
300

BRD3-1

BRD3-2

BRDT-1

260

BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1
BI2536
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1
BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1
BI2536
RO3280
LRRK2-IN-1
ERK5-IN-1
SG3-179
BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1

270

BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1

250

BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1

400
383
BRDT-2
400

150
BRDT-T

Ligand

240
150

BI2536
Volasertib
RO3280
LRRK2-IN-1
ERK5-IN-1
XMD8-92
SG3-179
JQ1
BI2536
RO3280
LRRK2-IN-1
ERK5-IN-1
SG3-179

[L]
(µM)
20
10

Temperature
(K)

Kd
(nM)
112 ± 5
317 ± 17
266.7 ± 23.8
183 ± 14
213.2 ± 10.8
735 ± 38
53.7 ± 4.9
70.9 ± 6.6

N

ΔH
-11.20
-9.97
-11.61
-8.96
-9.62
-8.93
-8.77
-10.51

TΔS
(kcal/mol)
-1.74
-1.10
-2.64
0.08
-0.52
-0.56
1.15
-0.75

1.06
1.12
0.91
1.12
1.23
1.16
0.90
1.12

-9.46
-8.86
-8.97
-9.04
-9.10
-8.37
-9.92
-9.76

298.15

469.5 ± 31
862.1 ± 134
456.6 ± 30.6
205 ± 23.3
2350 ± 250
67.1 ± 16.5
89.3 ± 8.2

1.07
1.02
1.12
1.33
1.14
0.98
1.09

-4.40
-4.36
-5.25
-4.43
-3.89
-6.85
-5.81

4.23
3.91
3.40
4.68
3.79
2.93
3.82

-8.63
-8.27
-8.65
-9.11
-7.68
-9.78
-9.62

298.15

301 ± 16
358 ± 20
435 ± 23
296 ± 11
361 ± 12.8
680 ± 42
136 ± 18
110 ± 4.5

1.16
0.65
0.57
0.66
0.82
0.70
0.64
0.59

-8.48
-13.10
-13.33
-14.97
-11.79
-13.57
-10.90
-14.30

0.42
-4.29
-4.65
-6.08
-3.01
-5.16
-1.54
-4.83

-8.90
-8.81
-8.68
-8.89
-8.78
-8.41
-9.36
-9.47

298.15

591.7 ± 49
1270 ± 100
847.5 ± 71
418.4 ± 71
270.3 ± 50.8

1.13
1.06
0.93
1.25
1.20

-3.66
-5.96
-6.22
-4.33
-4.20

4.83
2.08
2.06
4.38
4.77

-8.49
-8.04
-8.28
-8.71
-8.97

298.15

176.4 ± 14.2
518.1 ± 23.6
367.6 ± 23.9
194.2 ± 14.8
207 ± 8.4
676 ± 44
41.7 ± 5.2
42.7 ± 5.6

1.04
1.06
1.00
1.15
1.11
0.92
0.83
0.92

-9.97
-8.88
-10.97
-10.08
-11.03
-9.95
-9.89
-11.56

-0.76
-0.31
-2.19
-0.92
-2.19
-1.53
0.18
-1.51

-9.21
-8.57
-8.78
-9.16
-8.84
-8.42
-10.07
-10.05

298.15

621 ± 66.3
500 ± 58.7
485 ± 65.7
310.6 ± 36.9
155.8 ± 12.6
1150 ± 120
38 ± 6.2
51.3 ± 8.1

1.14
0.88
0.78
0.90
1.09
0.90
0.85
1.08

-6.41
-6.54
-7.27
-7.70
-8.09
-7.04
-6.80
-7.87

2.05
1.89
1.35
1.13
1.19
0.90
3.28
2.07

-8.47
-8.43
-8.62
-8.83
-9.29
-7.95
-10.08
-9.94

298.15

806 ± 31
1700 ± 160
1800 ± 70
1700 ± 90
2100 ± 100
4200 ± 180
59.2 ± 4.6
188 ± 7

1.06
1.11
1.04
1.15
1.14
1.09
1.13
1.10

-13.34
-12.37
-12.27
-11.91
-12.15
-11.84
-13.38
-14.05

-5.01
-4.50
-4.44
-4.03
-4.41
-4.50
-3.52
-4.89

-8.33
-7.87
-7.83
-7.88
-7.74
-7.34
-9.86
-9.16

298.15

1560 ± 90
2020 ± 110
3250 ± 300
1330 ± 50
552 ± 31
4020 ± 120
157.7 ± 14.5
200 ± 10.6

1.17
1.11
1.00
1.13
1.16
1.09
1.10
1.04

-6.72
-7.33
-7.09
-7.22
-8.28
-7.04
-6.86
-8.99

1.20
0.44
0.40
0.79
0.25
0.32
2.42
0.15

-7.92
-7.77
-7.48
-8.02
-8.53
-7.36
-9.28
-9.14

298.15

348 ± 32.9
110.5 ± 6.3
571 ± 115
434.8 ± 46.3
55.9 ± 6.9

2.16
2.08
2.74
2.27
2.13

-8.58
-8.22
-6.37
-8.81
-7.88

0.23
-0.09
2.14
-0.13
2.02

-8.81
-8.12
-8.51
-8.68
-9.89

298.15
20

25
35
25
25
22.5
25
25

25

25

25

40
25

25

20
10

20

40
22.5
36
40

20
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ΔG

SUPPLEMENTARY INFORMATION

Supplementary Figure S4.1. Binding affinity determination of dual BET/JAK2 inhibitor
MA9-060 for BRD4 by ITC.
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Table S4.1. BET BRD protein production and purification.

BRDs

Uniprot
ID

BRD4-1 O60885

BRD4-2 O60885

BRDT-1

BRDT-2

BRDT-T

Q58F21

Q58F21

Q58F21

BRD2-1 P25440

BRD2-2 P25440

BRD3-1 Q15059

BRD3-2 Q15059

Expressi Express
on
ion
Lysis buffer
duration temp
(Hr)
(°C)

Cleavage
duration,
Temp &
ratio

2nd IMAC buffer
(after cleavage, if
applicable)

Final
protein
conc.
(mg/mL)

UNP
residues

Sequence for crystallization Addgene Expression
(seq portion from plasmid) plasmid # plasmid

Tag

44-168

SM^NPPPPETSNPNKPKRQTN
QLQYLLRVVLKTLWKHQFAW
PFQQPVDAVKLNLPDYYKIIKTP
MDMGTIKKRLENNYYWNAQ
ECIQDFNTMFTNCYIYNKPGD
DIVLMAEALEKLFLQKINELPTE
E

38942

pNIC28-Bsa4

N-term
K+Chlor
6xHis

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 100 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

50 mM Na/K
phosphate buffer (pH
50 mM HEPES (pH
7.4), 100 mM NaCl, 40 O/N, 4, 1:30 7.5), 100 mM NaCl,
mM imidazole (to 500
1mM DTT
mM gradient elution)

10 mM HEPES
(pH 7.5), 100
mM NaCl,
1mM DTT

12

333-460

SM^KDVPDSQQHPAPEKSSKV
SEQLKCCSGILKEMFAKKHAAY
AWPFYKPVDVEALGLHDYCDII
KHPMDMSTIKSKLEAREYRDA
QEFGADVRLMFSNCYKYNPP
DHEVVAMARKLQDVFEMRFA
KMPDE

38943

pNIC28-Bsa4

N-term
K+Chlor
6xHis

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 150 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

50 mM Na/K
phosphate buffer (pH
7.4), 150 mM NaCl, 40 O/N, 4, 1:30
mM imidazole (to 500
mM gradient elution)

50 mM HEPES
(pH 7.5), 150
mM NaCl,
2mM DTT

28

29-137

GAAS^TNQLQYLQKVVLKDL
WKHSFSWPFQRPVDAVKLQL
PDYYTIIKNPMDLNTIKKRLENK
YYAKASECIEDFNTMFSNCYLY
NKPGDDIVLMAQALEKLFMQK
LSQMPQEE

18

50 mM Na/K phosphate
buffer (pH 7.4) containing
100 mM NaCl, 20 mM
imidazole, 0.01% w/v
lysozyme and 0.01% v/v
Triton X-100

50 mM Na/K
phosphate buffer (pH
Same as IMAC
7.4), 100 mM NaCl, 20 O/N, 4, 1:30
buffer
mM imidazole (to 500
mM gradient elution)

50 mM Na/K
phosphate
buffer (pH
7.4), 100 mM
NaCl, 1 mM
DTT

12

266-378

GAAS^TVKVTEQLRHCSEILKE
MLAKKHFSYAWPFYNPVDVN
ALGLHNYYDVVKNPMDLGTIK
EKMDNQEYKDAYKFAADVRL
MFMNCYKYNPPDHEVVTMA
RMLQDVFETHFSKIPI

18

50 mM Na/K phosphate
buffer (pH 7.4) containing
100 mM NaCl, 20 mM
imidazole, 0.01% w/v
lysozyme and 0.01% v/v
Triton X-100

50 mM Na/K
phosphate buffer (pH
Same as IMAC
7.4), 100 mM NaCl, 20 O/N, 4, 1:30
buffer
mM imidazole (to 500
mM gradient elution)

50 mM Na/K
phosphate
buffer (pH
7.4), 100 mM
NaCl, 1 mM
DTT

12

2 - 416

GAAS^LPSRQTAIIVNPPPPEYI
NTKKNGRLTNQLQYLQKVVLK
DLWKHSFSWPFQRPVDAVKL
QLPDYYTIIKNPMDLNTIKKRLE
NKYYAKASECIEDFNTMFSNC
YLYNKPGDDIVLMAQALEKLF
MQKLSQMPQEEQVVGVKERI
KKGTQQNIAVSSAKEKSSPSAT
EKVFKQQEIPSVFPKTSISPLNV
VQGASVNSSSQTAAQVTKGV
KRKADTTTPATSAVKASSEFSP
TFTEKSVALPPIKENMPKNVLP
DSQQQYNVVKTVKVTEQLRH
CSEILKEMLAKKHFSYAWPFYN
PVDVNALGLHNYYDVVKNPM
DLGTIKEKMDNQEYKDAYKFA
ADVRLMFMNCYKYNPPDHEV
VTMARMLQDVFETHFSKIPIEP
VESMPLCYIKTDITETTGRENT
NEASSEGNSSDDSE

18

50 mM Na/K phosphate
buffer (pH 7.4) containing
150 mM NaCl, 20 mM
imidazole, 0.01% w/v
lysozyme and 0.01% v/v
Triton X-100

50 mM Na/K
phosphate buffer (pH
Same as IMAC
7.4), 150 mM NaCl, 20 6 hr, 4, 1:30
buffer
mM imidazole (to 500
mM gradient elution)

50 mM Na/K
phosphate
buffer (pH
6.9), 100 mM
NaCl, 1 mM
DTT

12

73-194

GRVTNQLQYLHKVVMKALWK
HQFAWPFRQPVDAVKLGLPD
YHKIIKQPMDMGTIKRRLENN
YYWAASECMQDFNTMFTNC
YIYNKPTDDIVLMAQTLEKIFLQ
KVASMPQEEQELVVTIPKN

65376

50 mM Na/K
phosphate buffer (pH
7.4), 100 mM NaCl, 40 O/N, 4, 1:30
mM imidazole (to 500
mM gradient elution)

10 mM HEPES
(pH 7.5), 100
mM NaCl,
2mM DTT

11

344-455

SM^GKLSEQLKHCNGILKELLS
KKHAAYAWPFYKPVDASALGL
HDYHDIIKHPMDLSTVKRKME
NRDYRDAQEFAADVRLMFSN
CYKYNPPDHDVVAMARKLQD
VFEFRYAKMPD

39074

10 mM HEPES
(pH 7.5), 100
mM NaCl,
2mM DTT

~15

24-144

SM^PEVSNPSKPGRKTNQLQY
MQNVVVKTLWKHQFAWPFY
QPVDAIKLNLPDYHKIIKNPMD
MGTIKKRLENNYYWSASECM
QDFNTMFTNCYIYNKPTDDIVL
MAQALEKIFLQKVAQMPQEE

306-416

SM^GKLSEHLRYCDSILREMLS
KKHAAYAWPFYKPVDAEALEL
HDYHDIIKHPMDLSTVKRKMD
GREYPDAQGFAADVRLMFSN
CYKYNPPDHEVVAMARKLQD
VFEMRFAKMP

Antibiotics

N/A

N-term
Modified pET15b
Carb+Chlor
6xHis

N/A

N-term
Modified pET15b
Carb+Chlor
6xHis

N/A

N-term
Modified pET15b
Carb+Chlor
6xHis

O/N

O/N

12 hr

IMAC buffer

50 mM Na/K
phosphate buffer
(pH 7.4), 150 mM
NaCl, 1mM DTT

50 mM Na/K
phosphate buffer
(pH 7.4), 100 mM
NaCl, 40 mM
imidazole (to 500
mM gradient
elution)
50 mM Na/K
phosphate buffer
(pH 7.4), 100 mM
O/N, 4, 1:30 NaCl, 40 mM
imidazole (to 500
mM gradient
elution)

SEC buffer

Modified pET28

N-term
6xHis- K+Chlor
SUMO

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 100 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

pNIC28-Bsa4

N-term
K+Chlor
6xHis

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 150 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

50 mM Na/K
phosphate buffer (pH
7.4), 150 mM NaCl, 40
mM imidazole (to 500
mM gradient elution)

38940

pNIC28-Bsa4

N-term
K+Chlor
6xHis

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 100 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

50 mM Na/K
phosphate buffer (pH
7.4), 100 mM NaCl, 40 O/N, 4, 1:30
mM imidazole (to 500
mM gradient elution)

10 mM HEPES
(pH 7.5), 100
mM NaCl,
2mM DTT

~15

38941

pNIC28-Bsa4

N-term
K+Chlor
6xHis

O/N

18

50 mM Na/K phosphate
buffer (pH 7.4), 100 mM
NaCl, 40 mM imidazole,
0.01% w/v lysozyme and
0.01% v/v Triton X-100

50 mM Na/K
phosphate buffer (pH
7.4), 100 mM NaCl, 40
mM imidazole (to 500
mM gradient elution)

10 mM HEPES
(pH 7.5), 100
mM NaCl,
2mM DTT

10
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50 mM Na/K
phosphate buffer
(pH 7.4), 100 mM
NaCl, 40 mM
imidazole (to 500
mM gradient
elution)
50 mM Na/K
phosphate buffer
(pH 7.4), 100 mM
O/N, 4, 1:30 NaCl, 40 mM
imidazole (to 500
mM gradient
elution)

Table S4.2. Crystallization conditions of the BET BRDs with inhibitors.

Protein

Protein buffer

BRD4-1

0.01 M HEPES (pH 7.5),
0.1M NaCl, 1 mM DTT

[ Protein ]
mg/mL

Crystallization
Method

12

Hanging drop
vapour diffusion

Ligand

[ Ligand ]
mM

XMD8-92
1

0.05 M HEPES (pH 7.5),
0.15 M NaCl, 2 mM DTT

28

Soaking

SG3-179

1

0.05 M Na/K phosphate (pH
7.4), 0.1M NaCl, 1 mM DTT

10

Hanging drop
vapour diffusion

LRRK2-IN-1

1

0.05 M CaCl2, 2H2O, 0.1 M Bis-tris (pH 6.5),
and 30 % v/v PEG MME 550

Bromosporine
0.05 M Na/K phosphate (pH
7.4), 0.1M NaCl, 1 mM DTT

10

Hanging drop
vapour diffusion

ERK5-IN-1

1

0.1 M TRIS hydrochloride pH 8.5, 2.0 M
Ammonium phosphate monobasic

BI2536
Volasertib
0.01 M HEPES (pH 7.5),
0.1M NaCl, 2 mM DTT

Sitting drop vapour
diffusion

RO3280
1
ERK-5-IN-1

Bromosporine

0.01 M HEPES (pH 7.5),
0.1M NaCl, 2 mM DTT

Sitting drop vapour
diffusion

RO3280

1

LRRK2-IN-1
Bromosporine

BRD3-1

BRD3-2

0.01 M HEPES (pH 7.5),
0.1M NaCl, 2 mM DTT

0.01 M HEPES (pH 7.5),
0.1M NaCl, 2 mM DTT

Sitting drop vapour
diffusion

0.1 M Sodium chloride, 0.1 M BIS-TRIS pH 6.5,
1.5 M Ammonium sulfate
60 % v/v Tacsimate pH 7.0
0.2 M Magnesium chloride hexahydrate, 0.1 M
BIS-TRIS pH 5.5, 25 % w/v Polyethylene glycol
3,350
0.2 M Trimethylamine N-oxide dihydrate, 0.1 M
Tris pH 8.5, 20 % w/v Polyethylene glycol
monomethyl ether 2,000
0.2 M Sodium chloride, 0.1 M BIS-TRIS pH 5.5,
25 % w/v Polyethylene glycol 3,350

BI2536

BRD2-2

3.5 M Sodium formate
0.2 M Magnesium acetate tetrahydrate, 0.1 M
sodium cacodylate trihydrate (pH 6.5), 20 %
w/v PEG 8,000

Volasertib

BRD2-1

0.2 M (NH4) 2SO4, 0.1 M sodium cacodylate
trihydrate (pH 6.5), and 30 % w/v PEG 8,000
0.2 M NaCl, 0.1 M Bis-Tris pH5.5, 25% w/v
PEG 3,350

Ro3280

BRDT-2

0.1 M Hepes (pH 7.5), 25 % w/v PEG 3,350,
0.01 M KCl
0.05 M (NH4)2SO4, 0.05 M Bis-tris (pH 6.5), and
30 % Pentaerythritol ethoxylate

ERK5-IN-1
BRDT-1

0.2 M Ammonium acetate, 0.1 M Sodium citrate
tribasic dihydrate pH 5.6, 30% w/v Polyethylene
glycol 4,000
0.2 M Ammonium sulphate, 0.1 M Tris (pH 8.5),
25 % w/v PEG 3,350

ERK5-IN-1

BRD4-2

Crystallization conditions

ERK5-IN-1

0.2 M Ammonium acetate, 0.1 M BIS-TRIS pH
5.5, 25 % w/v Polyethylene glycol 3,350
0.1 M HEPES 7.5, 2.0 M Ammonium sulfate
0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH
6.5, 25 % w/v Polyethylene glycol 3,350
0.1 M HEPES pH 7.5, 4.3 M Sodium chloride

1
SG3-179

0.2 M Ammonium sulfate, 0.1 M BIS-TRIS pH
5.5, 25 % w/v Polyethylene glycol 3,350

BI2536

0.1 M HEPES pH 7.5, 10 % w/v Polyethylene
glycol 6,000, 5 % v/v (+/-)-2-Methyl-2,4pentanediol

RO3280

0.2 M L-Proline, 0.1 M HEPES pH 7.5, 10 % w/v
Polyethylene glycol 3,350

Sitting drop vapour
diffusion

1

ERK5-IN-1
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0.12 M Alcohols (0.2M 1,6-Hexanediol; 0.2M 1Butanol, 0.2M 1,2-Propanediol; 0.2M 2Propanol; 0.2M 1,4-Butanediol; 0.2M 1,3Propanediol), 0.1MBuffer System 3 (pH 8.5 Tris
(base) and BICINE 1.0M each), 37.5%
v/vPrecipitant Mix 4 (25% v/v MPD; 25% PEG
1000; 25% w/v PEG 3350)
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CHAPTER 5: CHARACTERIZATION OF BIVALENT BET INHIBITORS

ABSTRACT

Although significant progress has been achieved in BET bromodomain drug discovery, the
development of a selective BET inhibitor that can distinguish among the four BETs remains a
major challenge. A bivalent inhibitor that is capable of intramolecularly engaging the tandem BRD
of a BET can be exploited to develop a potent and selective BET inhibitor. Among the two series
of bivalent inhibitors, studied here, bivalent inhibitor NC-III-49-1 of the NC-series showed
remarkable high potency and activity compared to its monovalent parent compound whereas the
potency of bivalent inhibitors of the GXH-series remained unchanged. Using the size exclusion
column coupled small-angle X-ray scattering (SEC-SAXS) technique along with the X-ray
crystallography, we demonstrated that NC-III-49-1 interacts with the tandem BRD of BRDT in an
intramolecular fashion. To our knowledge, this is the first report presenting direct evidence of
bivalent inhibitor intramolecularly engaging a tandem BRD using SEC-SAXS. Our structural
studies showed that bivalent inhibitors induce dimerization of BRD4-1 and BRDT-1 to form
ternary complexes of two protein molecules with one inhibitor. Dimeric states of the BRDs in the
ternary complexes were dictated by the BRD domains and inhibitor warheads, but not by the
compound linkers. Combined, these studies provide a structural basis of significantly improved
inhibitory activity of a bivalent inhibitor the knowledge of which will be useful for developing a
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potent and selective BET inhibitor. Moreover, the SEC-SAXS methodology used in this study
presents a direct means to characterize ternary complex formation by bivalent inhibitors.

INTRODUCTION

Bivalent inhibitors are chemicals or chimeras where two target binding ligands are
connected with a linker. By design, a bivalent inhibitor can be homomeric bivalent inhibitor,
bisubstrate (also known as homo-bimodal) inhibitor or heterobifunctional inhibitor (Fig. 5.1). In
homomeric bivalent inhibitor, two linked warheads engage two molecules of the same target
protein enforcing dimerization and resulting in improved activity or increased effective drug
concentration. Whereas in bisubstrate inhibitor, a target site binding ligand is connected with a
second ligand that engages a different site on the same target protein, thereby improving target
selectivity and binding kinetics. Both the homomeric and bisubstrate bivalent inhibitors are
designed to inhibit one target protein.1 By contrast, in heterobifunctional inhibitor, two linked
ligands engage two distinct target proteins to produce selective induced effect such as heterodimerization mediated inhibition (also called hetero-dimeric inhibition), substrate catalysis or
ubiquitylation mediated target protein degradation (so-called proteolysis targeting chimera or
PROTAC).2 Diverse homomeric and bisubstrate bivalent inhibitors have been developed targeting
various target proteins,3-5 which showed potent in vitro and in vivo inhibitory activity against the
target proteins.
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BET proteins recognize the acetyl-lysine on histones and other proteins through its two
bromodomains (BD1 and BD2) in tandem to exert epigenetic regulation.6 Therefore, a large
number of small molecule inhibitors of BET bromodomains have been reported in the last decade.
Some of the inhibitors showed potent activity in vitro and in vivo and reached the clinic for human
trials. 7 Because of high sequence homology and structural conservation among the BET BRDs
small molecule inhibitors cannot distinguish between BD1 and BD2, and show poor inter-BET
selectivity among the four BET members (BRD2, BRD3, BRD4 and BRDT). Only this year, BD1
and BD2 selective three BET inhibitors are reported where BD1 selective inhibitor phenocopied
the pan-BET inhibition and BD2 selective inhibitor distinctly intervened only the inflammation
related specific pathways.8, 9 However, developing an inter-BET selective inhibitor remained a
considerable challenge in the bromodomain drug discovery.
The objective of the development of bivalent inhibitors of BETs was to achieve high
potency and inter-BET selectivity.3, 4 Earlier success of bisubstrate bivalent inhibitor to selectively
inhibit a target protein kinase among the closely related kinases sets an example to utilize this
approach for BET inhibitors.1, 10 However, bisubstrate bivalent approach is not applicable for BETs
as there is no second binding site close to the KAc site, reported so far. Therefore, only homomeric
bivalent BET inhibitors have been developed with the idea that two warheads connected by a linker
could engage tandem bromodomain in an intramolecular or intermolecular fashion leading to
domain-domain interaction or BET protein oligomerization.4 The first two bivalent BET inhibitors
MT1 and AZD5153 engaged two molecules of BRD4-2 (BRD4 BD2) and BRD4-1 (BRD4 BD1),
respectively. Both the MT1 and AZD5153 showed remarkable high potency (< 1 nM) in BET
BRD engagement and in cell proliferation assay with hematopoietic cancer cells as well as in
animal model. However, MT1 showed even more potency for BRD2 and BRD3, whereas
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AZD5153 was not studied to explore its differential selectivity within the BET subclass. Moreover,
a number of other BET bivalent inhibitors have been designed during the development of these
two bivalent inhibitors, which showed poor tandem BRD engagement and only showed negligible
improvement in cellular potency. It was reasoned that perhaps the linker length and chemical
nature of the bivalent compounds resulted in poor cell penetrance and activity.3, 4 In a latest study
with bivalent inhibitor, it was shown that certain linker-containing homomeric bivalent BET
inhibitors could inhibit two BRDs of BRD4 by spatially constraining the tandem BRD construct
resulting in improved cellular efficacy and inhibited solid tumor (triple-negative breast cancer,
TNBC) cells growth.11

RESULTS AND DISCUSSION

Development of bivalent inhibitors of BETs
In collaboration with G. Georg lab at the University of Minnesota, MN, a series of bivalent
inhibitors of BETs was developed based on our previously reported potent BET inhibitor SG3179.12 Based on the SG3-179 bound crystal structure of BRD4-1, we realized that solvent exposed
piperidine group of SG3-179 could be utilized as an exit vector for linker development without
affecting the KAc site binding in BETs (Fig. 5.2A). In the GXH-series of homomeric bivalent
inhibitors, two monovalent warheads of SG3-179 were connected with a PEG (polyethylene
glycol) linker of variable size (Fig. 5.2B). Developed bivalent inhibitors GXH-II-052 and GXHII-083 showed negligible potency improvement in multiple myeloma (MM1.S) cell growth
inhibition assay compared to its monovalent inhibitor SG3-179 (Fig. 5.2C). Effects of the GXH-
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series bivalent inhibitors on c-Myc level (cellular readout of BRD4 inhibition) was also very
similar compared to its monovalent congener SG3-179 and control inhibitor JQ1 (Fig. 5.2D).
Unexpectedly, these cellular studies indicate that GXH-series of bivalent inhibitors were not more
potent than monovalent inhibitors. Large size of these bivalent inhibitor molecules could
potentially hamper cell penetration and activity thereof. We also experienced significant solubility
issues with these GXH-series compounds during our attempt of biophysical assays (DSF and ITC).
A second series of bivalent BET inhibitors was developed based on potent BRD4 inhibitor
NC-III-53-1 (Fig. 5.3A). The solvent exposed methoxy-chlorobenzene group of NC-III-53-1 was
used as linkage vector for connecting the second warhead with a PEG linker to develop homomeric
bivalent inhibitor NC-III-49-1(Fig. 5.3B). Satisfactorily, NC-III-49-1 showed markedly improved
growth inhibitory activity (GI50 < 0.001 nM) compared to its monovalent counterpart (GI50 = 0.008
nM) or JQ1 (GI50 = 0.064 nM) (Fig. 5.3C-D). Of the two bivalent inhibitor series studied, NC-III
showed markedly improved activity where GXH-series maintained the activity of monovalent
counterpart.

Bivalent inhibitors lead to ligand-induced dimerization of BRDs
It was reported that homomeric bivalent inhibitor MT1 and heterobifunctional inhibitor
dBET23, a PROTAC, both lead to ligand-induced chemical proximity of the target proteins. Based
on the characteristics of other similar bivalent inhibitors developed in the same studies it was
shown that certain bivalent inhibitors can lead to ligand-induced proximity of the target proteins
producing high potency and activity. 4, 13 In our study on the GXH-series and NC-series of bivalent
inhibitors, we also observed similar phenomenon where only NC-III-49-1 bivalent inhibitor is
significantly more potent than its monovalent inhibitor. Therefore, to better understand the
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underlying basis of differential potency between GXH-series and NC-III-49-1 bivalent inhibitors,
we have determined a number of co-crystal structures of both types of bivalent inhibitors
complexed with BRD4-1 and BRDT-1. In all the bivalent inhibitor bound BET BRDs (Figs. 5.4 –
5.7), bromodomains remain as a dimer where two warheads of one bivalent inhibitor engage two
monomers of BRD. In Fig. 5.4, comparison of GXH-II-083 and GXH-II-052 bound BRD4-1
structures show that bivalent inhibitors of same warhead but with different linker lengths promote
association of BRD4-1 into the same dimer. The same phenomenon is also true for BRDT as shown
in Fig. 5.5, where two bivalent compounds with same warhead but different linker lengths promote
association of BRDT-1 into the same dimer. When we compare the same bivalent inhibitor GXHII-052 bound BRD4-1 and BRDT-1 structures, as shown in Fig. 5.6, it becomes evident that same
bivalent inhibitor stabilizes distinct dimeric states of BRD4-1 and BRDT-1. However, this
dimerization is not dependent on the target protein domain. As shown in Fig. 5.7, same linker
chain but different warhead-containing bivalent compounds GXH-II-052 and NC-III-49-1
promote different dimeric states of BRD4-1. Combined, our findings indicate that inhibition of
BRD4-1 and BRDT-1 by the same bivalent inhibitor results in distinctly different dimers (Fig. 5.6)
while inhibition of BRD4-1 by different warhead containing bivalent inhibitors results in different
dimers of the same protein (Fig. 5.7).

SAXS study indicates that bivalent inhibitor NC-III-49-1 interacts with tandem BRD in an
intramolecular fashion
BET proteins contain two N-terminal bromodomains, which are separated by a large
variable length linker region (Fig. 5.8A). The linker region length and residue composition differ
from one BET member to others. As example, the two BRDs in BRDT are separated by 121
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residues long linker whereas the two BRDs in BRD4 are separated by 179 residues long linker. In
the development of bivalent inhibitor of the BETs, a conceptual hypothesis was that certain chain
length or warhead containing homomeric bivalent inhibitors could engage two tandem BRD in a
BET protein by constraining the linker region. This unfavorable linker constrained intramolecular
BRD-ligand interactions will not be allowed in all BET members. Thus, a bivalent inhibitor could
selectively inhibit a BET subclass member while sparing the others, a challenge that remained
unattainable. However, assessing the intramolecular tandem BRD engagement by bivalent
inhibitors using X-ray crystallography is an enormous challenge. We attempted co-crystallization
of BRDT-T with the bivalent inhibitors, but this approach was not successful. Presence of the large
flexible linker (121 residues long) most likely prevented the formation of X-ray grade crystals. In
principle, a bivalent inhibitor in solution can engage the tandem bromodomain of BETs in an
intermolecular or intramolecular interaction mode (Fig. 5.8B).
To study the bivalent inhibitor engagement with tandem bromodomain of BRDT (BRDTT), we have utilized size exclusion column (SEC) coupled small-angle X-ray scattering (SECSAXS). SAXS is a biophysical technique suitable to study and structurally characterize
conformational changes of macromolecules in solution. Fig. 5.9 shows a typical SEC-SAXS setup
at BioCAT (beamline 18D) at the Argonne National Laboratory in Chicago.14 Besides the SEC,
SAXS beamline set up includes implementation of a coflow cell at the point of sample X-ray
exposure. In coflow cell method, a continuous buffer sheath is maintained surrounding the sample
dispensed from the dispensing needle. Combined application of SEC and coflow cell ensures data
collection on a homogeneous sample with minimum to no radiation damage during X-ray
exposure.15, 16 We have collected SEC-SAXS data on BRDT-T in the absence and presence of 5
μM NC-III-49-1. SEC column profile (Fig. 5.11A) of the two samples indicate a shift of the elution
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peak in presence of NC-III-49-1 toward a lower molecular weight size. The difference in SAXS
profiles (Fig. 5.10B), especially in the low and mid q region, indicate conformational changes of
BRDT-T due to the presence of NC-III-49-1. Calculated radius of gyration (Rg) from the Guinier
analysis of SAXS data (Fig. 5.10C) clearly shows that in presence of the bivalent inhibitor
molecule size of BRDT-T is reduced from (Rg =) 54.3 Å to (Rg =) 45.1 Å. This change in molecule
size becomes clearer in the p(r) function plot (Pair distance distribution plot) in Fig. 5.10D. p(r)
function represents the distribution of intraparticle distances calculated from experimental SAXS
data where Dmax is the maximum distance between two atoms in studied macromolecules. The
observed differences in p(r) function are significant as they show that due to the presence of NCIII-49-1 macromolecule particle shape decreased and importantly, the maximum intraparticle
distance was also decreased. These experimental observations negate the possibility of
intermolecular interaction mode of NC-III-49-1 with BRDT-T as in this case the macromolecule
size would increase. Moreover, Kratky plot (Fig. 5.10E) also show that without inhibitor BRDTT remains in an extended state whereas in complex with NC-III-49-1 the macromolecule was more
compact. The molecular weight was estimated by calculating the volume of correlation (Vc) and
Porod’s volume (Vp). Vc is more accurate for a non-globular or extended protein,17 which showed
molecular weight range of 45 – 57 kDa (Fig. 5.10F). However, since our studied protein is
multidomain protein connected with large flexible linker region the calculated Vc or Vp will have
large margin of uncertainty.
Ab initio low resolution shape (envelope) restored from the SAXS data show that in
solution unliganded BRDT-T remains in an extended shape (Fig. 5.11), but with NC-III-49-1
shape of the BRDT-T becomes more compact. Generated models of BRDT-T with globular
domain BD1 and BD2 as rigid body by Ensemble Optimization Method (EOM) suggest distant
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positioning of the two BRDs in unliganded state and proximal positioning of the two BRDs in
presence of NC-III-49-1. Although goodness of the fit (X2) for the EOM generated model are not
of high confidence (>2), for a multidomain protein with large flexible loops the generated model
will have high ambiguity from the flexible loops and the goodness of fit will always remain
reasonably high (range of 2 – 10). However, the flexibility measure (Rflex/Rσ) of the EOM model
show that the selected pool of 100 EOM ensembles of BRDT-T with best match to experimental
SAXS data is relatively less flexible than a large pool of 10,000 randomly generated models and
the measure is even higher for BRDT-T with NC-III-49-1. This also indicate relative rigidity of
BRDT-T / NC-III-49-1 complex compared to unliganded BRDT-T. Combined, our SEC-SAXS
study show that NC-III-49-1 binding to BRDT-T reduces the macromolecule size, shape and
flexibility, which support the intramolecular interaction mode of NC-III-49-1 with the tandem
bromodomain of BRDT (Fig. 5.12). Using SAXS study we show that structural characterization
of bivalent inhibitor-protein ternary complex could reveal valuable insights of inhibitor interaction
mode that can be utilized to design effective bivalent inhibitors.

EXPERIMENTAL SECTION

Protein expression and purification
DNA sequences encoding the human BRDT (Uniprot ID Q58F21) tandem bromodomain
(residues 2 – 416) was custom synthesized by GeneArt (Thermo Fisher Scientific) and cloned inframe of a modified pET15b vector providing an N-terminal hexa-histidine tag followed by a
Tobacco Etch Virus (TEV) cleavage site. BRD4-1 and BRDT-1 protein constructs and cloning
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was done as described before (see protein expression and purification method of the experimental
section in Chapter 4 part II). The encoded bromodomain proteins were expressed in the BL21
(DE3) strain of E. coli.
Plasmids were transformed into E. coli cells and grown at 37 °C in LB medium (Fisher
Scientific) containing carbenicillin (0.1 mg/mL). At OD600 of 0.6, the culture was cooled down
to 18 °C and induced with 0.1 mM IPTG. After 12 h growth, the culture was harvested by
centrifugation at 6,000 × g for 25 min and stored at -80 °C. Harvested cell pellets were resuspended in 50 mM Na/K phosphate buffer (pH 7.4) containing 150 mM NaCl, 0.01% w/v
lysozyme and 0.01% v/v Triton X-100 at 4 °C for 1 h, subjected to sonication and the lysate was
clarified by centrifugation (30,000 × g for 45 min at 4 °C). Proteins were purified by FPLC at 4
°C using columns and chromatography materials from GE Healthcare. The lysate was subjected
to an immobilized Ni2+ affinity chromatography column equilibrated with 50 mM Na/K
phosphate buffer (pH 7.4) containing 150 mM NaCl and 40 mM imidazole, and was eluted using
a gradient from 40 to 500 mM of imidazole. Fractions containing the target protein were combined
and incubated for 6 h with TEV protease at 4 °C, and the cleaved His6-tag was removed by a
second Ni2+ affinity column.

BRD-containing fractions were pooled and subjected to SP

Sepharose High Performance cation exchange column equilibrated with 50 mM Na/K phosphate
buffer (pH 7.4), 2mM DTT. The protein was eluted using a gradient from 0 to 1 M of NaCl. Lastly,
BRDT-T was purif ied to homogeneity by size exclusion chromatography using Superdex 200
with the elution buffer 50 mM Na/K phosphate buffer (pH 6.9) containing 2mM DTT. BRDT-T
eluted as monomeric proteins and were of crystallization grade quality (> 95% purity as judged by
SDS-PAGE). BRDT-T containing fractions were combined, concentrated to ~ 20 mg/ml and

216

aliquots were flash-frozen in liquid N2 and stored at -80 °C. BRD4-1 and BRDT-1 were purified
as described before in the experimental section of chapter 4 part II.

Crystallization and X-ray crystallography
All crystallization experiments for BRD4-1 and BRDT-1 were performed as described
before (see crystallization and X-ray crystallography method of the experimental section in
Chapter 4 part II, pp156).

SAXS data collection
Small angle X-ray scattering (SAXS) data collection was performed at BioCAT (beamline
18ID at the Advanced Photon Source, Lemont, IL) with in-line size exclusion chromatography
(SEC-SAXS). Experiments were conducted at room temperature in SAXS buffer: 50 mM HEPES
(pH7.5), 150mM NaCl, 5% v/v ethylene glycol, 2.5% v/v DMSO and 2 mM DTT. 250 μL of
samples of BRDT-T were loaded onto the Superdex 200 Increase 10/300 column (GE Life
Sciences) and eluted with SAXS buffer or SAXS buffer containing 5 μM NC-III-49-1 at a flow
rate of 0.7 mL/min. The elute for the SEC passed through the UV cell for size exclusion
chromatogram and reached the SAXS quartz capillary flow cell, where sample was exposed to Xray data for data collection. SEC column to X-ray beam dead volume was approximately 0.1
mL.

Sample scattering intensity was recorded on a Pilatus3 1M (Dectris) detector placed

3.5 m from the sample and a wavelength of λ = 1.03320164497, which yield range of momentum
transfer (scattering q-range) 0.004 < q < 0.4 Å-1 (q = 4𝛑sin𝛉/ λ, where 2𝛉 is the scattering angle).
0.5 second exposures were used with 0.5 second interval during the elution. Data were reduced at
the beamline using BioXTAS RAW 1.6.1. 18 The buffer scattering was determined by averaging
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frames from the SEC eluent of pre and post-peak, which contained baseline levels of integrated Xray scattering, UV absorbance and conductance. The frame intensities were corrected by
subtracting the buffer contribution. The corrected frames were investigated by radius of gyration,
Rg, derived by the Guinier approximation I(q) = I0 exp (-q2Rg2/3) with the limits q*Rg < 1.3. Final
q versus I(q) data sets were generated by averaging frames in the region of least Rg variation,
automatically selected by the BioXTAS RAW 1.6.4
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program, and merging. These merged

SAXS data with q range 0.00005 – 0.35 Å-1 were used for analysis. The singular value
decomposition (SVD) and evolving factor analysis (EFA) methodology was applied on the merged
SAXS data to separate out the scattering contribution of major homogenous species from the high
molecular weight scatterers as observable in the SAXS frame scattering plot (Supplementary Fig.
S5.1). SVD and EFA applied SAXS data were used to generate the SAXS scattering profile,
Guinier plots and normalized Kratky plots, and to calculate radius of gyration (Rg), volumes-ofcorrelation (Vc), Porod’s corrected volume (Vp), and pair distribution function p(r). The p(r)
functions were further assessed and computed manually with the program GNOM 19 for smooth
reaching to X-axis (Log(I(q) = ~ 0). The molecular mass (Vc and Vp) was computed according to
published methods

17, 20.

All the data analysis were done by using BioXTAS RAW 1.6.3
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and

Graphpad Prism was used for graphical representation. The Guinier plots in Fig. 5.10C indicate
aggregation free samples.

SAXS solution structure modeling
Ab initio shape of BRDT-T ( and NC-III-49-1 complex) were generated using the bead
modeling program DAMMIN21. Multiple runs were performed to generate 20 starting models and
the final ab initio envelope was reconstructed by averaging and refining the starting models. The
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low resolution bead model with an average core volume of 20 starting model computed by
DAMFILT in ATSAS suit22 are shown in Fig. 5.11E.
High resolution crystal structures of BRDT BD1 and BD2 were used to generate BD1 and
BD2 rigid body starting model. Two rigid body connected by the linker residues were used for
Ensemble Optimization Method (EOM)23 to generate 10,000 models. N-term 6xHis and TEV
cleavage site residues were not included in the EOM method for simplicity. CRYSOL 3.0 24 was
used to calculate the scattering profile for each model and comparison. A subset of 100 models
from the 10,000 model pool was selected within the EOM of which the calculated average
scattering statistically agrees with the experimental data. A representative EOM model among the
5 best ones that agrees with experimental SAXS data was fitted inside the ab initio shape as shown
in Fig. 5.11B,D.
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Figure 5.1. Types of bivalent inhibitors.
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Figure 5.2. Homomeric monovalent and bivalent BET inhibitors of the GXH-series. A)
Chemical structure of the monovalent inhibitor used as warhead for bivalent inhibitor
development. Exit vector is shown with an arrow. B) Chemical structures of representative GXHseries bivalent inhibitors. C) Cell growth inhibitory activity of the GXH-series inhibitors on
multiple myeloma (MM1.S) cells. D) Effect of inhibitor treatment on the expression of BRD4
mediated c-Myc level.
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Figure 5.3. Homomeric monovalent and bivalent BET inhibitors of the NC-series. A)
Chemical structure of the monovalent inhibitor used as warhead for NC-series bivalent inhibitor
development. Exit vector is shown with an arrow. B) Chemical structures of a representative NCseries bivalent inhibitor. C) Cell growth inhibitory activity of the NC-series inhibitors on multiple
myeloma (MM1.S) cells. D) Effect of inhibitor treatment on the expression of BRD4 mediated cMyc level.
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into the same dimer
A

n = 17

B

n=9

Figure 5.4. Bivalent inhibitors of different chain lengths promote association of BRD4-1 into
the same dimer. A) GXH-II-083 binding with two monomers of BRD4-1. B) Same as (A) for
GXH-II-052. 2Fo-Fc and F0-Fc electron density maps are shown in Supplementary Figure S5.2.
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into the same dimer
A

n=9

B

n = 14

Figure 5.5. Bivalent inhibitors of different chain lengths promote association of BRDT-1 into
the same dimer. A) GXH-II-052 binding with two monomers of BRDT-1. B) Same as (A) for
GXH-II-082. 2Fo-Fc and F0-Fc electron density maps are shown in Supplementary Figure S5.2.
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A

B

Figure 5.6. Same bivalent inhibitor stabilizes distinct dimeric states of BRD4-1 and BRDT1. A) GXH-II-052 binding with two monomers of BRD4-1. B) Same as (A) for binding to BRDT1.
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A
GXH-II-052

B
NC-III-49-1

Figure 5.7. Different warheads promote different dimeric states of BRD4-1. A) GXH-II-052
binding with two monomers of BRD4-1. B) Same as (A) for NC-III-49-1 binding to BRD4-1. 2FoFc and F0-Fc electron density maps are shown in Supplementary Figure S5.2.
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tandem BRDs in BETs
A

BD2

BD1

BD2/1

BD2

Biv-I

2
BD

BD1

/2
BD1

BD1

B

Biv-I

Intramolecular

Biv-I

Intermolecular

BD2

BD1

BD1/2

BD2/1

Intermolecular

Figure 5.8. Tandem BRD in BETs and the potential interaction modes of bivalent inhibitor
with tandem BRD. A) Tandem bromodomain (BD1 and BD2) in BETs. B) Different potential
modes of bivalent inhibitor (Biv-I) engagement with tandem BRD. Straight line connecting two
dots (⧿) represents the distance between two domains in an extended tandem BRD, two-headed
arrow (⟷) indicates linker constrain and the two arrows facing each other (→←) indicate potential
domain-domain interaction.
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Figure 5.9. A typical SEC-SAXS set up at BioCAT (beamline 18D) at the Argonne National
Laboratory, Lemont, IL.
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Figure 5.10. Characterization of macromolecules in solution by SAXS. A) SEC elution profile
(gray – BRDT-T + DMSO, red – BRDT-T + NC-III-49-1). B) SAXS profile. C) Guinier analysis
for Rg calculation. Residuals of Guinier analysis fitting are shown below the Rg plot. D) Pair
distance distribution function plots. E) Kratky plots. F) SAXS derived macromolecule parameters.
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Figure 5.11. Ab initio low resolution shape restored from SAXS data and fitting of Ensemble
Optimization Method (EOM) derived models. A) Ab initio shape for BRDT-T + DMSO. B)
EOM model fitting of BRDT-T in the generated shape from (A). C) same as (A) for BRDT-T +
NC-III-49-1. D) same as (B) for BRDT-T / NC-III-49-1 complex. (B, C) X2 is a measure of
goodness of fit and Rflex/R𝛔 is a measure of flexibility of the ensemble where low Rflex/R𝛔 value
indicates high flexibility and high Rflex/R𝛔 value indicates low flexibility. E) Ab initio bead model
(spheres) and average core (surface) of 20 bead models generated from SAXS data by DAMMIN
for BRDT-T + DMSO (left) and BRDT-T + NC-III-49-1 (right).
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Figure 5.12. SAXS data support intramolecular interaction of bivalent inhibitor (NC-III-491 = Biv-I) with the BRDT tandem.

232

SUPPLEMENTARY INFORMATION

Supplementary Figure S5.1. SEC-SAXS frame intensity and Rg profile.
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Supplementary Figure S5.2. Electron density maps of bivalent inhibitors bound in the KAc
site of BET BRDs. The 2Fo-Fc density map upon refinement with ligand is shown in blue
(contoured at 1σ). The Fo-Fc density map upon refinement omitting the ligand is shown in red
(contoured at 2σ).
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CHAPTER 6: INVESTIGATION OF ATYPICAL BROMODOMAINS

ATYPICAL BRDS

In the last decade, functions of the epigenetic “reader” domains BRDs have evolved from
the recognition of post-translationally modified acetylated lysine (KAc) on histones to other
cellular proteins particularly transcription factors and specific DNA binding sites. Utilization of
small molecule inhibitors played a critical role in this evolution by providing a means to decipher
the function of a specific BRD in a large multidomain containing BRD protein. However, a subset
of atypical BRDs, which contain a BRD fold without having the conserved asparagine in place, is
missing in the BRD landscape. It remained unanswered whether the atypical BRDs can recognize
acetyl-lysine on histones and other proteins. Importantly, reported cellular functions of some of
the atypical BRD proteins such as TRIM28, BRD8 and ASH1L suggest their critical role in
disease-relevant pathways that could be targeted for developing novel therapeutics.

Atypical bromodomain of TRIM28
Atypical BRD containing TRIM28 (tripartite motif-containing 28) (Uniprot ID Q13263 )
is also known as KAP1 (KRAB-associated protein 1), TIF1β (Transcription intermediary factor 1
beta) and KRAB domain-containing zinc finger proteins (KRAB-ZFPs). TRIM28 is a large
protein comprised of multiple domains (Fig. 6.1).1 The PHD (plant homeodomain) and BRD
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(bromodomain) domains at the C-terminus forms a PHD-BRD functional module, which facilitates
lysine SUMOylation mediated gene regulation and proteostasis.2

The profound biological

functions of TRIM28 range from its role in early embryonic development to target protein
degradation and neurodegenerative diseases.3, 4 5-7 Our attempt to produce a TRIM28 PHD-BRD
construct with an N-term solubilizing SUMO-tag protein was successful. However, crystallization
trial with the starting construct was unsuccessful. Therefore, we designed and successfully used a
high-throughput cloning method to clone fifteen PHD-BRD and two BRD constructs with various
N- and C-term residues (Fig. 6.1 and Fig. 6.2). Protein purification of the attempted six PHDBRD and one BRD constructs yielded milligram quantity of >95% pure proteins (Fig. 6.3). In
DSF experiments, TRIM28 PHD-BRD behaved as a regularly folded protein (Fig. 6.4) with
melting temperature, Tm, ranging from 56 °C to 61 °C whereas BRD did not produce any melting
curve (data not shown). However, crystallization attempts with all seven (6 PHD-BRD and 1 BRD)
TRIM28 constructs remained unsuccessful. Although TRIM28 has been implicated in HIV-1
latency,8 innate immunity, 9, 10 tauopathy3, 4 and tumorigenesis, 11-13 specific functions of the PHDBRD module is not yet clear. Moreover, there is no small molecule inhibitor of TRIM28.
Therefore, discovery of a small molecule inhibitor of the TRIM28 PHD-BRD module would be
critical to advance our understanding of the function of this module in TRIM28 biology and could
provide us a novel therapeutic strategy against HIV, neurodegenerative diseases and cancer.

Divergent bromodomain of BRD8
BRD8 (Uniprot ID Q9H0E9) is an underexplored BRD-containing protein which was
found to be overexpressed in colorectal carcinoma. 14 BRD8 contains a divergent BRD where
conserved asparagine is placed outside the KAc site in in silico model. BRD8 isoform 1 and
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isoform 2, two mostly abundant isoforms of BRD8, contains a C-term BRD and tandem BRD,
respectively (Fig. 6.5A).1 Of the two BRDs (BD1 and BD2) of BRD8, bacterial overexpression
attempts were successful only for BRD8 BD1 (BRD8-1). For successful protein overexpression
and purification of > 95% pure protein, BRD8-1 required an N-term thioredoxin (Trx) tag (Fig.
6.5B, C) presumably due to a stabilizing effect of Trx on BRD8-1. Unfortunately, crystallization
attempts of BRD8-1 remained unsuccessful. In DSF (Fig. 6.6A), BRD8-1 showed a typical thermal
denaturation curve with a somewhat low melting point (Tm = ~35 °C) for a BRD (typical Tm =
~50 °C) indicating an unstable state of the isolated BRD. Interestingly, pan-BRD inhibitor
bromosporine (BSP) showed a ∆Tm of 2.6 °C with (Trx-)BRD8-1 indicating that small molecule
inhibitors can be suitable binders for this divergent BRD. There is no small molecule inhibitor of
BRD8 reported so far. Therefore, in the future, it will be interesting to screen BRD8-1 against a
compound library by DSF to identify BRD8 inhibitor.
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Figure 6.1. TRIM28 domains and PHD-BRD construct design. A) Domain maps of TRIM28.
RING, RING domain; B1/B2, B-box 1 or 2; RBCC, RING B-box coiled-coil; HP1 BD,
Heterochromatin protein 1 (HP1) binding domain; PHD, Plant homeodomain; BRD,
Bromodomain. B) Designed constructs for high throughput cloning.

Figure 6.2. CPEC (circular polymerase extension cloning) based high throughput cloning
method used for TRIM28 constructs generation.
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Figure 6.3. TRIM28 protein production. A) TRIM28 PHD-BRDexpression construct. B) SEC
column profile showing the final step of purification. C) SDS gel of TRIM28 PHD-BRD (613835) purification, a representative summary showing the successful purification of TRIM28.

Figure 6.4. Thermal stability of TRIM28 in various buffer conditions tested by DSF.
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Figure 6.5. Protein production of BRD8 BD1. A) Domain maps of two isoforms of BRD8. B)
BRD8-1 expression construct. C) SEC profile of BRD8-1 representing the last step of purification.
D) SDS gel of BRD8-1 purification, a representative summary showing the successful purification
of crystallization grade BRD8-1.
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Figure 6.6. Thermal stability assessment of BRD8-1 by DSF. A) General stability of BRD8-1
assessed under various buffer conditions. B) Stabilization of BRD8-1 by the pan-BRD inhibitor
bromosporine (BSP).
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CHAPTER 7: CONCLUSION

Bromodomains, through their acetyl-lysine recognition ability, regulate a wide range of
cellular functions that are found to be dysregulated in various diseases. Therefore, small molecule
inhibitors of BRDs, particularly the bromodomain and extra-terminal domains (BETs), are
becoming a viable therapeutic strategy for cancer and inflammatory disorders. Although recently
a challenge has been met through the successful development of BD1 and BD2 selective BET
BRD inhibitors, development of a selective BET inhibitor that can distinguish among the BET
sub-class members remains unattained. However, investigation on the non-BETs BRDs is still in
infancy. Thus, there is an unmet need to develop effective small molecule inhibitors targeting the
non-BET BRDs. Lack of suitable chemical tools for non-BET BRDs significantly hampered our
understanding of the role of these underexplored BRDs in disease-related pathways. The body of
work presented here tried to address this gap.
In the first project (presented in chapter 2), using a cascade of biophysical and biochemical
methods, we have discovered and characterized a dual TAF1-ATR inhibitor AZD6738 along with
a known TAF1 inhibitor BAY299. This is the first report of a dual inhibitor of TAF1 bromodomain
and ATR kinase. Our studies show that TAF1 tandem bromodomain remains in multiple
conformational states, and binding of certain inhibitor induces large conformational changes
resulting in distinct conformational states or dimerization of TAF1 tandem bromodomain. Such a
large conformational change in TAF1 will have significant cellular implications, particularly in
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transcription initiation and nucleosome dynamics. Further studies are required to determine the
effect of these conformational changes on general transcription - more importantly - on
dysregulated transcription. Our cellular studies with these inhibitors along with ATR inhibitors
show that inhibition of the bromodomain of TAF1 activates p53 mediated DNA damage response
pathway. Previously, it was reported that inactivation of the pseudo-HAT domain of TAF1 can
activate the DNA damage response pathway, whether a similar effect could be achieved through
the bromodomain inhibition was not known. In summary, the studies presented in this chapter
offer a structural framework for understanding the cellular effect of the bromodomain inhibition
of TAF1 and sheds new light into the role of non-BET bromodomain of TAF1 in p53 mediated
DNA damage signaling.
In the second project (presented in chapter 3), we have investigated the structural basis for
differential potency and selectivity of BRD9 inhibitors in BRD7 and BRD9. Based on our
investigation, we report the major structural determinants in BRD7/9 that dictate inhibitor binding
potency, and thus, selectivity. We have also identified novel dual BRD7/9-kinase inhibitors for
effective pharmacological inhibition of BRD7/9. Our reported first-in-class dual bromodomainkinase inhibitors outside the BET family targeting BRD7 and BRD9 show that there is a potential
to discover dual BRD-kinase inhibitors outside the BETs. These studies afford a structural
framework to be utilized for developing a BRD9 or BRD7 selective inhibitor or a
polypharmacological agent with the desired activity.
In the third project (presented in chapter 4), we have developed and characterized dual
BET-kinase inhibitors. Part I presents the development of three lead compounds of dual BETJAK2 inhibitors. Using a structure-guided approach, we have studied 125 diaminopyrimidine
derivatives to understand the structure-activity relationship of these inhibitors for BRD4. Based
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on 27 high-resolution BRD4 structures complexed with inhibitors and DSF based activity data, we
have developed a set of 3 lead compounds to be tested in various cancer cell line models and
animal studies. Further studies on these lead compounds would yield an early drug candidate
suitable for studying in preclinical models. Part II presents the characterization of a set of six dual
BET-PLK1/ERK5 inhibitors against all eight BET BRDs using X-ray crystallography and
biophysical binding assays. Correlation analysis between the DSF and other direct binding assays
establishes the DSF as a benchmark assay to determine inhibitor binding potential and predict
binding affinity for BETs. Crystallographic studies show that the solvent-exposed functional
group of a compound affects the inhibitor binding to the KAc site of BETs, though it does not
mediate direct interactions with the binding site. Finally, the cellular studies evidence that dual
inhibition of BET and PLK1 intervene in two cellular processes, BET mediated Myc pathway and
PLK1 mediated phosphorylation of cell cycle proteins. Dual BET-PLK1 inhibition may
synergistically prevent cancer cell growth that could be exploited for developing a dual BET-PLK1
inhibitor as cancer therapeutics.
In the fourth project (presented in chapter 5), we have characterized bivalent BET
inhibitors binding to BRD4 and BRDT. Using cellular assay, X-ray crystallography, and smallangle X-ray scattering (SAXS), we show that bivalent inhibitor NC-III-49-1 interacts with the two
bromodomains of a tandem BRDT in an intramolecular fashion. This is the first direct evidence
for an intramolecular interaction of bivalent inhibitors rather than intermolecular interactions.
In the fifth and final project (presented in chapter 6), we have investigated two atypical
bromodomains of TRIM28 and BRD8. Using high throughput cloning method and utilizing
various expression tags, we have produced well-folded TRIM28 PHD-BRD and BRD8-1 proteins.
However, our crystallization attempts were unsuccessful. Presumably, due to the difficulties in
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crystallization, crystal structure determination of TRIM28 PHD-BRD and BRD8 remained
unsolved.
The studies presented here provide an in-depth structural basis of inhibition of the nonBET BRDs of TAF1 and BRD9 by small molecule inhibitors. The acquired knowledge will be
useful to develop highly effective small molecule dual BRD-kinase inhibitors and chemical tools
targeting the TAF1 and BRD9, which will help us to understand the role of these underexplored
BRDs in disease-related pathways. Moreover, studies with the dual BET-kinase inhibitors and
bivalent inhibitors provide a comprehensive analysis of differential binding of various inhibitors
to BET BRDs through the development of dual BET-JAK2 lead compounds and identify the
structural factors of markedly improved potency of bivalent inhibitors, respectively. Important
understanding of BET BRDs acquired from these studies will accelerate the development of a
selective and potent BET inhibitor as a potential therapeutic candidate.
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